THE LANCET Global Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. *Lancet Glob Health* 2017; published online Oct 23. http://dx.doi.org/10.1016/S2214-109X(17)30373-X.

Appendices for "Systematic review of global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs"

Sarah Larney, Amy Peacock, Janni Leung, Samantha Colledge, Prof. Matthew Hickman, Prof. Peter Vickerman, Jason Grebely, Kostyantyn V. Dumchev, Paul Griffiths, Lindsey Hines, Evan B. Cunningham, Prof. Richard P. Mattick, Prof. Michael Lynskey, Prof. John Marsden, Prof. Sir John Strang, Prof. Louisa Degenhardt

Contents

| Appendix 1: GATHER and PRISMA checklists | 3 |
|---|--------|
| 1.1 GATHER checklist | 3 |
| 1.2 PRISMA checklist | 5 |
| Appendix 2: Details of methods | 7 |
| 2.1 Search strategy and data extraction | 7 |
| 2.2 Data analysis | 9 |
| 2.3 References | 11 |
| Appendix 3: Search strings used in peer-reviewed literature searches | 12 |
| 3.1 Medline search strategy | 12 |
| 3.2 Embase search strategy | 13 |
| 3.3 PsycINFO search strategy | 13 |
| Appendix 4: Grey literature search | |
| Appendix 5: First round email and social media requests for information | 81 |
| 5.1 Example email | 81 |
| 5.2 Example social media request | |
| Appendix 6: Data extraction guidelines | |
| 6.1 Decision rules for identifying data for extraction | |
| 6.2 General Extraction Instructions | |
| Appendix 7: Decision rules for summarising data and making adjustments to standardise | data88 |
| 7.1 Assumptions and data adjustments for standardisation of estimates | |
| 7.2 Calculation of indicator denominators | |
| Appendix 8: Data verification – example email | |
| Appendix 9: Estimated regional and global populations of people who inject drugs, prima | |
| injectors, and people who inject drugs living with HIV | |
| 9.1 Reference | |
| Appendix 10: Country-level coverage of NSP, OST, HIV testing and counselling, and HIV a | |
| therapy, by region | |
| Table 10.1: Provision of needle-syringes, opioid substitution therapy, HIV testing and | • |
| and antiretroviral therapy for people who inject drugs in Europe | |
| Table 10.2: Provision of needle-syringes, opioid substitution therapy, HIV testing and | |
| and antiretroviral therapy for people who inject drugs in Asia | |
| Table 10.3: Provision of needle-syringes, opioid substitution therapy, HIV testing and | |
| and antiretroviral therapy for people who inject drugs in the Americas | |
| Table 10.4: Provision of needle-syringes, opioid substitution therapy, HIV testing and | |
| and antiretroviral therapy for people who inject drugs in Oceania | |
| Table 10.5: Provision of needle-syringes, opioid substitution therapy, HIV testing and | |
| and antiretroviral therapy for people who inject drugs in Africa and the Middle East | 100 |

| Appendix 11: Country-level needle and syringe program implementation indicators and reference | |
|--|-----|
| by region | 103 |
| Appendix 12: Country-level opioid substitution therapy implementation indicators and references by region | |
| Appendix 13: Country-level HIV testing and counselling implementation indicators and references by region | s, |
| Appendix 14: Country-level antiretroviral therapy implementation indicators and references, by region | |
| Appendix 15: Country-level condom distribution program indicators and references, by region Appendix 16: Countries with coverage estimates for both NSP and OST, with coverage category | 144 |
| according to WHO/UNAIDS/UNODC suggested implementation targets | 154 |
| Appendix 17: Acknowledgement of individuals who provided data for this review | 156 |

Appendix 1: GATHER and PRISMA checklists

1.1 GATHER checklist

| Item # | Checklist item | Reported on page # |
|----------|---|---|
| Objectiv | res and funding | |
| 1 | Define the indicator(s), populations (including age, sex, and geographic entities), and | Table 1; p. 6 |
| | time period(s) for which estimates were made. | |
| 2 | List the funding sources for the work. | 18 |
| Data In | outs | |
| For all | data inputs from multiple sources that are synthesized as part of the study: | |
| 3 | Describe how the data were identified and how the data were accessed. | 6-7 |
| 4 | Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. | 6; appendix 2 |
| 5 | Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, | Appendices 10-14 |
| - | diagnostic criteria or measurement method, and sample size, as relevant. | |
| 6 | Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5). | N/A |
| | ta inputs that contribute to the analysis but were not synthesized as part of the study: | |
| 7 | Describe and give sources for any other data inputs. | N/A |
| | data inputs: | |
| 8 | Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. | 14 |
| Data an | | _ |
| 9 | Provide a conceptual overview of the data analysis method. A diagram may be helpful. | 6 |
| 10 | Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s). | 7-9 |
| 11 | Describe how candidate models were evaluated and how the final model(s) were selected. | Appendices 6, 7 |
| 12 | Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis. | N/A |
| 13 | Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis. | 7-9 |
| 14 | State how analytic or statistical source code used to generate estimates can be accessed. | N/A |
| Results | and Discussion | |
| 15 | Provide published estimates in a file format from which data can be efficiently extracted. | Will be provided; see also p. 14 |
| 16 | Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals). | Throughout results |

| 17 | Interpret results in light of existing evidence. If updating a previous set of estimates, | 13, 15 |
|----|--|--------|
| | describe the reasons for changes in estimates. | |
| 18 | Discuss limitations of the estimates. Include a discussion of any modelling assumptions or | 15-16 |
| | data limitations that affect interpretation of the estimates. | |

1.2 PRISMA checklist

| Section/topic | # | Checklist item | Reported on page # |
|------------------------------------|----|---|---------------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 5 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 6 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 6, appendices 2,6,7 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Appendix 3 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | Appendix 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | pp. 6-7, Appendix 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | Table 1, Appendices 6, |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | N/A |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | Table 1 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., l²) for each meta- analysis. | 8 |

| Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. RESULTS Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a finding diagram. | N/A w Figure 1 |
|---|--|
| Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a f | w Figure 1 |
| | w Figure 1 |
| uagiani. | Ĭ |
| Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Appendices 10-14 |
| Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | N/A |
| Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimated and confidence intervals, ideally with a forest plot. | es 10-12 |
| Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). | No formal RoB assessment; RoB discussed at length pp. 14- 16 |
| Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| DISCUSSION | |
| Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 13 |
| Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 14-16 |
| Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 16 |
| FUNDING | |
| Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 18 |

Appendix 2: Details of methods

2.1 Search strategy and data extraction

We searched for data relating to 17 pre-defined standardised indicators relating to needle and syringe programmes (NSP), opioid substitution therapy (OST), HIV testing and counselling, HIV antiretroviral therapy (ART) and condom distribution programmes. Indicators were selected from the WHO/UNOCD/UNAIDS target setting guide (see **Manuscript: Table 1**).

Our approach included multiple stages of searches of the peer-reviewed and 'grey' literature to identify relevant data sources published from 2010 onwards, and international expert consultation to seek additional data and/or confirm data that had been collected.

Peer-reviewed literature search. Medline, Embase and PsycINFO peer-reviewed literature database was searched using the OVID™ interface/platform for articles likely to contain data describing the provision of HIV prevention and care services for PWID. Sets of search strings were developed for searching these databases incorporating both keywords and database-specific terms for the following: <injecting drug use>; <needle and syringe program>; <opioid substitution treatment>; and <anti-retroviral treatment>. These search strings were developed in consultation with a librarian specialising in drug and alcohol research and are detailed in **Appendix 3**. Searches were conducted in September 2016. Searches were limited to the time period 2010 and later. No other restrictions were applied to the search; citations for papers in languages other than English were included.

Grey literature search. An online search was undertaken between October 2016 and February 2017 for material describing the provision of HIV prevention and care services for people who inject drugs. Websites previously identified as sources of information relating to HIV and injecting drug use, particularly grey literature, were accessed and searched along with additional websites of national ministries of health, national AIDS committees, United Nations agencies and harm reduction networks. In the case of many of the websites accessed, it was necessary to search for documents and relevant information within these sites using either the search functions these sites contained or using the advanced search function of Google which allows for keyword searches using Boolean search terms within a particular site. In all other cases the websites were small, and searched manually. A list of all websites searched and description of the search terms and strategies employed to identify material within these sites is detailed in **Appendix 4**.

Supplementary searches. Key documents and websites for various relevant international agencies were searched for relevant data, including UNAIDS (country progress reports), UNODC World Drug Report, the Global Fund to Fight AIDS, Tuberculosis and Malaria (grant reports) and the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA; annual country reports and European Drug Report). In October 2016, emails requesting material describing HIV prevention and care services for PWID were sent to various individuals and organisations, with the request to forward emails to relevant contacts. An example of these email requests is provided in **Appendix 5**. One member of the research team (SL) posted a request for data via Twitter, which was delivered to 5,525 individual feeds.

Documents collected through the processes described above were catalogued in an Endnote (version X.8) library. Sources screened by researchers at the National Drug and Alcohol Research Centre, Kirby Institute, University of Queensland, University of Bristol and Ukrainian Institute of Health Policy. In addition to English, members of the research team could read French, Spanish, Portuguese, Hebrew, Russian, Ukrainian, Chinese and Bahasa Malaysian. Google Translate was used to translate other non-English language documents.

All peer-reviewed literature citations were reviewed first by title. If it was judged that the title indicated the paper could potentially contain relevant data then the abstract was read. If on reading the abstract the reviewer assessed that the paper might contain relevant data then the paper was retrieved and read in full. Grey literature documents were reviewed initially by either reviewing the executive summary or the table of contents, or for documents without these, searching the document for relevant key words (e.g. "injecting", "intravenous drug use", "opioid substitution", "needle", "syringe" etc.) to identify relevant sections which were then reviewed in detail. All sources identified from international organisations and via expert requests were reviewed in full for eligibility.

Sources identified as containing information relevant to the indicators following this process were categorised by country. All UN Member States were included, as were countries/territories where injecting drug use has been reported,{Degenhardt, under review #1817} or where we identified evidence that an intervention for people who inject drugs was being implemented. All data sources for each country were reviewed by two people and the single most recent national estimate across these sources was identified for each indicator. In the absence of a national estimate, the most recent sub-national estimate was identified to be used in the derivation of indicators estimating

service coverage. The process of selecting the final estimate for each indicator for each country was guided by defined decision rules outlined in **Appendix 6**.

All potentially relevant data identified in the documents reviewed were extracted and entered into a database built using Microsoft Excel 2016. The process of extraction and data entry was guided by defined decision rules outlined in **Appendix 6**. Data were extracted independently by research assistants, and reviewed for accuracy by LD, SL or AP; discrepancies were resolved by consensus. Country specific summaries of data were compiled and detailed country-specific reports were generated detailing all data selected for inclusion in the estimates. These were emailed to key experts and organisations in each country requesting feedback on the accuracy of the data that had been collected and for further data to be submitted where no data had so far been identified. Examples of these reports are provided in **Appendix 7**. These emails were frequently forwarded on to additional recipients.

All additional or revised material received in response to our emails was catalogued and added to the Endnote™ library. This material was reviewed, and potentially relevant data were extracted and entered into the database (SL). These new data were reviewed in full, and the dataset revised accordingly.

2.2 Data analysis

National estimates of intervention coverage were constructed using the definitions outlined in Manuscript: Table 1. Programme data (e.g. number of needle-syringes distributed; number of opioid substitution therapy clients) were used for numerators, although survey data were also collected and are provided in Appendix 10-14. To allow for comparison between countries, it was necessary for the data to have common parameters, such as the time period over which distribution of equipment or client access are measured. Data were adjusted to allow for such comparisons; the methods employed to standardise these data are outlined in Appendix 8. Denominators for national estimates of NSP, OST and HIV testing coverage were PWID population sizes estimated in Degenhardt et al.¹ Denominators for national estimates of ART coverage were derived from the prevalence of PWID living with HIV infection as estimated in Degenhardt et al.¹

National estimates for NSP and OST coverage were compared to targets suggested by WHO, UNODC and UNAIDS.² For NSP, coverage was assessed as low if the number of needle-syringes distributed per person who inject drugs per year was <100, moderate for estimates ≥100-200, and high for

estimates \geq 200. OST coverage was assessed as low if there were less than 20 OST clients per 100 people who inject drugs, moderate for estimates \geq 20-40, and high for estimates \geq 40.

To determine regional estimates of NSP coverage, we calculated the weighted average number of needle-syringes distributed per region. Denominators included the estimated population size of people who inject drugs for all countries in the region where injecting has been reported. For countries where NSP was known to be implemented, but the number of needle-syringes distributed was not known, we assumed the same level of coverage as in other countries in the region. The global estimate of NSP coverage was developed following a similar approach to the regional estimates, weighting the regional estimates by the size of the population of people who inject drugs.

We calculated regional and global OST coverage with reference to two denominators: the number of people who inject drugs (as in the endorsed indicators published by WHO/UNAIDS/UNODC³), and the number of people who inject drugs whose main drug injected is opioids.¹ Examining OST coverage specifically among people who inject opioids provides additional information to contextualise the estimate among people who inject drugs.

The process of determining regional and global estimates of OST coverage among all people who inject drugs proceeded as for the regional and global estimates of NSP coverage. We determined the weighted average number of people receiving OST per 100 people who inject drugs in each region, assuming the same level of coverage as in other countries in the region in those countries where OST is known to be implemented but no coverage estimate was available. The global estimate was determined by weighting the regional estimates by the size of the regional population of people who inject drugs.

To determine regional and global estimates of OST coverage among opioid injectors specifically, we used data from our recent review on the epidemiology of injecting drug use.¹ In that review, we presented results on the estimated proportion of people who mainly inject opioids (hereafter primary opioid injectors) among people who inject drugs in a country. To estimate the number of primary opioid injectors in this review, we multiplied the country population prevalence of injecting drug use by the proportion of primary opioid injectors among people who inject drugs. We multiplied this product by the country population size, then 95% uncertainty intervals were estimated using Monte Carlo simulation taking 100,000 draws. We used a binomial distribution as the parameters of interest were proportions. Sample sizes were derived based on the 95% confidence intervals and standard errors of estimates in each country. The simulated uncertainty intervals incorporated the uncertainty of both the injecting drug use prevalence and opioid injecting proportion estimates. The process of

determining regional and global estimates of OST coverage among primary opioid injectors thereafter was as above for OST coverage estimates among people who inject drugs.

2.3 References

- 1. Degenhardt L, Peacock A, Colledge S, et al. A global profile of people who inject drugs: Systematic review of characteristics, prevalence of injecting and of HIV, hepatitis B and hepatitis C. *The Lancet* under review.
- 2. World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization, 2012.
- 3. WHO/UNODC/UNAIDS. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: WHO/UNODC/UNAIDS, 2012.

Appendix 3: Search strings used in peer-reviewed literature searches

Three peer reviewed literature databases were searched in this exercise: Medline, EMBASE, and PubMed.

Listed below are the different literature and search strategies and terminologies used for each of the different databases for locating sources with coverage data related to needle-syringe programmes, opioid substitution treatment, and anti-retroviral therapy for people who inject drugs. Because different databases use different terminologies and require searching in different ways it was necessary to develop search strategies for each database.

These searches were developed in close consultation with a specialist drug and alcohol archivist and with a generalist university librarian with expertise across all the databases searched. Searches were conducted in September 2016.

3.1 Medline search strategy

The search strategy was as follows:

- **NSP**: results were restricted to those articles for containing terms from Search 1 and 2 (combined using 'AND') published 2010-Current.
- **OST:** results were restricted to those articles containing terms from Search 1 and Search 3 (combined using 'AND') published 2010-Current.
- ART: results were restricted to those articles containing terms from Search 1 and Search 4 (combined using 'AND') published 2010-Current.

Key-words are noted in regular type, 'MESH' (Medical subject heading) terms in **bold**.

Search 1: Injecting drug use

IDU\$1 OR IVDU\$1 OR PWID\$1 OR "injecting drug" OR "intravenous drug" OR "injecting substance" OR "intravenous substance" OR **exp substance abuse, intravenous/**

Search 2: Needle syringe program (NSP)

NSP\$1 or NSEP\$1 OR "needle syringe program\$" OR "needle syringe exchange program\$" OR "needle exchange\$1" OR "syringe exchange \$1" OR exp needle-exchange programs/ OR exp harm reduction/

Search 3: Opioid substitution treatment (OST)

OST OR MMT OR BMT OR "opioid substitution treatment" OR "methadone" OR "methadone maintenance" OR "buprenorphine" OR "buprenorphine maintenance" OR "opioid replacement" OR exp buprenorphine/

OR exp methadone/ OR exp opiate substitution treatment/ OR exp buprenorphine, naloxone drug combination/

Search 4: Anti-retroviral therapy (ART)

HAART OR "anti?retroviral therapy" OR "anti?retroviral treatment" OR "highly active anti?retroviral therapy" OR "highly active anti?retroviral treatment" OR "HIV treatment" OR "anti-HIV agents" OR "AIDS treatment" OR exp anti-hiv agents/ OR exp HIV fusion inhibitors/ OR exp HIV integrase inhibitors/ OR exp HIV protease inhibitors/ OR exp antiretroviral therapy, highly active/

3.2 Embase search strategy

The search strategy was as follows:

- **NSP**: results were restricted to those articles for containing terms from Search 1 and 2 (combined using 'AND') published 2010-Current.
- **OST:** results were restricted to those articles containing terms from Search 1 and Search 3 (combined using 'AND') published 2010-Current.
- ART: results were restricted to those articles containing terms from Search 1 and Search 4 (combined using 'AND') published 2010-Current.

Key-words are noted in regular type, 'EMTREE' terms in **bold**.

Search 1: Injecting drug use

IDU\$1 OR IVDU\$1 OR PWID\$1 OR "injecting drug" OR "intravenous drug" OR "injecting substance" OR "intravenous substance" OR exp intravenous drug abuse/ OR exp substance abuse, intravenous/

Search 2: Needle syringe program (NSP)

NSP\$1 or NSEP\$1 OR "needle syringe program\$" OR "needle syringe exchange program\$" OR "needle exchange\$1" OR "syringe exchange \$1" OR exp preventative health service/

Search 3: Opioid substitution treatment (OST)

OST OR MMT OR BMT OR "opioid substitution treatment" OR "methadone" OR "methadone maintenance" OR "buprenorphine" OR "buprenorphine maintenance" OR "opioid replacement" OR exp buprenorphine/ OR exp methadone/ OR exp opiate substitution treatment/ OR exp methadone treatment/ OR exp buprenorphine plus naloxone/

Search 4: Anti-retroviral therapy (ART)

HAART OR "anti?retroviral therapy" OR "anti?retroviral treatment" OR "highly active anti?retroviral therapy" OR "highly active anti?retroviral treatment" OR "HIV treatment" OR "anti-HIV agents" OR "AIDS treatment" OR exp anti human immunodeficiency virus agent/ OR exp anti human immunodeficiency virus fusion inhibitors/ OR exp highly active antiretroviral therapy/

3.3 PsycINFO search strategy

The search strategy was as follows:

• **NSP**: results were restricted to those articles for containing terms from Search 1 and 2 (combined using 'AND') published 2010-Current.

- **OST:** results were restricted to those articles containing terms from Search 1 and Search 3 (combined using 'AND') published 2010-Current.
- ART: results were restricted to those articles containing terms from Search 1 and Search 4 (combined using 'AND') published 2010-Current.

Key-words are noted in regular type, 'PsycINFO thesaurus' terms in **bold.**

Search 1: Injecting drug use

IDU\$1 OR IVDU\$1 OR PWID\$1 OR "injecting drug" OR "intravenous drug" OR "injecting substance" OR "intravenous substance" OR exp intravenous drug abuse/ OR exp intravenous injections/

Search 2: Needle syringe program (NSP)

NSP\$1 or NSEP\$1 OR "needle syringe program\$" OR "needle syringe exchange program\$" OR "needle exchange\$1" OR "syringe exchange \$1" OR exp needle-exchange programs/ OR exp harm reduction/

Search 3: Opioid substitution treatment (OST)

OST OR MMT OR BMT OR "opioid substitution treatment" OR "methadone" OR "methadone maintenance" OR "buprenorphine" OR "buprenorphine maintenance" OR "opioid replacement" OR **exp buprenorphine**/ OR **exp methadone**/ OR **exp methadone** maintenance

Search 4: Anti-retroviral therapy (ART)

HAART OR "anti?retroviral therapy" OR "anti?retroviral treatment" OR "highly active anti?retroviral therapy" OR "highly active anti?retroviral treatment" OR "HIV treatment" OR "anti-HIV agents" OR "AIDS treatment"

Appendix 4: Grey literature search

| Source | Strategy/ Comments | Documents Found N | Relevant Documents N |
|--|--|-------------------------|----------------------------|
| Asian Pacific ATS Information Centre (APAIC) http://www.apaic.org/ | Searched website using Google advanced search. Used the terms: | 41 | 0 |
| | "Inject Drug Use" OR IDU OR "People Who Inject Drugs" OR PWID | | |
| | Some relevant results so then searched: | | |
| | HIV OR AIDS OR "HIV/AIDS " | | |
| | OST OR "opiate substitution treatment" OR "Methadone Maintenance Treatment" OR MMT or | | |
| | Methadone OR Buprenorphine OR "Drug Treatment" OR "harm reduction" OR "needle provision" OR | | |
| | "Needle and Syringe Programme" OR NSP OR "Syringe Exchange Programme" OR SEP | | |
| | "Anti-Retroviral Therapy" OR ART OR "Highly Active Antiretroviral Therapy" OR HAART OR "HIV | | |
| | Treatment" OR Condom OR "Targeted Information" OR Counseling OR VCT OR Testing | | |
| | Checked SMART publications | | |
| Bahrain: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.bh/ | "Inject Drug Use" OR IDU OR "People Who Inject Drugs" OR PWID No responses | 0 | |
| Bangladesh Ministry of Health and Family | Google advanced search using the terms: | | |
| Welfare | "Inject Drug Use" OR IDU OR "People Who Inject Drugs" OR PWID | | |
| http://www.mohfw.gov.bd/ | Some relevant results so then searched: | | |
| | HIV OR AIDS OR "HIV/AIDS" | 47 | 0 |
| | OST OR "opiate substitution treatment" OR "Methadone Maintenance Treatment" OR MMT or | 17 | 2 |
| | Methadone OR Buprenorphine OR "Drug Treatment" OR "harm reduction" OR "needle provision" OR | | |
| | "Needle and Syringe Programme" OR NSP OR "Syringe Exchange Programme" OR SEP | | |
| | Note: of the two documents I found, one is a newsletter which I highly doubt will be relevant. However, | | |
| | has in English "National Strategic Plan for HIV/AIDS", but the rest is in Bengali and Google translate cannot give me anything meaningful from the document. | | |
| | "Anti-Retroviral Therapy" OR ART OR "Highly Active Antiretroviral Therapy" OR HAART OR "HIV | | |
| | Treatment" OR Condom OR "Targeted Information" OR Counseling OR VCT OR Testing | 20 | |
| | | 38 | 3 |

| | Looked at annual reports 2010 – 2016. Mostly Bengali, but translated refs to ART indicates these were the targets to achieve and not current prevalence | | |
|--|---|-----|---|
| | | 4 | 1 |
| Brunei Ministry of Health http://www.moh.gov.bn/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID No responses | 0 | |
| Dangerous Drugs Board: Republic of the Philippines http://www.ddb.gov.ph/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID No responses | 0 | |
| Hong Kong Dept of Health http://www.dh.gov.hk | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results so then searched: OST "opiate substitution" "Methadone Maintenance" MMT Methadone Buprenorphine "Drug Treatment" "harm reduction" "needle provision" "Needle and Syringe Program" NSP "Syringe Exchange Program" SEP "Anti-Retroviral Therapy" ART "Highly Active Antiretroviral Therapy" HAART "HIV Treatment" Condom "Targeted Info" Counselling VCT "HIV Testing" "Hepatitis C" "Hepc" | 936 | 3 |

| | "HIV" OR "AIDS" OR "HIV/AIDS" | | |
|--|---|-----|---|
| Iranian National Centre for Addiction Studies (INCAS) http://incas.tums.ac.ir/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results, but all in Arabic. Searching the website not bringing up any relevant hits. | 0 | |
| Japan - Ministry of Health, Labour and Welfare http://www.mhlw.go.jp/index.html | Google advanced search in Japanese using the terms: 注射薬物使用 ("Inject Drug Use") | 0 | |
| | 薬物を注射人々 (People Who Inject Drugs) And in the English version of the site (http://www.mhlw.go.jp/english/ using the terms "Inject Drug Use" OR IDU OR "People Who Inject Drugs" OR PWID | | |
| Malaysian AIDS Council & Malaysian AIDS Foundation http://www.mac.org.my/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results so then searched: OST "Opiate substitution" MMT Methadone Buprenorphine Opioid agonist OAT Medication Assisted MAT "Drug Treatment" "harm reduction" "needle provision" "Needle and Syringe Program" NSP "Syringe Exchange Program" SEP "Antiretroviral Therapy" ART "Highly Active Antiretroviral Therapy" HAART "HIV Treatment" Condom | 790 | 7 |

| | Counselling VCT "HIV Testing" "Hepatitis C" "Hep C" "HIV" OR "AIDS" OR "HIV/AIDS" | | |
|---|--|---|-----------------------|
| Maldives: Ministry of Health and family http://www.health.gov.mv/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results so then searched: OST "opiate substitution" MMT Methadone Buprenorphine Opioid agonist OAT Medication Assisted MAT "Drug Treatment" "harm reduction" "needle provision" "Needle and Syringe Program" NSP "Syringe Exchange Program" SEP "Antiretroviral Therapy" ART "Highly Active Antiretroviral Therapy" HAART "HIV Treatment" Condom "Targeted Info" Counselling VCT "HIV Testing" "Hepatitis C" "Hep C" "HIV" OR "AIDS" OR "HIV/AIDS" | 5 0 4 4 4 1 1 0 0 0 1 1 1 4 0 0 0 2 4 8 8 2 8 0 0 0 0 0 1 1 1 2 0 0 0 0 0 0 0 0 0 0 0 | 0 0 0 1 0 |
| | THE ON THES ON THEY THE | | _ |

| Myanmar: Ministry of Health http://www.moh.gov.mm/ | Google advanced search using the terms: "Injust Price Use" IPU "People Who Injust Price" PAUD Some relevant recults so then searched. "Injust Price Use" IPU "People Who Injust Price" PAUD Some relevant recults so then searched. | | |
|---|---|----|---|
| ttp://www.mon.gov.mm/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results so then searched: OST | | |
| | "opiate substitution" | 1 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 1 | 1 |
| | Buprenorphine | 2 | 1 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 4 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 0 | 0 |
| | "harm reduction" | 2 | 0 |
| | "needle provision" | 2 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 0 | 0 |
| | "Syringe Exchange Program" | 2 | 0 |
| | SEP | 0 | 0 |
| | "Antiretroviral Therapy" | 2 | 0 |
| | ART | 1 | 1 |
| | "Highly Active Antiretroviral Therapy" | 6 | 1 |
| | HAART | 0 | 0 |
| | "HIV Treatment" | 0 | 0 |
| | Condom | 22 | 1 |
| | "Targeted Info" | 3 | 1 |
| | Counselling | 2 | 0 |
| | VCT | 1 | 0 |
| | "HIV Testing" | 0 | 0 |
| | "Hepatitis C" | 3 | 0 |
| | "Hep C" | 4 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 4 | 0 |
| | | 36 | 1 |
| linistry of Public Health of Afghanistan | Google advanced search using the terms: | | |
| http://www.moph.gov.af/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| arcotics Division, Security Bureau Hong | Google advanced search using the terms: | | |
| Cong | "Inject Drug Use" IDU "People Who Inject Drugs" PWID Looked at website – in Chinese. Searched " | 0 | 0 |
| ttp://www.nd.gov.hk/whatnews.htm | 注入" (inject) and " | | |
| | 药物" (drug) | | |
| | Checked main website in English – lists services for heroin users: | 4 | 4 |

| | http://www.nd.gov.hk/en/services_ha.htm | | |
|--|---|----|---|
| Nai Zindagi Trust Pakistan | Google advanced search using the terms: | | |
| http://www.naizindagi.com | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Some relevant results so then searched: | | |
| | OST | 0 | 0 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 0 | 0 |
| | Buprenorphine | 0 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 1 | 0 |
| | "harm reduction" | 17 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 0 | 0 |
| | "Syringe Exchange Program" | 0 | 0 |
| | SEP | 0 | 0 |
| | "Antiretroviral Therapy" | 0 | 0 |
| | ART | 4 | 0 |
| | "Highly Active Antiretroviral Therapy" | 0 | 0 |
| | HAART | 0 | 0 |
| | "HIV Treatment" | 0 | 0 |
| | Condom | 0 | 0 |
| | "Targeted Info" | 0 | 0 |
| | Counselling | 0 | 0 |
| | VCT | 1 | 0 |
| | "HIV Testing" | 1 | 0 |
| | "Hepatitis C" | 0 | 0 |
| | "Hep C" | 0 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 25 | 0 |
| | Searched website reports | | 2 |
| lational Statistical Institutes in Asia ttp://www.stat.fi/tup/tilvir/julkaisijat aasi | Used google advanced search to search the sites of the following countries using the terms "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| <u>tilastovirastot_en.html</u> | Afghanistan | | |
| | Armenia | 0 | 0 |

| | Azerbaijan | 0 | 0 |
|------------------------------------|--|----|---|
| | Bahrain | 0 | 0 |
| | Also checked health reports on website – no relevant info | 0 | 0 |
| | Bangladesh | | |
| | Bhutan | 0 | 0 |
| | Cambodia | 0 | 0 |
| | East Timor | 0 | 0 |
| | Georgia | 0 | 0 |
| | Hong Kong | 0 | 0 |
| | • India | 0 | 0 |
| | • Indonesia | 46 | 2 |
| | • Japan | 0 | 0 |
| | Jordan | 0 | 0 |
| | Korea | 0 | 0 |
| | Kyrgyzstan | 0 | 0 |
| | • Lebanon | 0 | 0 |
| | Macao | 4 | 0 |
| | Malaysia | 0 | 0 |
| | Maldives | 0 | 0 |
| | Mongolia | 0 | 0 |
| | Myanmar | 0 | 0 |
| | Nepal | 0 | 0 |
| | Palestine | 0 | 0 |
| | | 0 | 0 |
| | • Singapore | | 0 |
| | Sri Lanka Tri Canka | 0 | 0 |
| | • Taiwan | | _ |
| | Thaimaa | 0 | 0 |
| | • Turkey | 0 | 0 |
| | • Vietnam | 0 | 0 |
| | • Yemen | 0 | 0 |
| | Countries listed on site but not here had broken click through links | U | U |
| Recovering Nepal | Google advanced search using the terms: | | |
| http://www.recoveringnepal.org.np/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Some relevant results so then searched: | | |
| | OST | 6 | 2 |
| | "opiate substitution" | 2 | 0 |
| | MMT | 0 | 0 |
| | | | |

| | Buprenorphine | 5 | 0 |
|--------------------------|---|----|---|
| | Opioid agonist | 1 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 1 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 5 | 0 |
| | "harm reduction" | 24 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 2 | 0 |
| | "Syringe Exchange Program" | 1 | 0 |
| | SEP | 1 | 0 |
| | "Antiretroviral Therapy" | 3 | 0 |
| | ART | 3 | 0 |
| | "Highly Active Antiretroviral Therapy" | 2 | 0 |
| | HAART | 1 | 0 |
| | "HIV Treatment" | 12 | 0 |
| | Condom | 9 | 0 |
| | "Targeted Info" | 2 | 0 |
| | Counselling | 3 | 0 |
| | VCT | 4 | 0 |
| | "HIV Testing" | 5 | 0 |
| | "Hepatitis C" | 5 | 0 |
| | "Hep C" | 6 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 16 | 0 |
| | THE ON THE ON THE PARTY OF THE | 10 | Ü |
| Oman: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.om/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID Some relevant results so then searched: | 2 | 0 |
| | OST | | |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 0 | 0 |
| | Buprenorphine | 0 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 0 | 0 |
| | "harm reduction" | 0 | 0 |
| | | 0 | 0 |
| | "needle provision" | U | U |

| | "Needle and Syringe Program" | 0 | 0 |
|--|--|------------|---|
| | NSP | 1 | 0 |
| | "Syringe Exchange Program" | 0 | 1 |
| | SEP | 0 | 0 |
| | "Antiretroviral Therapy" | 17 | 0 |
| | ART | 4 (1 would | 1 |
| | "Highly Active Antiretroviral Therapy" | not open) | |
| | HAART | | 0 |
| | "HIV Treatment" | 5 | 0 |
| | Condom | 3 (1 would | 0 |
| | "Targeted Info" | not open) | 0 |
| | Counselling | 3 | 0 |
| | VCT | 20 | 0 |
| | "HIV Testing" | 2 | 0 |
| | "Hepatitis C" | 1 | 0 |
| | "Hep C" | 2 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 0 | 0 |
| | | 8 | 0 |
| | | 21 | 0 |
| | | 0 | |
| | | 89 | |
| Saudi Arabia: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.sa/en/index.php | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| Singapore: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.sg/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID No relevant results | 1 0 |) |
| | | | |
| Syrian Arab Republic: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.sy/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 0 |) |
| Tajikistan: Ministry of Health | Google advanced search using the terms: | | |
| http://www.health.tj/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 0 |) |
| | Google advanced search "дору фиристондан" (inject) | | |
| | O | 0 0 |) |
| Thailand: Ministry of Public Health | Google advanced search using the terms: | | |
| http://www.moph.go.th/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 0 |) |
| | Google advanced search " an" (inject) | 3 | |
| | Soogle dataficed section will (inject) | 3 0 |) |
| Tunisia: Ministère de la santé Publique | Google advanced search using the terms: | | |
| http://www.santetunisie.rns.tn/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 0 | |
| United Arab Emirates: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.ae/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 0 |) |
| interit i and an interinguality | inject brug ose ibo reopie wito inject brugs rwib | 0 0 | , |

| Alcohol Advisory Council of New Zealand | Google advanced search using the terms: | | |
|--|--|-----|---|
| (ALAC) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| http://www.alac.org.nz/ | inject 5.46 535 150 Teopie Willo inject 51465 TWID | | |
| Australian Government Department of Health | Google advanced search using the terms: | | |
| http://www.health.gov.au | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Many relevant results so then searched: | | |
| | OST | 54 | 0 |
| | "opiate substitution" | 5 | 0 |
| | MMT | 20 | 0 |
| | Methadone | 130 | 1 |
| | Buprenorphine | 71 | 0 |
| | Opioid agonist | 11 | 0 |
| | OAT | 58 | 0 |
| | Medication Assisted | 7 | 0 |
| | MAT | 62 | 0 |
| | "Drug Treatment" | 215 | 3 |
| | "harm reduction" | 173 | 1 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 67 | 0 |
| | NSP | 70 | 1 |
| | "Syringe Exchange Program" | 14 | 0 |
| | SEP | - | - |
| | "Antiretroviral Therapy" | 57 | 0 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 176 | 0 |
| | "Highly Active Antiretroviral Therapy" | | |
| | HAART | | |
| | "HIV Treatment" | | |
| | Condom | | |
| | "Targeted Info" | | |
| | Counselling | | |
| | VCT | | |
| | "HIV Testing" | | |
| | "Hepatitis C" | | |
| | "Hep C" | | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | | |
| | Stopped searching as Louisa said that Australia was already covered. | | |
| Fiji: Ministry of Health | Google advanced search using the terms: | | |
| http://www.health.gov.fj/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |

| amoa: Ministry of Health | Google advanced search using the terms: | | 0 |
|---|--|-----|---|
| tp://www.health.gov.ws/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| aribbean Public Health Agency | Google advanced search using the terms: "" | | |
| tp://carpha.org/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Some relevant results so then searched | | |
| | OST | 2 | 0 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 0 | 0 |
| | Buprenorphine | 0 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 10 | 0 |
| | "harm reduction" | 2 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 15 | 0 |
| | "Syringe Exchange Program" | 0 | 0 |
| | SEP | 27 | 0 |
| | "Antiretroviral Therapy" | 12 | 0 |
| | ART | 35 | 0 |
| | "Highly Active Antiretroviral Therapy" | 6 | 0 |
| | HAART | 5 | 0 |
| | "HIV Treatment" | 54 | 0 |
| | Condom | 23 | 0 |
| | "Targeted Info" | 10 | 0 |
| | Counselling | 21 | 0 |
| | VCT | 11 | 0 |
| | "HIV Testing" | 45 | 0 |
| | "Hepatitis C" | 28 | 0 |
| | "Hep C" | 28 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 124 | 0 |
| | | | |
| cohol Concern (UK) | Google advanced search using the terms: | | |
| :p://www.alcoholconcern.org.uk/serv me | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| dorra: Ministry of Health and Welfare | Google advanced search using the terms: | | |

| h.u., // | Western Down Health (Decorate Miles Indicate Downson) DMID | | |
|---|---|----|---|
| http://www.salutibenestar.ad | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| Acceptaint Fording I Ministry of an Hoolth Q Manage | Searched "injectar" (inject in Catalan) | 0 | 0 |
| Austria: Federal Ministry for Health & Women | Google advanced search using the terms: "" "" "" "" "" "" "" "" "" | | |
| http://www.bmgf.gv.at | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Some relevant results so then searched (only English results) | | 2 |
| | OST | 9 | 2 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 6 | 0 |
| | Buprenorphine | 7 | 0 |
| | Opioid agonist | 1 | 0 |
| | OAT | 3 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 10 | 0 |
| | "harm reduction" | | |
| | "needle provision" | 21 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 0 | 0 |
| | "Syringe Exchange Program" | 0 | 0 |
| | SEP | 0 | 0 |
| | "Antiretroviral Therapy" | 7 | 0 |
| | ART | 2 | 0 |
| | "Highly Active Antiretroviral Therapy" | 77 | 0 |
| | HAART | 2 | 0 |
| | "HIV Treatment" | 1 | 0 |
| | Condom | 18 | 0 |
| | "Targeted Info" | 3 | 0 |
| | Counselling | 14 | 0 |
| | VCT | 39 | 0 |
| | "HIV Testing" | 0 | 0 |
| | "Hepatitis C" | 6 | 0 |
| | "Hep C" | 13 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 0 | 0 |
| | • | 41 | 0 |
| Belgium: Scientific Institute of Public Health | Google advanced search using the terms: | | |
| http://www.iph.fgov.be | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 3 | 0 |
| Harriet had issues using above page. Found | , | | |
| that website may have changed to: | | | |
| https://www.wiv-isp.be | | | |

| | "Inject drug use" and People who Inject Drugs | 129 | 0 |
|---|---|------|---|
| | OST | 261 | 1 |
| | "opiate substitution" | 8 | 1 |
| | MMT | 0 | 0 |
| | Methadone | 162 | 2 |
| | | 81 | 0 |
| | Buprenorphine | 13 | 0 |
| | Opioid agonist OAT | 2 | 0 |
| | | 23 | 0 |
| | Medication Assisted | | |
| | MAT | 126 | 0 |
| | "Drug Treatment" | 160 | 0 |
| | "harm reduction" | 100 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 1 | 0 |
| | NSP | 36 | 0 |
| | "Syringe Exchange Program" | 1 | 0 |
| | SEP | | |
| | "Antiretroviral Therapy" | 590 | 0 |
| | ART | 28 | 2 |
| | "Highly Active Antiretroviral Therapy" | 810 | 0 |
| | HAART | 5 | 0 |
| | "HIV Treatment" | 10 | 0 |
| | Condom | 5 | 0 |
| | "Targeted Info" | 127 | 0 |
| | Counselling | 2 | 0 |
| | VCT | 83 | 0 |
| | "HIV Testing" | 3 | 0 |
| | "Hepatitis C" | 87 | 0 |
| | "Hep C" | 608 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 3 | 0 |
| | *Found report on drug consumptions rooms in EU while searching methadone in this search.* | 1530 | 0 |
| Bulgaria: Ministry of Health | Google advanced search using the terms: | | |
| www.mh.government.bg | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 2 | 0 |
| Centre for Drug Misuse Research, University | Google advanced search using the terms: | | |
| of Glasgow | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| http://www.gla.ac.uk/departments/drugmis | Looked at website- site not found | | |
| use/ | ESONOU AC TOUSING THE HOLF TOUTING | | |
| Centre for Drug Research, University of | Google advanced search using the terms: | | |
| | | 0 | 0 |
| Amsterdam, the Netherlands | | 0 | 0 |

| http://www.cedro-uva.org/index.html | Looked at website- site discontinued | | |
|--|---|----|---|
| Chile: Ministry of Health | Google advanced search using the terms: | | |
| http://www.minsal.cl/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| | | | |
| | searched "inyectar" and "droga" | 3 | 0 |
| | Note: for some reason this is in the Europe section and not South America in the tech report | | |
| Croatia: Ministry of Health and Social Welfare | Website in Croatian. Searched: | | |
| http://www.mzss.hr/ | Ubrizgati (injecting) | 0 | 0 |
| | Droga (drug) | 75 | |
| | As droga results all in croatian refined to: | | |
| | ubrizgati lijek (inject drug) | 0 | 0 |
| | See if Easern European team can work on this | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Cyprus: Ministry of Health | Google advanced search using the terms: | | |
| http://www.moh.gov.cy | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| | • | | |
| Czech Republic: Ministry of Health | Eastern Europe country offices are providing information to study directly | | |
| http://www.mzcr.cz/ | | | |
| Czech Republic: National Institute of Public | Eastern Europe country offices are providing information to study directly | | |
| Health (NIPH) | | | |
| http://www.szu.cz | | | |
| Department of Health, England | Advanced Search got no results from site recommended in tech report | | |
| https://www.gov.uk/government/publicatio | (http://www.dh.gov.uk/en/index.htm) but searching publications for injecting drug use got 21611 | | |
| <u>ns</u> | results. Advanced searched publications link instead. | | |
| | | | |
| | Google advanced search using the terms: | | |
| | "Inject Drug Use" IDU "People Who Inject Drugs" PWID – some relevant results | | |
| | Searched: | | |
| | OST | | |
| | "opiate substitution" | 5 | 0 |
| | MMT | 2 | 0 |
| | Methadone | 0 | 0 |
| | Buprenorphine | 4 | 0 |
| | Opioid agonist | 2 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 5 | 0 |
| | MAT (excluding "multi-academy" and "maternity) | 0 | 0 |

| "Drug Treatment" | 27 | 0 |
|--|-----|---|
| "harm reduction" (excluding "self harm") | 68 | 0 |
| "needle provision" | 24 | 0 |
| "Needle and Syringe Program" | 0 | 0 |
| NSP | 0 | 0 |
| "Syringe Exchange Program" | 5 | 0 |
| SEP (excluding "september", "to sep" "-sep") | 0 | 0 |
| "Antiretroviral Therapy" | 0 | 0 |
| ART | 10 | 1 |
| "Highly Active Antiretroviral Therapy" | 330 | 0 |
| HAART | 0 | 0 |
| "HIV Treatment" | 100 | 0 |
| Condom | 7 | 0 |
| "Targeted Info" | 90 | 0 |
| Counselling | 59 | 0 |
| VCT (excluding "Venture Capital Trust") | 11 | 0 |
| "HIV Testing" | 70 | 3 |
| "Hepatitis C" | 124 | 1 |
| "Hep C" | 136 | 1 |
| "HIV" OR "AIDS" OR "HIV/AIDS" | 353 | 1 |
| | | |

| New Zealand: Ministry of Health | Google advanced search using the terms: | | |
|---------------------------------|--|-----|---|
| http://www.moh.gov.nz | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 29 | 0 |
| | OST | 74 | 0 |
| | "opiate substitution" | 6 | 0 |
| | MMT | 31 | 0 |
| | Methadone | 278 | 0 |
| | Buprenorphine | 39 | 0 |
| | Opioid agonist | 6 | 0 |
| | OAT | 34 | 0 |
| | Medication Assisted | 1 | 0 |
| | MAT | 130 | 0 |
| | "Drug Treatment" | 283 | 0 |
| | "harm reduction" | 140 | 0 |
| | "needle provision" | 205 | 0 |

| | "Needle and Syringe Program" | 1 | 0 |
|--|--|-----|---|
| | NSP | 29 | 0 |
| | "Syringe Exchange Program" | 2 | 0 |
| | SEP | 80 | 0 |
| | "Antiretroviral Therapy" | 29 | 0 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 506 | 0 |
| | "Highly Active Antiretroviral Therapy" | 8 | 0 |
| | HAART | 6 | 0 |
| | "HIV Treatment" | 5 | 0 |
| | Condom | 87 | 0 |
| | | | _ |
| | "Targeted Info" | 13 | 0 |
| | Counselling (1090 results, changed to Testing and counselling) | 9 | 0 |
| | VCT | 0 | 0 |
| | "HIV Testing" | 66 | 0 |
| | "Hepatitis C" | 238 | 0 |
| | "Hep C" | 8 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | | |
| | | 679 | 1 |
| | | | |
| African Development Bank Group | Google advanced search using the terms: | 0 | 0 |
| (African Development Bank, The African | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| Development Fund and The Nigeria Trust | | | |
| Fund) | | | |
| http://www.afdb.org/en/ | | | |
| AIDS Foundation South Africa | Google advanced search using the terms: | 0 | 0 |
| http://www.aids.org.za/index.htm | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | U | U |
| ittp://www.aius.org.za/iiiuex.iitiii | | 2 | 0 |
| | Tried again omitting /index.htm | 3 | 0 |
| Egypt: Ministry of Health and Population | Google advanced search using the terms: | 2 | |
| http://www.mohp.gov.eg/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Inject drug use - "حقن تعاطي المخدرات" | 0 | |
| | People who inject drugs "الناس الذين يتعاطون المخدرات بالحقن" | 0 | |
| Mauritius: Ministry of Health and Quality of | Google advanced search using the terms: | | |
| Life | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| http://health.govmu.org/English/the- | | | |
| ministry/Pages/default.aspx | Tried again omitting /English/the-ministry/Pages/default.aspx from domain search | 2 | 0 |
| | Searched in French: | | |
| | "Injecter de la drogue" -Inject drug use | 0 | 0 |
| | "Personnes qui s'injectent des drogues" -People who inject drugs | 0 | 0 |
| National Ctatistical Institutes in Africa | | U | U |
| National Statistical Institutes in Africa | Google advanced search using the terms: | 0 | 0 |
| | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |

| http://www.stat.fi/tup/tilvir/julkaisijat afri | | | | |
|--|--|---|-------|--|
| kka tilastovirastot en.html | | | | |
| Nicaragua: Ministerio de Salud | Google advanced search using the terms: | | | |
| http://www.minsa.gob.ni/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 | |
| nttp.//www.mmsa.gob.m/ | "Inyectar drogas" -Inject drug use | 0 | | |
| | "Personas que se inyectan drogas" –People who inject drugs | 0 | | |
| South African Ministries of Health | | Ü | U | |
| | Google advanced search using the terms: | 0 | 0 | |
| http://www.doh.gov.za | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | _ | |
| | "mense wat dwelms te spuit" –People who inject drugs | 0 | _ | |
| | "spuit dwelmgebruik" –Inject drug use | 0 | 0 | |
| South African Community Epidemiology | Google advanced search using the terms: | | | |
| Network on drug Use (SACENDU) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | | |
| http://www.mrc.ac.za/adarg/sacendu.htm | "mense wat dwelms te spuit" –People who inject drugs | 0 | | |
| | "spuit dwelmgebruik" –Inject drug use | 0 | 0 | |
| Sudan: Ministry of Health | Google advanced search using the terms: | | | |
| http://www.fmoh.gov.sd/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | _ | |
| | Inject drug use - "حقن تعاطي المخدرات" | 0 | | |
| | People who inject drugs– "الناس الذين يتعاطون المخدرات بالحقن" | 0 | 0 | |
| National Statistics Institutes in the Americas | Google advanced search using the terms: | | | |
| http://www.stat.fi/tup/tilvir/julkaisijat_ame | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 | |
| rikka_tilastovirastot_en.html | Tried again omitting: /tup/tilvir/julkaisijat_amerikka_tilastovirastot_en.html | 0 | 0 | |
| Honduras: Secretaría de Salud | Google advanced search using the terms: | | | |
| http://www.salud.gob.hn/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 | |
| | "Inyectar drogas" -Inject drug use | 0 | 0 | |
| | "Personas que se inyectan drogas" –People who inject drugs | 0 | 0 | |
| Inter-American Drug Abuse Control | Google advanced search using the terms: | | | |
| Commission (CICAD) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 | |
| http://www.cicad.oas.org/Main/default_EN | Tried again omitting /Main/default_ENG.asp | 1 | 8 | |
| G.asp | OST | | | |
| | "opiate substitution" | 4 | 1 | |
| | MMT | 0 | 0 | |
| | Methadone | 1 | 41 1 | |
| | Buprenorphine | 5 | 0 2 | |
| | Opioid agonist | 3 | | |
| | OAT | 1 | | |
| | Medication Assisted | 1 | | |
| | MAT | 1 | | |
| Searched "Drug Treatment" minus | "Drug Treatment" | _ | 390 0 | |
| words "court" and "courts" | "harm reduction" | | 17 0 | |
| words court and courts | "needle provision" | 0 | | |
| | needle provision | 0 | 0 | |

| • 7 hits for "needle provision" search | "Needle and Syringe Program" | 82 | 0 |
|--|--|------|---|
| without quotation marks | NSP | 64 | 0 |
| | "Syringe Exchange Program" | 1 | 0 |
| | SEP | 169 | 0 |
| | "Antiretroviral Therapy" | 6 | 0 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 1110 | 0 |
| | "Highly Active Antiretroviral Therapy" | 2 | 0 |
| | HAART | 3 | 0 |
| | "HIV Treatment" | 3 | 0 |
| | Condom | 5 | 0 |
| | "Targeted Info" | 0 | 0 |
| | Counselling (1090 results, changed to Testing and counselling) | 124 | 1 |
| | VCT | 3 | 0 |
| | "HIV Testing" | 4 | 0 |
| | "Hepatitis C" | 100 | 3 |
| | | | |
| | "Hep C" | 5 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 468 | 0 |
| Denmark: Ministry of Health and Prevention | Google advanced search using the terms: | | |
| http://www.sum.dk/English.aspx | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| | Searched website publications using term "indsprøjte" (inject) | 0 | 0 |
| | Sectioned Resolve publications doing term interpretation (inject) | | |
| Denmark: Statens Serum Institute | Google advanced search using the terms: | | |
| http://www.ssi.dk/English.aspx | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| | Searched website publications using term "indsprøjte" (inject) | 0 | 0 |
| | | | |
| Drug Misuse Information, Scotland | Site could not be reached | | |
| www.drugmisuse.isdscotland.org | | | |
| DrugWise (formerly DrugScope UK) | Google advanced search using the terms: | | |
| http://www.drugwise.org.uk/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Relevant results so then searched | | |
| | OST | 11 | 0 |
| | "opiate substitution" | 18 | 0 |
| | MMT | 7 | 0 |
| | Methadone | 313 | 0 |
| | Buprenorphine | 64 | 0 |
| | Opioid agonist Control of the Contro | 3 | 0 |
| | OAT | 1 | 0 |
| | Medication Assisted | 6 | 0 |
| | MAT | 21 | 0 |
| | IVIAT | 21 | U |

| | "Drug Treatment" | 170 | 2 |
|--|---|-----|---|
| | "harm reduction" | 301 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 5 | 1 |
| | Needle exchange program (added based on google recommendation) | 86 | 0 |
| | "Syringe Exchange Program" | 1 | 0 |
| | SEP | | |
| | "Antiretroviral Therapy" | | |
| | ART (specified not "Assisted -Reproductive –Technologies") | | |
| | "Highly Active Antiretroviral Therapy" | | |
| | HAART | | |
| | "HIV Treatment" | | |
| | Condom | | |
| | "Targeted Info" | | |
| | Counselling (1090 results, changed to Testing and counselling) | | |
| | VCT | | |
| | "HIV Testing" | | |
| | "Hepatitis C" | | |
| | "Hep C" | | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | | |
| | | | |
| Inter-American Observatory on Drugs | Advanced Google search using the terms: | 8 | 0 |
| http://www.cicad.oas.org/OID/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| publications: | Many duplicates from 28 Nov search. | | |
| http://www.oas.org/en/information_center | 7.4 | 0 | 0 |
| /publications.asp | Also searched "Inject drug use", "IDU", "People who inject drugs", "PWID" | | |
| Panama: Ministerio de Salud | Google advanced search using the terms: | | |
| http://www.minsa.gob.pa/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 | 0 |
| | "Inyectar drogas" -Inject drug use | 0 | 0 |
| | "Personas que se inyectan drogas" –People who inject drugs | 0 | 0 |
| Paraguay: Ministerio de Salud Pública y | Google advanced search using the terms: | | - |
| Bienestar Social | "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 1 | 0 |
| http://www.mspbs.gov.py/ | "Inyectar drogas" -Inject drug use | 0 | 0 |
| | "Personas que se inyectan drogas" –People who inject drugs | 0 | 0 |
| Uruguay: Ministerio de Salud Pública | Google advanced search using the terms: | | |
| , <u> </u> | "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 0 | 0 |
| | "Inyectar drogas" -Inject drug use | 0 | 0 |
| | "Personas que se inyectan drogas" –People who inject drugs | 0 | 0 |
| | | | |

| North America: CDC Behavioural Risk Factor Surveillance System (BRFSS) http://www.cdc.gov/brfss/ | Google advanced search using the terms: "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 0 | 0 |
|---|--|-----|---|
| North America: Bureau of Justice Statistics | Google advanced search using the terms: "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 2 | 0 |
| Finland: Ministry of Social Affairs and Health http://www.stm.fi/ | Google advanced search using the terms: "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 0 | 0 |
| | Searched publications on website in English | 0 | 0 |
| Sweden: Ministry of Health and Social Affairs | IDU | 0 | |
| http://www.government.se/government-of- | Inject Drug Use | 0 | |
| sweden/ministry-of-health-and-social- | PWID | 0 | |
| affairs/ | People who inject drugsx | 0 | |
| French Monitoring Centre for Drugs and Drug Addiction ("Observatoire Français des Drogues et des Toxicomanies": OFDT) http://en.ofdt.fr/publications/ | Searched publications by hand | 8 | 1 |
| France: Institut de veille sanitaire http://www.invs.sante.fr | Searched "injecter" (google translate French for inject), no results. Scanned results for alternative spelling "injector", no relevant results | 24 | 0 |
| Germany: The Federal Ministry of Health http://www.bmg.bund.de/en.html | Google advanced search using the terms: "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 0 | 0 |
| Greenland Population Health Survey http://www.si-folkesundhed.dk/?lang=en | Google advanced search using the terms: "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 2 | 0 |
| Ministry of Healthcare Armenia | IDU | 0 | |
| http://www.moh.am | Inject Drug Use | 0 | |
| | PWID | 0 | |
| | People who inject drugs | 0 | |
| Malta: Ministry of Social Policy | IDU | 0 | |
| http://www.sahha.gov.mt/pages.aspx | Inject Drug use | 0 | |
| | PWID | 0 | |
| | People who inject drugs | 0 | |
| | Redirects to - http://health.gov.mt/en/Pages/health.aspx Have searched both sites | | |
| Turkey: Ministry of Health | In Turkish – translations | | |
| http://www.saglik.gov.tr | IDU – IDU | 33 | _ |
| | Inject Drug Use - İlaç Kullanımını Enjekte Edin | 121 | _ |

| PWID - PWID | 0 | - |
|--|---------------|-----|
| People who Inject Drugs - Uyuşturucu enjekte e | edenler 36 | - |
| | - | - |
| "Afyon ikamesi" – opiate substitution | 22 | 0 |
| MMT | 25 | 0 |
| metadon | 61 | 0 |
| Buprenorfin | 5 | 0 |
| Opioid agonisti | 1 | 0 |
| İlaç Destekli | No results in | - |
| "İlaç Tedavisi" | quotes- | - |
| "Zarar azaltma" | 45 | 0 |
| "Iğne sağlama" | 3 | |
| "İğne ve Şırınga Programı" | No results in | |
| NSP | quotes | 0 |
| "Şırınga Değişimi Programı" | 89 | |
| SEP | No results in | |
| | quotes | |
| "Antiretroviral Terapi" | Did not | 0 |
| | search – does | |
| | not translate | |
| ART ("Destekli-Üreme Teknikleri" değil) | Also searched | 1 |
| The Control of the Co | the English 0 | _ |
| | | |
| | 20 | |
| | Filtered with | |
| "Yüksek Aktif Antiretroviral Terapi" | Search HIV | 0 |
| HAART | OR AIDS & - | 1 |
| "HIV Tedavisi" | Destekli- | 0 |
| kondom | Üreme | 0 |
| "Hedeflenen Bilgi" | Teknikleri | 0 |
| Danışmanlık | No results in | · · |
| VCT | quotes | 0 |
| "HIV Testi" | 2 | 0 |
| "HIV" VEYA "AIDS" VEYA "HIV / AIDS" | 2 | 0 |
| THE VEHA AIDS VEHA HIV / AIDS | 575 | U |
| | 2 – searched | |
| | with HIV to | |
| | filter | |
| | filter 1 | |
| | | |
| | 0 | |

| Germany: Robert Koch-Institut | Updated web address as the one listed in the technical report was for a French website. | 56 | |
|--|---|----|---|
| Germany: Robert Roch-Institut | Google advanced search: | | |
| http://www.rki.de/EN/Home/homepage_no | IDU | | |
| de.html | Inject Drug Use | 0 | |
| de.iidiii | PWID | 0 | |
| | People who inject drugs | 0 | |
| | Teopie who inject drugs | 0 | |
| | Publications found on website were peer reviewed articles. | Ŭ | |
| Public Health England | Google advanced search: | | |
| https://www.gov.uk/government/organisati | IDU | 0 | |
| ons/public-health-england | Inject Drug Use | 0 | |
| | PWID | 0 | |
| | People who inject drugs | 0 | |
| | | | |
| | Went to publications section of site – redirects to | | |
| | https://www.gov.uk/government/publications, which has already been searched (see above) | | |
| Health Protection Scotland | Google advanced search using the terms: | | |
| http://www.hps.scot.nhs.uk | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Relevant results so then searched | | |
| | OST | 1 | 0 |
| | "opiate substitution" | 1 | 0 |
| | MMT | 1 | 0 |
| | Methadone | 7 | 0 |
| | Buprenorphine | 0 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 2 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 7 | 0 |
| | "Drug Treatment" | 19 | 0 |
| | "harm reduction" | 12 | 0 |
| | needle provision | 21 | 1 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 4 | 0 |
| | "Syringe Exchange Program" | 0 | 0 |
| | SEP (excluding September and Sept) | 11 | 0 |
| | "Antiretroviral Therapy" | 40 | 3 |
| | ART | 42 | 0 |
| | "Highly Active Antiretroviral Therapy" | 11 | 0 |
| | HAART | 12 | 0 |

| Condom | | | | | |
|--|-------------------------------------|--|------|-----|----|
| Targeted Info" 20 1 0 0 0 0 0 0 0 0 | | "HIV Treatment" | | | |
| Counselling | | | | | |
| VCT | | | | | |
| WHIV Texting** 0 0 Hepatitis C** OR *Hep C** (search limited to results including *inject**) 91 3 Hepatitis C** OR *Hep C** (search limited to results including *inject**) 91 3 Hepatitis C** OR *Hep C** (search limited to results including *inject**) 91 3 HIV** OR *AIDS** OR *HIV/AIDS** 117 4 Prevention (US) *Inject Drug Use** (DU *People Who Inject Drugs** PWID **Inject Drug Use** (DU *People Who Inject Drugs** PWID Inject drug use 0 Total saved: 56 IDU 911 56 People who inject drugs 315 5 OST 368 4 5 "opiate substitution" 10 4 | | | | | |
| "Hepatitis C" OR "Hep C" (search limited to results including "inject") 91 3 117 4 4 117 2 | | | | | |
| CDC Centers for Disease Control and Prevention (US) | | | | 91 | 3 |
| Coocease for Disease Control and Prevention (US) "Inject Drug Use" IDU "People Who Inject Drugs" PWID Relevant results so then searched Inject drug use | | "HIV" OR "AIDS" OR "HIV/AIDS" | | | |
| Prevention (US) http://www.cdc.gov/ "inject Drug Use" IDU "People Who Inject Drugs" PWID Total saved: 56 Inject drug use 0 Total saved: 56 IDU 911 96 People who inject drugs 315 PWID 191 96 OST 368 97 "OST 368 97 What T 123 97 Methadone 816 98 Buprenorphine 213 97 Opioid agonist 25 97 OAT 310 98 MAT 1830 97 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 38 Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral treatment" 59 SEP N/A | CDC Contage for Discose Control and | Condend and according to the towns | | 121 | 2 |
| IDU 911 Fee | Prevention (US) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | | |
| DU | | Inject drug use | 0 | | |
| PWID 191 OST 368 "opiate substitution" 10 MMT 123 Methadone 816 Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results "Syringe Exchange Program" 71 Elitered to Inject OR IDU "antiretroviral the control or | | IDU | 911 | | 30 |
| OST 368 "opiate substitution" 10 MMT 123 Methadone 816 Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral to the provision or the program or the pro | | People who inject drugs | 315 | | |
| "opiate substitution" 10 MMT 123 Methadone 816 Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" SEP | | PWID | 191 | | |
| MMT 123 Methadone 816 Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antirietroviral the properties of the paper" N/A | | OST | 368 | | |
| Methadone 816 Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" N/A | | "opiate substitution" | 10 | | |
| Buprenorphine 213 Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 22 NSP 98 Antiretroviral brought back 7020 results. 5EP Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral the provision or the proper of the provision or the proper of the provision or the proper of the provision or the proper of the provision or the proper of the provision or the proper of the prope | | MMT | 123 | | |
| Opioid agonist 25 OAT 310 Medication Assisted 178 MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" SEP | | Methadone | 816 | | |
| OAT Medication Assisted MAT MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" SEP OAT MEdication Assisted 178 1290 1297 1297 1297 1297 1297 1297 1297 1297 | | Buprenorphine | 213 | | |
| Medication Assisted MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" SEP Medication Assisted 178 1830 297 297 70 97 71 71 71 71 71 | | Opioid agonist | 25 | | |
| MAT 1830 "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | OAT | 310 | | |
| "Drug Treatment" 1290 "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | Medication Assisted | 178 | | |
| "harm reduction" 297 "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | MAT | 1830 | | |
| "needle provision" 0 "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | "Drug Treatment" | 1290 | | |
| "Needle and Syringe Program" 2 NSP 98 Antiretroviral brought back 7020 results. "Syringe Exchange Program" 71 Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | "harm reduction" | 297 | | |
| NSP 98 Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" SEP NSP NSP N/A | | "needle provision" | 0 | | |
| Antiretroviral brought back 7020 results. Filtered to Inject OR IDU "antiretroviral therapy" "Syringe Exchange Program" 5EP N/A | | "Needle and Syringe Program" | 2 | | |
| Filtered to Inject OR IDU "antiretroviral therapy" SEP N/A | | NSP | 98 | | |
| therapy" | | "Syringe Exchange Program" | 71 | | |
| "Antiretroviral Therapy" 894 | | SEP | N/A | | |
| · | | "Antiretroviral Therapy" | 894 | | |

| ART brought back 26,000 same filter applied | ADT (specified not "Assisted Decreedusting Technologies") | F2C | | |
|---|---|------|---------|---|
| 110 | ART (specified not "Assisted -Reproductive –Technologies") | 536 | | |
| Condom brought back 9330 results. Filtered to HIV OR AIDS OR HIV/AIDS Inject OR IDU | "Highly Active Antiretroviral Therapy" | 1030 | | |
| | HAART | 1140 | | |
| "condom" | "HIV Treatment" | 2590 | | |
| | Condom | 2150 | | |
| HIV Testing has 67,700 results. Filtered to | "Targeted Info" | 83 | | |
| inject OR IDU "HIV testing". Hepatitis C | Counselling | 2550 | | |
| brought back 11,000 results applied same filter. | VCT | 473 | | |
| HIV brought back 25,700 results. Filtered to | "HIV Testing" | 3090 | | |
| HIV OR AIDS OR HIV/AIDS OD INJECT OR IDU | "Hepatitis C" | 1690 | | |
| | · | | | |
| | "Hep C" | 99 | | |
| tested b Plantagete of Health | "HIV" OR "AIDS" OR "HIV/AIDS" | 3400 | 0 | |
| Iceland: Directorate of Health http://www.landlaeknir.is/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | 0 | 0 |
| ittp://www.iaiiuiaekiiii.is/ | No results | | | |
| | Searched "sprauta lyfinu"(inject drug) – no results. | | | |
| National Centre of Addiction Medicine | Google advanced search using the terms: | | 0 | 0 |
| Iceland | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | | |
| http://www.saa.is | No results | | | |
| | Searched "sprauta lyfinu" (inject drug) – no results. | | | |
| Israel: Ministry of Health | Google advanced search using the terms: | | | |
| http://www.health.gov.il | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | | |
| | Relevant results so then searched | | | |
| | OST | | 5 | 0 |
| | "opiate substitution" | | 0 | 0 |
| | MMT | | 9 34 | 0 |
| | Methadone | | 24 | 0 |
| | Buprenorphine Opioid agonist | | 1 | 0 |
| | OAT | | 6 | 0 |
| | Medication Assisted | | 0 | 0 |
| | MAT | | 14 | 0 |
| | "Drug Treatment" | | 24 | 0 |
| | "harm reduction" | | 5 | 2 |
| | needle provision | | 0 | 0 |
| | "Needle and Syringe Program" | | 0 | 0 |

| | NSP | 3 | 0 |
|-------------------------------------|---|-----------------|---|
| | "Syringe Exchange Program" | 6 (could not | |
| | | open 2 | |
| | | relevant- | |
| | SEP (excluding September and Sept) | looking sites) | 0 |
| | "Antiretroviral Therapy" | 78 | 0 |
| | ART | 15 | 0 |
| | "Highly Active Antiretroviral Therapy" | 119 | 0 |
| | HAART | 6 | 0 |
| | "HIV Treatment" | 5 | 0 |
| | | 138 (could | |
| | | not open 2 | |
| | Condom | potentially | 1 |
| | "Targeted Info" | relevant sites) | 0 |
| | Counselling | 0 | 0 |
| | VCT | 7 | 0 |
| | "HIV Testing" | 19 | 1 |
| | | 8 | |
| | | 58 (could not | |
| | "Hepatitis C" OR "Hep C" | open 1 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | potentially | 3 |
| | | relevant site) | |
| | Relevant web links: | 4 | |
| | http://www.health.gov.il/NewsAndEvents/SpokemanMesseges/Pages/28112013_2.aspx = number o | 157 | |
| | fneedle and syringe exchange (in Hebrew) | | |
| | http://www.health.gov.il/Subjects/disease/HIV/Pages/HIV_centers.aspx = HIV testing centres | | |
| | Have emailed website tech support with a list of the relevant-looking sites I could not access. | | |
| Italy: Istituto Superiore di Sanità | Google advanced search using the terms: | | |
| http://www.iss.it | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Relevant results so then searched | | |
| | OST | | |
| | "opiate substitution" | | |
| | MMT | | |
| | Methadone | | |
| | Buprenorphine | | |
| | Opioid agonist | | |
| | OAT | | |
| | Medication Assisted | | |
| | MAT | | |

| | "Drug Treatment" | | |
|--|---|---------|--------|
| | "harm reduction" | | |
| | needle provision | | |
| | "Needle and Syringe Program" | | |
| | NSP | | |
| | "Syringe Exchange Program" | | |
| | SEP (excluding September and Sept) "Antiretroviral Therapy" | | |
| | ART | | |
| | "Highly Active Antiretroviral Therapy" | | |
| | HAART | | |
| | "HIV Treatment" | | |
| | Condom | | |
| | "Targeted Info" | | |
| | Counselling | | |
| | VCT | | |
| | "HIV Testing" | | |
| | "Hepatitis C" OR "Hep C" | | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | | |
| Luxembourg: Direction de la Santé | Google advanced search using the terms: | 0 | 0 |
| http://www.ms.etat.lu | "Inject Drug Use" IDU "People Who Inject Drugs" PWID – no results | | |
| | Searched "injecter" (google translate French for inject), no results. | | |
| National Institute for Public Health & the | Google advanced search using the terms: | | |
| Environment, Netherlands | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| http://www.rivm.nl | Relevant results so then searched | | |
| | OST | 13 | 0 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 28 | 0 |
| | Methadone | 30 6 | 0 0 |
| | Buprenorphine Opicid agenist | 0 | 0 |
| | Opioid agonist OAT | 25 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 59 | 0 |
| | "Drug Treatment" | 42 | 0 |
| | "harm reduction" | 80 | 0 |
| | | | |

| | needle provision | 0 | 0 |
|--|---|-------------|---|
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 13 | 0 |
| | Syringe Exchange Program | 1 | 0 |
| | SEP (excluding September and Sept) | 140 | 0 |
| | "Antiretroviral Therapy" | 30 | 0 |
| | ART | 281 | 0 |
| | "Highly Active Antiretroviral Therapy" | 25 | 0 |
| | HAART | 55 | 0 |
| | "HIV Treatment" (and "inject") | 86 | 3 |
| | Condom | 66 | 0 |
| | "Targeted Info" (and "inject") | 10 | 0 |
| | Counselling | 75 | 0 |
| | VCT | 14 | 0 |
| | "HIV Testing" (and "inject") | 36 | 1 |
| | "Hepatitis C" OR "Hep C" (and "inject") | 18 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS"(and "inject") | 40 | 0 |
| http://assda.anu.edu.au/ | IDU | 0 | |
| Australian Social Science Data Archive | Inject Drug Use | 0 | |
| (ASSDA) | PWID | 0 | |
| | People who inject drugs | 0 | |
| | | | |
| http://www.afro.who.int/ | IDU | 13 | |
| WHO REGIONAL OFFICE AFRICA | Inject Drug Use | 0 | |
| | PWID | 4 | |
| | People who inject drugs | 38 | |
| | | | |
| | OST | 14 | 2 |
| | "opiate substitution" | 0 | |
| | MMT | 0 | |
| | Methadone | 10 | 2 |
| | Buprenorphine | 2 | 0 |
| | Opioid agonist | 1 | 0 |
| | OAT | 1 | 0 |
| | Medication Assisted | 0 in quotes | 0 |
| | MAT | 42 | 0 |
| | "Drug Treatment" | 63 | 0 |
| | "harm reduction" | 31 | 0 |
| | needle provision | 0 in quotes | 0 |
| | "Needle and Syringe Program" | 0 in quotes | 0 |
| | Needle and Symble Frogram | o in quotes | U |

| | NSP | 40 | 1 |
|---|---|-------------|---------|
| | "Syringe Exchange Program" | 0 in quotes | 0 |
| | SEP (excluding September and Sept) "Antiretroviral Therapy" | 73 1350 | 0 |
| | ART | 1350 | 2 |
| | "Highly Active Antiretroviral Therapy" | 34 | 0 |
| | HAART | - | |
| | "HIV Treatment" | 484 | 1 |
| | Condom | 408 | 1 |
| | "Targeted Info" | 0 in quotes | 0 |
| | Counselling | 1030 | 0 |
| | VCT | 827 | 317 - 0 |
| | "HIV Testing" | 214 | 1 |
| | "Hepatitis C" OR "Hep C" | 8550 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | | 0 |
| Korea Centers for Disease Control and | Google advanced search using the terms: | 0 | 0 |
| Prevention (KCDC) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID – no results | | |
| http://www.cdc.go.kr/CDC/eng/main.jsp | Tried again omitting /CDC/eng/main.jsp. | 14 | 2 |
| Casuah ad in hath Fusiish than Kasasa | OCT. Nathanasland | C | |
| Searched in both English then Korean. Numbers in brackets indicate the number of | OST –Not translated | 6 | |
| Korean hits if any. | "opiate substitution" -아편 대체 | 0 | |
| Notice in the in entry. | MMT –Not translated | 4 | |
| Also found UNAIDs progress report for 2016 | Methadone -메타돈 | 8 (3) | |
| via grey lit (hand) searching. | Buprenorphine -부 프레 노르 핀 | 0 | |
| | Opioid agonist -오피오이드 작용제 | 0 | |
| | OAT –Not translated | 2 | |
| | Medication Assisted -약물 보조 | 0 | |
| | MAT –Not translated | 84 | |
| | "Drug Treatment" -마약 치료 | 8 (1) | |
| | "harm reduction" -해로운 감소 | 6 | |
| | "needle provision" -바늘 공급 | 0 | |
| | "Needle and Syringe Program" -바늘 및 주사기 프로그램 | 0 | |
| | | | |
| | NSP –Not translated | 9720 | 3 |
| | "Syringe Exchange Program" -주사기 교환 프로그램 | 0 | |

| | SEP –Not Translated | 9210 |
|---|--|---------------------|
| | "Antiretroviral Therapy" -항 레트로 바이러스 요법 | 91 (9) ₁ |
| | ART (specified not "Assisted –Reproductive –Technologies") –Not translated | 202 1 |
| | "Highly Active Antiretroviral Therapy" -고 활성 항 레트로 바이러스 | 2 2 |
| | 요법 - 유법 | 46 (1) |
| | HAART –Not translated | 98 |
| C 형 간염 13,900 hits, filtered to: | "HIV Treatment" -HIV 치료 | 6 (66) |
| inject OR drug OR use, OR HIV, OR 약물 OR 사용을 OR 주사하다 "C 형 간염" | Condom -콘돔 | 63 (343) |
| 70 2 0 7 7 7 7 0 0 2 1 | "Targeted Info" -대상 정보 | 0 (60) |
| | Counselling -카운셀링 | 42 (7) |
| | VCT –Not translated | 53 |
| | "HIV Testing" -HIV 테스트 | 276 (46) |
| | "Hepatitis C" C 형 간염 | 511 (671) |
| | "Hep C" –Not translated | 2 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" –Same in Korean | 8740 |
| | | 0740 |
| United Republic of Tanzania: Tanzania | Google advanced search using the terms: | 14 results |
| Commission for AIDS | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| http://www.tacaids.go.tz/ | OST | 1 |
| | "opiate substitution" | 0 |
| Many of the results returned the following | MMT | 0 |
| message once clicked: "404 error. Not found The requested URL | Methadone | 1 |
| /index.php was not found on this server. | Buprenorphine | 0 |
| Additionally, a 404 Not Found error was | Opioid agonist | 0 |
| encountered while trying to use an ErrorDocument to handle the request." Info Sheets appear to have been uploaded in | OAT | 1 |
| | Medication Assisted | 1 |
| | MAT | 2 |
| 2015 from following URL: http://tacaids.go.tz/tacaids/2015-08-06-06- | "Drug Treatment" | 4 1 |
| 43-48 | "harm reduction" | 8 |
| | "needle provision" | 0 |
| | | |

| | "Needle and Syringe Program" | 1 | |
|---|--|------|---|
| | NSP | 2 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 3 | |
| | "Antiretroviral Therapy" | 23 | 1 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 72 | |
| | "Highly Active Antiretroviral Therapy" | 4 | |
| | HAART | 9 | |
| | "HIV Treatment" | 13 | 1 |
| | Condom | 142 | |
| | "Targeted Info" | 2 | |
| | Counselling | 113 | 1 |
| | VCT | 129 | |
| | "HIV Testing" | 79 | 1 |
| | "Hepatitis C" | 1 | |
| | "Hep C" | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 1020 | |
| Uganda: AIDS Commission http://www.aidsuganda.org/ | Google advanced search using the terms: "Inject Drug Use" IDU "People Who Inject Drugs" PWID – no results | 0 | 0 |
| South African National AIDS Council | Google advanced search using the terms: | 85 | |
| nttp://www.sanac.org.za/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | OST | 8 | 1 |
| | "opiate substitution" | 3 | (|
| Found the 2015 UNAIDS progress report for South Africa through Grey lit (hand) search | MMT | 0 | |
| south Africa through Grey IIt (nand) search | Methadone | 4 | |
| | Buprenorphine | 0 | |
| | Opioid agonist | 0 | |
| | OAT | 0 | |
| | Medication Assisted | 1 | |

| | MAT | 2 |
|--|--|--------|
| | "Drug Treatment" | 6 |
| | "harm reduction" | 21 |
| | "needle provision" | 0 |
| | "Needle and Syringe Program" | 0 |
| | NSP | 938 |
| | "Syringe Exchange Program" | 0 |
| | SEP | 116 |
| | "Antiretroviral Therapy" | 76 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 276 |
| | "Highly Active Antiretroviral Therapy" | 4 |
| | HAART | 30 |
| | "HIV Treatment" | 86 |
| | Condom | 172 |
| | "Targeted Info" | 2 |
| | Counselling | 179 |
| | VCT | 16 |
| | "HIV Testing" | 85 |
| | "Hepatitis C" | 3 |
| | "Hep C" | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 1530 |
| | • | 2550 |
| Jetherlands: Ministry of Health, Welfare and | Google advanced search using the terms: """ """ """ """ """ """ """ | 0 |
| port http://english.minvws.nl/en/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID – no results • | |
| ligeria: National Agency for the Control of | Google advanced search using the terms: | 105 |
| IV/AIDS | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | _ |
| tp://www.naca.gov.ng/ | OST "opiate substitution" | 5 0 |
| | MMT | 0 |
| | Methadone | 0 |
| | Buprenorphine | 0 |

| | OAT | 0 | |
|--------------------------------------|--|--------|---|
| | Medication Assisted | 0 | |
| | MAT | 1 | |
| | "Drug Treatment" | 3 | |
| | "harm reduction" | 13 | 1 |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 0 | |
| | NSP | 60 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 5 | |
| | "Antiretroviral Therapy" | 87 | 3 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 199 | 2 |
| | "Highly Active Antiretroviral Therapy" | 6 | |
| | HAART | 7 | |
| | "HIV Treatment" | 287 | |
| | Condom | 132 | |
| | "Targeted Info" | 2 | |
| | Counselling | 180 | 1 |
| | VCT | 44 | _ |
| | "HIV Testing" | 141 | |
| | "Hepatitis C" | 5 | |
| | "Hep C" | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 968 | |
| Norwegian Institute of Public Health | Google advanced search using the terms: | 300 | |
| nttp://www.fhi.no | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | Relevant results so then searched | | |
| | OST | 76 | 2 |
| | "opiate substitution" | 1 | 0 |
| | MMT | 3 | 0 |
| | Methadone | 57 | 0 |
| | Buprenorphine | 28 | 0 |
| | Opioid agonist | 7 | 0 |
| | OAT | , 5 | 0 |
| | Medication Assisted | 3 | 0 |
| | MAT | 8 | 0 |
| | "Drug Treatment" | 35 | 0 |
| | "harm reduction" | 33 | 0 |
| | | 0 | 0 |
| | needle provision | 0 | 0 |
| | "Needle and Syringe Program" | 1 | 0 |
| | NSP | 1 | U |

| | Syringe Exchange Program | 0 | 0 |
|--|--|----|---|
| | SEP (excluding September and Sept) | 82 | 0 |
| | "Antiretroviral Therapy" | 23 | 0 |
| | ART (and "inject") | 4 | 0 |
| | "Highly Active Antiretroviral Therapy" | 13 | 0 |
| | HAART | 13 | 0 |
| | "HIV Treatment" (and "inject") | 70 | 3 |
| | Condom | 26 | 0 |
| | "Targeted Info" (and "inject") | 0 | 0 |
| | Counselling | 50 | 0 |
| | VCT | 0 | 0 |
| | "HIV Testing" (and "inject") | 26 | 1 |
| | "Hepatitis C" OR "Hep C" (and "inject") | 20 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS"(and "inject") | 24 | 0 |
| Switzerland: Federal Office of Public Health | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| (FOPH) | Relevant results so then searched | | |
| http://www.bag.admin.ch/index.html?lang= | OST | 3 | 0 |
| <u>en</u> | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 0 | 0 |
| | Buprenorphine | 0 | 0 |
| | "Opioid agonist" | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 0 | 0 |
| | "harm reduction" | 0 | 0 |
| | needle provision | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 0 | 0 |
| | Syringe Exchange Program | 0 | 0 |
| | SEP | 12 | 0 |
| | "Antiretroviral Therapy" | 1 | 0 |
| | ART (and "inject") | 2 | 0 |
| | "Highly Active Antiretroviral Therapy" | 1 | 0 |
| | HAART | 0 | 0 |
| | "HIV Treatment" | 9 | 0 |
| | Condom | 0 | 0 |
| | "Targeted Info" | 0 | 0 |
| | Counselling | | 0 |

| | | | _ |
|--|--|---------------|-------------|
| | | 7 (2 sites | |
| | VCT | would not | 0 |
| | | load) | |
| | "HIV Testing" (and "inject") | 6 (4 sites | 0 |
| | | would not | |
| | "Hepatitis C" OR "Hep C" (and "inject") | load) | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS"(and "inject") | 1 (site would | 0 |
| | | not load) | |
| | | 2 | |
| | | 1 | |
| Correlation - European Network of Social | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| nclusion and Health | Relevant results so then searched | | |
| http://www.correlation-net.org | OST | 17 | 0 |
| | "opiate substitution" | 4 | 0 |
| | MMT | 1 | 0 |
| | Methadone | 14 | 1 |
| | Buprenorphine | 2 | 0 |
| | | 0 | 0 |
| | "Opioid agonist" | 0 | 0 |
| | OAT | | |
| | Medication Assisted | 3 | 0 |
| | MAT | 13 | 0 |
| | "Drug Treatment" | 17 | 0 |
| | "harm reduction" | 60 | 0 |
| | needle provision | 0 | 0 |
| | Needle and Syringe Program | 7 | 0 |
| | NSP | 12 | 0 |
| | Syringe Exchange Program | 1 | 0 |
| | SEP | 2 | 0 |
| | "Antiretroviral Therapy" | 3 | 0 |
| | ART (and "inject") | 33 | 0 |
| | "Highly Active Antiretroviral Therapy" | 1 | 0 |
| | HAART | | |
| | "HIV Treatment" (and "inject") | 7 | 0 |
| | Condom | 31 | 0 |
| | "Targeted Info" | 2 | 0 |
| | Counselling | 3 | 0 |
| | VCT | 18 | 0 |
| | | | |
| | | | |
| | | | |
| | "HIV Testing" "Hepatitis C" OR "Hep C" "HIV" OR "AIDS" OR "HIV/AIDS" | 0 14 17 | 0 0 0 |

| | | 41 | 0 |
|---|--|-----|---|
| National AIDS Council Zimbabwe | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| http://www.nac.org.zw/ | Relevant results so then searched | 4 | |
| Could only search through attached files (such | OST | 4 | |
| as PDFs) as the following error occurred on any pages form the NAC site: "Error 500 - | "opiate substitution" | 0 | |
| Internal Server Error An error was | MMT | 0 | |
| encountered while processing your request. | Methadone | 3 | |
| Typically this is a temporary condition. Please | Buprenorphine | 1 | |
| contact the web site owner for further assistance." | Opioid agonist | 0 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 47 | |
| | "Drug Treatment" | 4 | |
| | "harm reduction" | 9 | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 2 | |
| | NSP | 2 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 152 | |
| | "Antiretroviral Therapy" | 462 | 1 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 0 | |
| | "Highly Active Antiretroviral Therapy" | 0 | |
| | HAART | 3 | |
| | "HIV Treatment" | 368 | |
| | Condom | 141 | |
| | "Targeted Info" | 1 | |
| | Counselling | 494 | |
| | VCT | 70 | |
| | "HIV Testing" | 355 | |
| | "Hepatitis C" | 7 | _ |

| | "Hep C" | 0 |
|--|--|------|
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 1640 |
| National AIDS Control Council Kenya | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| http://www.nacc.or.ke | Relevant results so then searched | |
| | OST | 2 |
| | "opiate substitution" | 3 |
| | MMT | 0 |
| | Methadone | 1 |
| | Buprenorphine | 0 |
| | Opioid agonist | 0 |
| | OAT | 0 |
| | Medication Assisted | 0 |
| | MAT | 4 |
| | "Drug Treatment" | 0 |
| | "harm reduction" | 7 |
| | "needle provision" | 0 |
| | "Needle and Syringe Program" | 3 1 |
| | NSP | 7 |
| | "Syringe Exchange Program" | 0 |
| | SEP | 8 |
| | "Antiretroviral Therapy" | 37 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 162 |
| | "Highly Active Antiretroviral Therapy" | 5 |
| | HAART | 19 |
| | "HIV Treatment" | 41 |
| | Condom | 51 |
| | "Targeted Info" | 0 |
| | Counselling | 43 |
| | VCT | 27 |
| | "HIV Testing" | 66 |
| | "Hepatitis C" | 0 |
| | "Hep C" | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 544 |
| Malawi: National AIDS Commission | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| http://www.aidsmalawi.org/ | No results. Not searched further. | |
| Ghana AIDS Commission | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 0 |
| http://ghanaids.gov.gh/gac1/aids_info.ph | | |
| | OST | 0 |
| | "opiate substitution" | 0 |

| | MMT | 0 | |
|----------------------------------|--|-----|---|
| | Methadone | 1 | |
| | Buprenorphine | 0 | |
| | Opioid agonist | 0 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 0 | |
| | "Drug Treatment" | 2 | |
| | "harm reduction" | 2 | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 0 | |
| | NSP | 23 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 0 | |
| | "Antiretroviral Therapy" | 22 | 2 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 22 | |
| | "Highly Active Antiretroviral Therapy" | 3 | |
| | HAART | 2 | |
| | "HIV Treatment" | 6 | |
| | Condom | 26 | |
| | "Targeted Info" | 0 | |
| | Counselling | 40 | |
| | VCT | 2 | |
| | "HIV Testing" | 32 | |
| | "Hepatitis C" | 0 | |
| | "Hep C" | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 142 | |
| France: Conseil national du sida | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 112 | |
| http://www.cns.sante.fr/ | Relevant results so then searched | | |
| neep.// www.cns.sunce.m/ | OST | 0 | 0 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 1 | 0 |
| | Buprenorphine | 2 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT MAT | 0 | 0 |
| | "Drug Treatment" | 0 | 0 |
| | "harm reduction" | 1 | 0 |
| | nami reduction | 1 | U |

| | "needle provision" | 0 | (|
|---------------------------------|--|----------|---|
| | "Needle and Syringe Program" | 0 | (|
| | NSP | 0 | C |
| | "Syringe Exchange Program" | 2 | (|
| | SEP | 0 | (|
| | "Antiretroviral Therapy" | 11 | (|
| | ART | 4 | (|
| | "Highly Active Antiretroviral Therapy" | 5 | (|
| | HAART | 1 | C |
| | "HIV Treatment" | 41 | C |
| | Condom | 3 | 0 |
| | "Targeted Info" | 0 | 0 |
| | Counselling | 4 | 0 |
| | VCT | 0 | C |
| | "HIV Testing" | 11 | 0 |
| | "Hepatitis C" | 5 | 0 |
| | "Hep C" | 5 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 43 | 0 |
| Eurasian Harm Reduction Network | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| nttp://www.harm-reduction.org | Relevant results so then searched (searches limited to results including "inject") | | |
| | OST | | |
| | "opiate substitution" | 97 | 2 |
| | MMT | 35 | C |
| | Methadone | 15 | 1 |
| | Buprenorphine | 86 | 2 |
| | Opioid agonist | 58 | 1 |
| | OAT | 12 | C |
| | Medication Assisted | 0 | C |
| | MAT | 16 | 0 |
| | "Drug Treatment" | 20 | 0 |
| | "harm reduction" | 89 | 3 |
| | "needle provision" | 169 | 2 |
| | "Needle and Syringe Program" | 103 | 0 |
| | NSP | 19 | 2 |
| | "Syringe Exchange Program" | 79 | 3 |
| | SEP (excluding September and sept) | 79 15 | 1 |
| | | | _ |
| | "Antiretroviral Therapy" | 11 | C |
| | ART | 80 | 0 |
| | "Highly Active Antiretroviral Therapy" | 89 | 2 |
| | HAART | 19 | C |

| | "HIV Treatment" | 12 | 0 | |
|--|---|------|-----|--|
| | Condom | 164 | 0 | |
| | "Targeted Info" | 47 | 1 | |
| | Counselling | 72 | 0 | |
| | VCT | 48 | 0 | |
| | "HIV Testing" | 27 | 0 | |
| | "Hepatitis C" | 117 | 0 | |
| | "Hep C" | 132 | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 5 | 0 | |
| | | 150 | 0 | |
| Cote d'Ivoire Ministère de lutte contre le SIDA http://www.mlsida.gouv.ci/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID No Relevant results, tried in French: "injecter l'usage de drogues" –inject drug use "les personnes qui consomment des drogues injectables" –people who inject drugs -No results. | | | |
| Brazil: Programa Nacional de DST e Aids http://www.aids.gov.br | "Inject Drug Use" IDU "People Who Inject Drugs" PWID relevant results indicated. Then searched: | | | |
| ittp.//www.aius.gov.bi | OST | 6 | 0 | |
| | "opiate substitution" | 0 | 0 | |
| | MMT | 6 | 0 | |
| | Methadone | 27 | 0 | |
| | Buprenorphine | 4 | 0 | |
| | Opioid agonist | 1 | 0 | |
| | OAT | 3 | 0 | |
| | Medication Assisted | 0 | 0 | |
| | MAT | 196 | 0 | |
| | | 30 | | |
| | "Drug Treatment" "harm reduction" | 97 | 0 2 | |
| | | | | |
| | "needle provision" | 0 | 0 | |
| | "Needle and Syringe Program" | 0 | 0 | |
| | NSP | 4 | 0 | |
| | "Syringe Exchange Program" | 2 | 0 | |
| | SEP | 116 | 0 | |
| | "Antiretroviral Therapy" | 404 | 1 | |
| | ART (specified not "Assisted -Reproductive –Technologies") | 1170 | 0 | |
| | "Highly Active Antiretroviral Therapy" | 127 | 1 | |
| | HAART | 305 | 0 | |
| | "HIV Treatment" | 96 | 0 | |
| | Condom | 1090 | 3 | |

| | "Targeted Info" | 3 | 0 |
|--|--|-----|---|
| | Counselling | 143 | 0 |
| | VCT | 14 | 0 |
| 79,000 hits for "HIV" OR "AIDS" OR | "HIV Testing" | 235 | 0 |
| "HIV/AIDS" so filtered to: "Inject" HIV OR | "Hepatitis C" | 648 | 0 |
| AIDS OR HIV/AIDS | "Hep C" | 6 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 29 | 0 |
| Jamaica: National AIDS Committee | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| http://www.nacjamaica.org/ | No results. | | |
| Caribbean Harm Reduction Coalition (CHRC) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| www.caribbeanharmreductioncoalition.html | Only one result: for IDU – out of date, did not search further. | | |
| planet.com | , | | |
| AIDS Society of the Philippines | Google advanced search for: | | |
| http://www.aidsphil.org/about/ | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| | No results. Omitted /about/ | | |
| | Only 5 results, none relevant, did not search further. | | |
| | 5 Only 5 results, none relevant, and not scarch farther. | | |
| Nepal: National Center for AIDS and STD | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| Control | Relevant results indicated. Continued to searched: | | |
| http://www.ncasc.gov.np | OST | 45 | 4 |
| | "opiate substitution" | 2 | |
| | MMT | 0 | |
| | Methadone | 31 | |
| | Buprenorphine | 20 | 1 |
| | Opioid agonist | 1 | - |
| | OAT . | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 2 | |
| | "Drug Treatment" | 23 | |
| | "harm reduction" | 55 | 1 |
| | "needle provision" | 0 | - |
| | "Needle and Syringe Program" | 3 | |
| | NSP | 14 | |
| | "Syringe Exchange Program" | 9 | |
| | SEP | 7 | |
| | "Antiretroviral Therapy" | 60 | |
| | ART (specified not "Assisted -Reproductive –Technologies") | 221 | 5 |
| | "Highly Active Antiretroviral Therapy" | 3 | 5 |
| | HAART | 4 | |
| | "HIV Treatment" | 35 | |
| | niv ireatilient | 35 | |

| | Condom | 154 | |
|---|--|-------|---|
| | "Targeted Info" | 5 | |
| | Counselling | 102 | |
| | VCT | 120 | |
| | "HIV Testing" | 151 | 2 |
| | "Hepatitis C" | 27 | |
| | "Hep C" | 1 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 651 | |
| Indonesia: National AIDS Commission | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 031 | |
| http://www.aidsindonesia.or.id | Relevant results indicated. Continued to searched: | | |
| ittp://www.aiusiiiuoiiesia.oi.iu | | 10 | |
| | OST | 18 | |
| | "opiate substitution" | 1 | |
| | MMT | 15 | |
| | Methadone | 61 | |
| | Buprenorphine | 10 | 1 |
| | Opioid agonist | 1 | |
| | OAT | 13 | |
| | Medication Assisted | 2 | |
| | MAT | 10 | |
| | "Drug Treatment" | 13 | |
| | "harm reduction" | 835 | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 3 | |
| | NSP | 16 | |
| | "Syringe Exchange Program" | 2 | |
| | SEP | 28 | |
| | "Antiretroviral Therapy" | 70 | |
| | | | |
| | ART (specified not "Assisted -Reproductive –Technologies") | 881 | |
| | "Highly Active Antiretroviral Therapy" | 15 | |
| | HAART | 18 | |
| | "HIV Treatment" | 44 | |
| | Condom | 164 | |
| | "Targeted Info" | 2 | |
| | Counselling | 91 | |
| | VCT | 649 | |
| | "HIV Testing" | 72 | 1 |
| | "Hepatitis C" | 76 | |
| | "Hep C" | 6 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 2,930 | |
| India: National AIDS Control Organisation | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | _, | |
| | george and independent inject bridge i trib | | |

| http://naco.gov.in/NACO/ | Relevant results indicated. Continued to searched: | |
|--|--|-------|
| | OST | 47 |
| | "opiate substitution" | 0 |
| Most of the results were images of poster | MMT | 0 |
| campaigns. | Methadone | 2 |
| | Buprenorphine | 20 |
| | Opioid agonist | 0 |
| | OAT | 0 |
| | Medication Assisted | 0 |
| | MAT | 10 |
| | "Drug Treatment" | 0 |
| | "harm reduction" | 1 |
| | "needle provision" | 0 |
| | "Needle and Syringe Program" | 0 |
| | NSP | 0 |
| | "Syringe Exchange Program" | 0 |
| | SEP | 52 |
| | "Antiretroviral Therapy" | 150 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 446 |
| | "Highly Active Antiretroviral Therapy" | 0 |
| | HAART | 0 |
| | "HIV Treatment" | 27 |
| | Condom | 1220 |
| | "Targeted Info" | 0 |
| | Counselling | 185 |
| | VCT | 0 |
| | "HIV Testing" | 146 |
| | "Hepatitis C" | 8 |
| | "Hep C" | 9 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 3,530 |
| China AIDS Info | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | , |
| http://www.china.org.cn/english/features/a | No results | |
| ids/112999.htm | Omitted <u>/features/aids/112999.htm</u> from the site search: | |
| | Only a couple of results, most out of date range. | |
| | Did not continue to search | |
| Cambodia National AIDS Authority | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| http://www.naa.org.kh/ | Results only from UNAids reports. | |
| | | |
| | Did not search further | |
| Open Society Institute & Soros Foundation | Did not search further "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |

| https://www.opensocietyfoundations.org/t | Did not search further | |
|--|---|-------|
| opics/harm-reduction | | |
| Mauritius National Agency For The | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| Treatment And Rehabilitation of Substance | No results | |
| Abusers (NATRESA) | Omitted /Pages/default.aspx from the site search: | |
| http://natresa.govmu.org/English/Pages/def | Only a couple of results, most out of date range. | |
| ault.aspx | Did not continue search | |
| Global Network of People Living with | Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| HIV/AIDS | • Relevant results indicated. Continued to searched: | |
| http://www.gnpplus.net/ | OST | 19 |
| | "opiate substitution" | 6 |
| | MMT | 0 |
| | Methadone | 20 |
| | Buprenorphine | 8 |
| | Opioid agonist | 0 |
| | OAT | 0 |
| | Medication Assisted | 2 |
| | MAT | 6 |
| | "Drug Treatment" | 16 |
| | "harm reduction" | 124 |
| | "needle provision" | 0 |
| | "Needle and Syringe Program" | 1 |
| | NSP | 18 |
| | "Syringe Exchange Program" | 0 |
| | SEP | 30 |
| | "Antiretroviral Therapy" | 187 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 308 |
| | "Highly Active Antiretroviral Therapy" | 23 |
| | HAART | 34 |
| | "HIV Treatment" | 269 |
| | Condom | 184 |
| | "Targeted Information" | 4 |
| | Counselling | 245 |
| | VCT | 88 |
| | "HIV Testing" | 327 |
| | "Hepatitis C" | 81 |
| | "Hep C" | 3 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 1,600 |
| | Inject Drug Use" IDU "People Who Inject Drugs" PWID | 1,000 |
| Ireland: Health Protection Surveillance | | |

| 1 // | | 4 | 0 |
|---|---|-----|---|
| http://www.hpsc.ie/ | OST | 4 | 0 |
| | "opiate substitution" | 0 | 0 |
| | MMT | 0 | 0 |
| | Methadone | 11 | 0 |
| | Buprenorphine | 0 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 0 | 0 |
| | MAT | 8 | 0 |
| | "Drug Treatment" | 27 | 0 |
| | "harm reduction" | 11 | 0 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 0 | 0 |
| | NSP | 4 | 0 |
| | "Syringe Exchange Program" | 0 | 0 |
| | SEP | 83 | 0 |
| | "Antiretroviral Therapy" | 34 | 1 |
| | ART | 27 | 0 |
| | "Highly Active Antiretroviral Therapy" | 23 | 0 |
| | HAART | 24 | 0 |
| | "HIV Treatment" | 193 | 1 |
| | Condom | 51 | 0 |
| | "Targeted Info" | 57 | 0 |
| | Counselling | 49 | 0 |
| | VCT | 1 | 0 |
| | "HIV Testing" | 19 | 4 |
| | "Hepatitis C" (and 'inject') | 36 | 2 |
| | "Hep C" (and 'inject') | 90 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS"(and 'inject') | 56 | 1 |
| The Global Fund to fight AIDS, Tuberculosis | Inject Drug Use" IDU "People Who Inject Drugs" PWID | 30 | 1 |
| and Malaria (GFATM) | Relevant results found. Continued to search | | |
| http://www.theglobalfund.org/en/ | OST | 18 | |
| nttp://www.tnegiobairung.org/en/ | | | |
| | "opiate substitution" | 1 | |
| Note: many of the hits in this search linked to | MMT | 4 | |
| an .xml document that was just code. | Methadone | 32 | |
| | Buprenorphine | 1 | |
| | Opioid agonist | 0 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 8 | _ |

| | "Drug Treatment" | 3 |
|---------------------------------|--|-------|
| | "harm reduction" | 55 |
| | "needle provision" | 0 |
| | "Needle and Syringe Program" | 1 |
| | NSP | 17 |
| | "Syringe Exchange Program" | 1 |
| | SEP | 8 |
| | "Antiretroviral Therapy" | 165 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 97 |
| | "Highly Active Antiretroviral Therapy" | 1 |
| | HAART | 6 |
| | "HIV Treatment" | 102 |
| | Condom | 77 |
| | "Targeted Information" | 0 |
| | Counselling | 66 |
| | VCT | 63 |
| | "HIV Testing" | 92 |
| | "Hepatitis C" | 12 |
| | "Hep C" | 2 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 1,330 |
| Portugal: Fundacao Portuguesa A | Google advanced search using the terms: | , |
| Communidade Contra a SIDA | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| http://www.fpccsida.org.pt/ | No relevant results | 0 |
| HI360 | Inject Drug Use" IDU "People Who Inject Drugs" PWID | |
| ttp://www.fhi360.org/ | Relevant results found. Continued to search | |
| | OST | 44 |
| | "opiate substitution" | 0 |
| | MMT | 80 |
| | Methadone | 174 |
| | Buprenorphine | 27 |
| | Opioid agonist | 5 |
| | OAT | 23 |
| | Medication Assisted | 4 |
| | MAT | 128 |
| | "Drug Treatment" | 104 |
| | "harm reduction" | 168 |
| | "needle provision" | 1 |
| | "Needle and Syringe Program" | 3 |
| | | |
| | NSP | 29 |

| | SEP | 146 | |
|--|--|---------|---|
| | "Antiretroviral Therapy" | 755 | 5 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 1200 | |
| | "Highly Active Antiretroviral Therapy" | 64 | 1 |
| | HAART | 89 | |
| | "HIV Treatment" | 318 | |
| | Condom | 1580 | 1 |
| | "Targeted Information" | 9 | |
| | Counselling | 564 | |
| | VCT | 493 | |
| | "HIV Testing" | 941 | 1 |
| | "Hepatitis C" | 95 | _ |
| | "Hep C" | 3 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 4,500 | |
| Virtual AIDS Office (VAO) of Hong Kong | Inject Drug Use" IDU "People Who Inject Drugs" PWID | 4,500 | |
| http://www.info.gov.hk/aids/english/index. | No relevant searches. | | |
| | | | |
| <u>htm</u> | Omitted /index.htm | | |
| | Relevant results found. Continued to search: | | |
| | OST | | |
| | "opiate substitution" | 0 | |
| | MMT | 0 | |
| | Methadone | 0 | |
| | Buprenorphine | 693 | 1 |
| | Opioid agonist | 1 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 0 | |
| | "Drug Treatment" | 0 | |
| | "harm reduction" | 27 | |
| | "needle provision" | 627 | |
| | "Needle and Syringe Program" | 0 | |
| | NSP | 0 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 0 | |
| | | 86 | |
| | "Antiretroviral Therapy" | 38 | |
| | ART (specified not "Assisted -Reproductive –Technologies") | 4 | |
| | "Highly Active Antiretroviral Therapy" | 4 17 | |
| | HAART | | |
| | "HIV Treatment" | 52 | |
| | Condom | 27 | |

| | "Targeted Information" | 154 | |
|------------------------------|--|---------------|---|
| | Counselling | 0 | |
| | VCT | 663 | |
| | | 13 | |
| | "Hepatitis C" | 696 | |
| | "Hep C" | 8 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 0 | |
| | | 955 | |
| Vho – Western pacific Region | Inject Drug Use | 0 | - |
| ttp://www.wpro.who.int/en/ | IDU | 93 | 5 |
| | People Who Inject Drugs | 202 | |
| | PWID | 78 | 0 |
| | | | |
| | OST | 44 | 0 |
| | "opiate substitution" | 5 | 0 |
| | MMT | 45 | 0 |
| | Methadone | 130 | 3 |
| | | 18 | 0 |
| | Opioid agonist | 3 | 0 |
| | OAT | 2 | 0 |
| | Medication Assisted | No results in | |
| | MAT | quotes | 0 |
| | "Drug Treatment" | 86 | 0 |
| | "harm reduction" | 109 | 0 |
| | | 192 | 0 |
| | "Needle and Syringe Program" | No results in | 0 |
| | NSP | quotes | 2 |
| | "Syringe Exchange Program" | 3 | 0 |
| | SEP | 61 | |
| | | No results in | |
| | | quotes | |
| | | Did not | |
| | "Antiretroviral Therapy" | search | 0 |
| | Antiretroviral inerapy | because no | O |
| | "Highly Active Antiretroviral Therapy" | results found | 0 |
| | | for above | U |
| | HANNI | "Syringe" | |
| | | 381 | |
| | | 201 | |
| | "HIV Treatment" | 22 | 0 |

| | Condom | Did not | 0 |
|---------------------------------------|--|----------------|---|
| | "Targeted Information" | search | 0 |
| | Counselling | because no | 0 |
| | | results found | |
| | | for above | |
| | VCT | "Highly | 0 |
| | "HIV Testing" | active" | 0 |
| | "Hepatitis C" | 139 | 0 |
| | | 457 | |
| | | 13 | |
| | "Hep C" | 540- searched | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | "counselling" | 0 |
| | | "HIV" to | |
| | | narrow field | |
| | | 107 | |
| | | 397 | |
| | | 252 – | |
| | | searched | |
| | | Hepatitis C" + | |
| | | "HIV" to | |
| | | narrow field | |
| | | 6 | |
| | | 288 – Added | |
| | | "injecting" to | |
| | | the search to | |
| | | narrow | |
| | | results | |
| he UK Harm Reduction Alliance (UKHRA) | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | resuits | |
| www.ukhra.org | Relevant results so then searched | | |
| · · · · · · · · · · · · · · · · · · · | OST Televant results so their searched | 4 | 0 |
| | "opiate substitution" | 3 | 0 |
| | MMT | 1 | 0 |
| | Methadone | 28 | 0 |
| | | | |
| | Buprenorphine Opinid propriet | 4 | 0 |
| | Opioid agonist | 0 | 0 |
| | OAT | 0 | 0 |
| | Medication Assisted | 2 | 0 |
| | MAT | 0 | 0 |
| | "Drug Treatment" | 27 | 0 |
| | "harm reduction" | 63 | 0 |

| "needle provision" altered to "needle exchange" based on website language "Needle and Syringe" NSP "Syringe Exchange Program" SEP "Antiretroviral Therapy" ART "Highly Active Antiretroviral Therapy" HAART Condom "argeted info" Counselling VCT "HIV Testing" "Hepatitis C" "Hepatitis C" "Hepatitis C" "Hepatitis C" "Help" or "Alors" or "HIV/AIDS" "Hill" or "Alors" or "HIV/AIDS" "Hill" or "Alors" or "HIV/AIDS" "Hill" or "Alors" or "HIV/AIDS" "Hill" or "Alors" or "HIV/AIDS" "Inject Drug Use" IDU "People Whol Inject Drugs" PWID * Relevant results so then searched OST Ospital Substitution" MMT Methadone Buprenorphine Opioid agonist OAR Medication Assisted MAT "Drug Treatment" "Drug Treatment" "Anar "Bruge Program" NSP NSP "Needle and Syringe Program" NSP "Needle and Syringe Program" ART (specified not "Assisted Aeproductive —Technologies") Highly Active Antiretroviral Therapy" Highly Active Antiretroviral | | | | _ |
|--|--|---|------|----|
| NSP Spr Syringe Exchange Program" 2 0 0 0 0 0 0 0 0 0 | | "needle provision" altered to "needle exchange" based on website language | 48 | 0 |
| "Syringe Exchange Program" 2 0 SEP 0 0 "Antiretroviral Therapy" 1 0 Highly Active Antiretroviral Therapy" 0 0 "Highly Active Antiretroviral Therapy" 0 0 "HART 0 0 "HIV Treatment" 28 0 Condom 3 0 "Targeted Info" 1 0 Courselling 5 0 VCT 0 0 "Hey Esting" 7 0 "Hep C" 27 0 "Hy Testing" 7 0 "Hep C" 27 0 "Hep C" 27 0 "Hep C" 27 0 "Me Call S | | | 13 | 0 |
| SEP | | | 3 | 0 |
| "Antiretroviral Therapy" 1 0 0 0 1 | | "Syringe Exchange Program" | 2 | 0 |
| ART 0 0 0 | | | 0 | 0 |
| "Highly Active Antiretroviral Therapy" 0 0 0 0 0 0 0 0 0 | | "Antiretroviral Therapy" | 1 | 0 |
| HAAFT | | ART | 0 | 0 |
| #INIV Treatment" 28 0 Condom 3 0 Condom 3 0 "Targeted Info" 1 0 Counselling 5 0 VCT 0 0 0 "Hill V Testing" 7 0 "Hept C" 27 0 "Hept C" 27 0 "Hept C" 27 0 "Hept C" 27 0 "Hill "On "AIDS" 0 1 0 "Inject on Action — HIV and AIDS Data Hub for Asia-Pacific 1 | | "Highly Active Antiretroviral Therapy" | 0 | 0 |
| Condom | | HAART | 0 | 0 |
| ### Targeted Info" Counselling Counselling VCT 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 1 1 0 | | "HIV Treatment" | 28 | 0 |
| Counselling | | Condom | 3 | 0 |
| VCT 0 0 "HIV Testing" 7 0 "Hepatitis C" 27 0 "Hep C" 27 0 "Hiv" OR "AIDS" OR "HIV/AIDS" 30 0 Evidence to Action − HIV and AIDS Data Hub for Asia-Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID ** * Relevant results so then searched 270 10 * OST 270 10 "opiate substitution" 60 2 MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "NSP 560 0 "Syringe Exchange Program" 42 0 SEP 236 0 "Antiretroviral Therapy" 102 | | "Targeted Info" | 1 | 0 |
| "Hobatils C" 27 0 "Hepatils C" 27 0 "Hep C" 27 0 "HIV" OR "AIDS" OR "HIV/AIDS" 30 0 Evidence to Action – HIV and AIDS Data Hulf for Asia-Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID *** *** *** ** *** | | Counselling | 5 | 0 |
| "Hepatitis C" 27 0 "Hep C" 27 0 "HU" "OR "AIDS" OR "HIV/AIDS" 30 0 Evidence to Action − HIV and AIDS Data Hub for Asia-Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID ** <t< td=""><td></td><td></td><td>0</td><td>0</td></t<> | | | 0 | 0 |
| "Hepatitis C" 27 0 "Hep C" 27 0 "HU" "OR "AIDS" OR "HIV/AIDS" 30 0 Evidence to Action − HIV and AIDS Data Hub for Asia-Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID ** <t< td=""><td></td><td>"HIV Testing"</td><td>7</td><td>0</td></t<> | | "HIV Testing" | 7 | 0 |
| "Hep C" "HIV" OR "AIDS" OR "HIV/AIDS" 27 0 Evidence to Action – HIV and AIDS Data Hub for Asia- Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID Tight of Thighet Drugs" PWID http://www.aidsdatahub.org/ Relevant results so then searched 270 10 MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "brug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 NSP 560 0 "NSP 560 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 27 | 0 |
| Evidence to Action − HIV and AIDS Data Hub for Asia-Pacific "Inject Drug Use" IDU "People Who Inject Drugs" PWID http://www.aidsdatahub.org/ SEP 270 10 muscaliss 152 3 3 muscaliss 428 2 2 MMT 428 2 2 3 4 3 3 4 3 3 4 3 3 4 3 3 4 3 4 3 4 4 3 4 | | | 27 | 0 |
| Fividence to Action – HIV and AIDS Data Hub for Asia-Pacific http://www.aidsdatahub.org/ OST "opiate substitution" MMT Methadone Buprenorphine Opioid agonist OAT OAT Opioit agonist OAT Medication Assisted MAT "Drug Treatment" "Drug Treatment" "harm reduction" "heedle provision" "eneedle provision" "Reedle and Syringe Program" SEP "Syringe Exchange Program" SEP "Antitertoviral Therapy" ART (specified not "Assisted -Reproductive –Technologies") "Highly Active Antiretroviral Therapy" Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly Active Antiretroviral Therapy Highly | | | | 0 |
| Relevant results so then searched http://www.aidsdatahub.org/ OST 270 10 "opiate substitution" 60 2 MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Ant (specified not "Assisted -Reproductive -Technologies") 1120 9 "Highly Active Antiretroviral Therapy" 102 0 | Evidence to Action – HIV and AIDS Data Hub | | | |
| "opiate substitution" 60 2 MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | for Asia-Pacific | | | |
| "opiate substitution" 60 2 MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | http://www.aidsdatahub.org/ | OST | 270 | 10 |
| MMT 152 3 Methadone 428 2 Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "brug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | "opiate substitution" | 60 | 2 |
| Buprenorphine 144 3 Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 152 | 3 |
| Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | Methadone | 428 | 2 |
| Opioid agonist 9 0 OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | Buprenorphine | 144 | 3 |
| OAT 4 0 Medication Assisted 7 0 MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 9 | 0 |
| MAT 43 0 "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 4 | 0 |
| "Drug Treatment" 325 1 "harm reduction" 755 2 "needle provision" 2 0 "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 560 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive –Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | Medication Assisted | 7 | 0 |
| "harm reduction"7552"needle provision"20"Needle and Syringe Program"420NSP5600"Syringe Exchange Program"670SEP2360"Antiretroviral Therapy"11209ART (specified not "Assisted -Reproductive –Technologies")17207"Highly Active Antiretroviral Therapy"1020 | | MAT | 43 | 0 |
| "harm reduction"7552"needle provision"20"Needle and Syringe Program"420NSP5600"Syringe Exchange Program"670SEP2360"Antiretroviral Therapy"11209ART (specified not "Assisted -Reproductive –Technologies")17207"Highly Active Antiretroviral Therapy"1020 | | "Drug Treatment" | 325 | 1 |
| "needle provision"20"Needle and Syringe Program"420NSP5600"Syringe Exchange Program"670SEP2360"Antiretroviral Therapy"11209ART (specified not "Assisted -Reproductive –Technologies")17207"Highly Active Antiretroviral Therapy"1020 | | | 755 | 2 |
| "Needle and Syringe Program" 42 0 NSP 560 0 "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive –Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 2 | 0 |
| NSP "Syringe Exchange Program" SEP 236 "Antiretroviral Therapy" ART (specified not "Assisted -Reproductive –Technologies") "Highly Active Antiretroviral Therapy" 102 0 | | | 42 | 0 |
| "Syringe Exchange Program" 67 0 SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive –Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | | 0 |
| SEP 236 0 "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive –Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | "Syringe Exchange Program" | | 0 |
| "Antiretroviral Therapy" 1120 9 ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 236 | 0 |
| ART (specified not "Assisted -Reproductive -Technologies") 1720 7 "Highly Active Antiretroviral Therapy" 102 0 | | | 1120 | 9 |
| "Highly Active Antiretroviral Therapy" 102 0 | | | | 7 |
| | | | | |
| | | | | |

| | "HIV Treatment" | 807 | 3 |
|--|--|-------|---|
| | Condom | 2460 | 0 |
| | "Targeted Information" | 62 | 0 |
| | Counselling | 1530 | 0 |
| | VCT | 976 | 3 |
| When searched "HIV AND "AIDS" AND | "HIV Testing" | 1470 | 1 |
| HIV/AIDS" came up with 5510 resultd. | "Hepatitis C" | 485 | 0 |
| earched: "HIV" OR "AIDS" OR "HIV/AIDS" | "Hep C" | 29 | 0 |
| IND INJECT, instead. | "HIV" OR "AIDS" OR "HIV/AIDS" | 1,450 | 0 |
| VHO Regional office for SE Asia | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | 1,430 | 0 |
| The Regional office for 32 Asia | Relevant results so then searched | 104 | 4 |
| ttp://www.searo.who.int/ | Nelevant results so then searched | 0 | 4 |
| ttp.//www.searo.wno.mt/ | OST | 32 | |
| | "opiate substitution" | 117 | |
| | MMT | 46 | |
| | Methadone | 6 | |
| | Buprenorphine | 19 | |
| | Opioid agonist | 0 | |
| | OAT | 372 | |
| | Medication Assisted | 282 | |
| | MAT | | 4 |
| | | 224 | 1 |
| | "Drug Treatment" | 0 | |
| | "harm reduction" | 0 | |
| | "needle provision" | 115 | |
| | "Needle and Syringe Program" | 1 | |
| | NSP | 775 | |
| | "Syringe Exchange Program" | 457 | 8 |
| | SEP | 971 | 2 |
| 660 for "HIV" OR "AIDS" OR "HIV/AIDS" | "Antiretroviral Therapy" | 45 | |
| dded AND INJECT | ART (specified not "Assisted -Reproductive –Technologies") | 68 | |
| | "Highly Active Antiretroviral Therapy" | 225 | |
| | HAART | 505 | |
| | "HIV Treatment" | 15 | |
| | Condom | 1340 | |
| | "Targeted Information" | 203 | |
| | Counselling | 439 | |
| | VCT | 307 | |
| | "HIV Testing" | 5 | |
| | "Hepatitis C" | 257 | |
| | "Hep C" | | |

| | "HIV" OR "AIDS" OR "HIV/AIDS" AND INJECT | | |
|------------------------------------|--|---------------|---|
| Malta Ministry of Social Policy | Inject Drug Use | No Results in | 0 |
| http://www.sahha.gov.mt/pages.aspx | IDU | quotes | 0 |
| | People Who Inject Drugs | 27 | 0 |
| | PWID | 1 | 0 |
| | No relevant results – did not continue searching the website | 0 | |

| Poland: National AIDS Centre | Inject Drug Use | No Results in | 0 |
|--|---|---------------|---|
| http://www.aids.gov.pl/epidemiology/polan | IDU | quotes | 1 |
| <u>d/</u> | People Who Inject Drugs | 90 | 1 |
| | PWID | 9 | 0 |
| | | 8 | |
| | OST | | |
| | "opiate substitution" - opioid substytucji | | 0 |
| | MMT | 3 | |
| | Methadone - Metadon | | 0 |
| | Buprenorphine - buprenorfina | 34 | 0 |
| | Opioid agonist - agonista opioidów | 8 | 0 |
| | OAT | 0 | |
| | Medication Assisted - leki Assisted | | |
| | MAT | No Results in | |
| | "Drug Treatment" - "Drug Treatment" | quotes | 0 |
| | "harm reduction" - "redukcja szkód" | | 0 |
| | "needle provision" - "Przepis Igła" | 4 | |
| | | 35 | |
| | NO RESULTS SO STOPPED SEARCHING | No Results in | |
| | | quotes | |
| WHO Regional office for Eastern | "Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| Mediterranean | Relevant results so then searched | | |
| http://www.emro.who.int/ | OST | 235 | |
| | "opiate substitution" | 6 | |
| A few of the sites had a privacy error and did | MMT | 63 | |
| not let me click through the link | Methadone | 239 | |
| | Buprenorphine | 129 | |
| | Opioid agonist | 68 | |
| | OAT | 122 | |
| | Medication Assisted | 0 | |

| | MAT | 446 | |
|--|--|------|---|
| | "Drug Treatment" | 407 | |
| | "harm reduction" | 282 | 2 |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 1 | |
| | NSP | 31 | |
| | "Syringe Exchange Program" | 1 | |
| | SEP | 3370 | |
| | "Antiretroviral Therapy" | 584 | 3 |
| | ART -competition | 1940 | |
| | "Highly Active Antiretroviral Therapy" | 73 | |
| | HAART | 93 | |
| | "HIV Treatment" | 367 | 1 |
| | Condom | 408 | |
| | "Targeted Information" | 2 | |
| | Counselling | 1810 | 1 |
| | VCT | 144 | |
| | "HIV Testing" | 530 | |
| | "Hepatitis C" | 2230 | |
| | "Hep C" | 50 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" AND INJECT | 168 | |
| lational Institute of Public Health – National | Google advanced search using the terms: | | |
| nstitute of Hygiene (NIPH – NIH) | "Inject Drug Use" "IDU" "People Who Inject Drugs" "PWID" | 0 | 0 |
| ttp://www.pzh.gov.pl/ | | | |
| /HO Regional office for Europe | Inject Drug Use" IDU "People Who Inject Drugs" PWID | | |
| ttp://www.euro.who.int/ | Relevant results so then searched | | |
| | | | |
| | OST | 20 | |
| | "opiate substitution" | 4 | |
| | MMT | 1 | |
| | Methadone | 32 | 1 |
| | Buprenorphine | 1 | |
| | Opioid agonist | 1 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 5 | |
| | "Drug Treatment" | 39 | |
| | "harm reduction" | 208 | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 0 | |

| | NSP | 3 | |
|-----------------------------------|---|-----|---|
| | "Syringe Exchange Program" | 0 | |
| | SEP | 6 | |
| | "Antiretroviral Therapy" | 116 | 1 |
| | ART | 255 | |
| | "Highly Active Antiretroviral Therapy" | 1 | |
| | HAART | 5 | |
| | "HIV Treatment" | 102 | 5 |
| | Condom | 38 | |
| | "Targeted Information" | 5 | |
| | Counselling | 327 | 1 |
| | VCT | 0 | _ |
| | "HIV Testing" | 127 | |
| | "Hepatitis C" | 192 | |
| | "Hep C" | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" AND INJECT | 176 | 2 |
| Czech Republic Ministry of Health | Inject Drug Use" IDU "People Who Inject Drugs" PWID | 170 | |
| http://www.mzcr.cz/ | Relevant results will continue search with translation. | | |
| incep.// www.inizer.cz/ | OST | 241 | |
| | "opiate substitution" | 0 | |
| | MMT | 1 | |
| | Methadone | 4 | |
| | Buprenorphine | 9 | |
| | Opioid agonist | 0 | |
| | OAT | 2 | |
| | Medication Assisted | 0 | |
| | MAT | 289 | |
| | "Drug Treatment" | 9 | |
| | "harm reduction" | 34 | |
| | | | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" NSP | 0 | |
| | | 126 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 79 | |
| | "Antiretroviral Therapy" | 6 | |
| | ART | 746 | |
| | "Highly Active Antiretroviral Therapy" | 0 | |
| | HAART | 1 | |
| | "HIV Treatment" | 0 | |
| | Condom | 3 | |

| | // | | |
|---|--|--|--|
| | "Targeted Information" | 3 | |
| | Counselling | 27 | |
| | VCT | 1 | |
| | "HIV Testing" | 5 | |
| | "Hepatitis C" | 12 | |
| | "Hep C" | 0 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" AND INJECT | 1 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 8190 | |
| | Translated from English to Czech: | | |
| | Not translated (OST) | | |
| | Opiátový substituce (Opiate Substitution | 0 | |
| | Not translated (MMT) | | |
| | Metadon (Methadone) | 89 | |
| | buprenorfin (Buprenorphine) | 56 | |
| | opioidní agonista (opioid agonist) | 0 | |
| | Not translated (OAT) | | |
| | léky Asistovaná (medication assisted) | 1 | |
| | Not translated (MAT) | | |
| | Drug léčba (Drug treatment) | 0 | |
| | Harm reduction (Harm reduction) | | |
| | Poskytování jehla (needle provision) | 0 | |
| | Jehel a stříkaček Program (needle and syringe program) | 0 | |
| | Not translated (NSP) | | |
| | Program výměny injekčních stříkaček (Syringe exchange program) | 0 | |
| | Not translated (SEP) | | |
| | Antiretrovirální terapii (antiretroviral therapy) | 0 | |
| | Not translated (ART) | • | |
| | Vysoce aktivní antiretrovirální terapie (Highly Active Antiretroviral Therapy) | 0 | |
| | Not translated (HAART) | , and the second second second second second second second second second second second second second second se | |
| | HIV Léčba (HIV Treatment) | 0 | |
| | Kondom (condom) | 41 | |
| | Cílená informace (Targeted information) | 0 | |
| | poradenství (counselling) | • | |
| | Not translated (VCT) | | |
| | Testování HIV (HIV Testing) | 80 1 | |
| | Hepatitida C (Hepatitis C) | 22 | |
| | Not translated (Hep C) | 0 | |
| | " ""HIV"" OR ""AIDS"" OR ""HIV/AIDS"" AND | 12 | |
| | injekčním" | 12 | |
| Czech National Institute of Public Health | injekeniini | | |

| http://www.szu.cz | Inject Drug Use" IDU "People Who Inject Drugs" PWID No relevant results, or out of date range. Translated: injekci užívání drog –Inject drug use lidé, kteří drogy injekčně –people who inject drugs No relevant results. Did not continue further. | | |
|---|--|------------------|------------------|
| Slovenia: Ministrstvo za zdravje http://www.mz.gov.si/ | Inject Drug Use - Wstrzykiwać narkotyki IDU People Who Inject Drugs - Ludzie, którzy wstrzykiwania narkotyków PWID No relevant sites found, no further searching | 0 4 0 0 | 0 0 0 0 |
| Italy Istituto Superiore di Sanita | Inject Drug Use" IDU "People Who Inject Drugs" PWID No relevant results, or out of date range. Translated to Italian: iniettare l'uso di droghe –inject drug use le persone che si iniettano droghe –Peopl e who inject drugs No relevant results. Checked "Sostituzione degli oppiacei" – opiate substitution and "metadone" – methadone as well to make sure. No relevant results. | | |
| Slovakia: Ministerstvo zdravotníctva http://www.health.gov.sk/Index.aspx | Inject Drug Use - Vstreknúť užívania drog IDU People Who Inject Drugs - Ľudia, ktorí drogy injekčne PWID | 0 2 0 0 | 0 0 0 0 |
| Romania: Comisia Nationala de Lupta Anti- SIDA http://www.cnlas.ro/ | Inject Drug Use" IDU "People Who Inject Drugs" PWID No relevant results. Translated into Romanian: injecta consumul de droguri –Inject drug use persoanele care injectează droguri –people who inject drugs | | |
| The Harm Reduction Coalition (HRC) www.harmreduction.org | No relevant results. Inject Drug Use IDU People Who Inject Drugs PWID | 0 0 0 | 0 0 0 |

| | No relevant results. | | |
|--|---|------|--------------|
| | | | |
| | | | |
| Canadian Harm Reduction Network | Inject Drug Use | 0 | 0 |
| http://www.canadianharmreduction.com/ | IDU | 62 | 19 |
| | People Who Inject Drugs | 84 | 12 |
| | PWID | 8 | 3 |
| | | | |
| | OST | 17 | 6 |
| | "opiate substitution" | 19 | 4 |
| | MMT | 98 | 6 |
| | Methadone | 273 | 30 |
| | Buprenorphine | 117 | 7 |
| | Opioid agonist | 7 | 4 |
| | OAT | 0 | 0 |
| | Medication Assisted | 7 | 2 |
| | MAT | 6 | 1 |
| | "Drug Treatment" | 135 | 22 |
| | "harm reduction" | 1170 | (search |
| | "needle provision" | 86 | stopped from |
| | "Needle and Syringe Program" | 113 | hereon) |
| | NSP | 36 | |
| | "Syringe Exchange Program" | 75 | |
| | SEP | 44 | |
| | "Antiretroviral Therapy" | 73 | |
| | ART (specified not "Assisted -Reproductive –Technologies") | 93 | |
| | "Highly Active Antiretroviral Therapy" | 9 | |
| | HAART | 6 | |
| | "HIV Treatment" | 307 | |
| | Condom | 38 | |
| | "Targeted Info" | 27 | |
| | Counselling | 134 | |
| | VCT | 2 | |
| | "HIV Testing" | 56 | |
| | "HIV" OR "AIDS" OR "HIV/AIDS"(this one can be searched using the "any of these words" box, as long as | 560 | |
| | OR is between them). | | |
| | | | |
| SAMHSA | Inject Drug Use | 0 | 0 |
| http://store.samhsa.gov/home | IDU | 0 | 0 |
| | People Who Inject Drugs | 0 | 0 |

| | PWID | 0 | 0 |
|--|--|-----|--------------|
| | No relevant results. | | |
| | | | |
| | | | |
| Public Health Agency of Canada | Inject Drug Use | 0 | 0 |
| | IDU | 0 | 0 |
| http://www.phac-aspc.gc.ca/index- | | - | |
| eng.php?utm_source=VanityURL&utm_medi | People Who Inject Drugs | 0 | 0 |
| um=URL&utm_campaign=publichealth.gc.ca | PWID | 0 | 0 |
| | No relevant results. | | |
| | | | |
| | | | |
| Office of National Drug Control Policy | Inject Drug Use | 1 | 0 |
| (ONDCP) | IDU | 2 | 0 |
| https://www.whitehouse.gov/ondcp (link | People Who Inject Drugs | 1 | 0 |
| error) | PWID | 0 | 0 |
| (checked https://www.whitehouse.gov/ | No relevant results. | | |
| instead) | | | |
| msteady | Inject Drug Use | 0 | 0 |
| | IDU | | 1 (many site |
| | | 44 | |
| | People Who Inject Drugs | 42 | errors) |
| | PWID | 5 | 1 |
| | | | 1 |
| | OST | 278 | |
| | "opiate substitution" | 1 | 0 |
| | MMT | 49 | 0 page error |
| | Methadone | 106 | 0 |
| | Buprenorphine | 78 | 0 |
| | Opioid agonist | 17 | 0 |
| | OAT | 22 | 0 page error |
| | Medication Assisted | 132 | 0 |
| | MAT | 252 | 1 |
| | "Drug Treatment" | 515 | 3 |
| | "harm reduction" | 21 | |
| | | | 1 |
| | "needle provision" | 0 | 0 |
| | "Needle and Syringe Program" | 118 | 0 |
| | NSP | 0 | 0 |
| | "Syringe Exchange Program" | 3 | 0 |
| | SEP | 0 | 0 |
| | "Antiretroviral Therapy" | 55 | 0 |
| | ART (specified not "Assisted -Reproductive –Technologies") | 0 | 5 |

| | "Highly Active Antiretroviral Therapy" HAART "HIV Treatment" Condom "Targeted Info" Counselling VCT "HIV Testing" "HIV" OR "AIDS" OR "HIV/AIDS"(this one can be searched using the "any of these words" box, as long as OR is between them). | 9 25 127 43 0 27 2 329 3660 | 0 0 0 7 3 0 0 0 5 14 |
|--|--|---|---|
| Canadian Community Epidemiology Network on Drug Use (CCENDU) http://www.ccsa.ca/Eng/collaboration/CCE NDU/Pages/default.aspx | Inject Drug Use IDU People Who Inject Drugs PWID No relevant results. | 0 0 0 | 0 0 0 0 |
| Canadian Centre on Substance Abuse (CCSA) http://www.ccsa.ca/Pages/default.aspx | Inject Drug Use IDU People Who Inject Drugs PWID No relevant results. | 0 0 0 0 | 0 0 0 |
| http://www.narko.ee/ Estonia National Institute for Health Development | Inject Drug Use - süstida uimastitarbimise IDU People Who Inject Drugs - Inimesed, kes süstivad narkootikume PWID No Relevant results | 0 in quotes 0 0 in quotes 0 | |
| http://sam.lrv.lt/ Lithuania Ministry of Health | Inject Drug Use - Sušvirkškite narkotikų vartojimo IDU - ŠNV People Who Inject Drugs - Švirkščiamuosius narkotikus vartojančių žmonių PWID – PWID Did not continue search – the 1 result I have is general harm reduction program with other countries not Lithuania specific. | 0 in quotes 2 1 2 | 0 0 1 |
| http://www.minzdrav.by/ Ministry of Health of the Republic of Belarus (MH RB) | Inject Drug Use - Вводят употребления наркотиков IDU – IDU People Who Inject Drugs - Люди, потребляющие инъекционные наркотики | 0 0 0 | |

| | PWID | 0 | |
|-------------------------------------|---|---|---|
| | | | |
| | | | |
| http://aidscenter.ge/index_eng.html | Inject Drug Use | 0 | |
| Georgia: AIDS & Clinical Immunology | IDU | 2 | 0 |
| Research Centre | People Who Inject Drugs | 0 | |
| | PWID | 0 | |
| | | | |
| | *** Cannot find language it is written in*** nothing works well in google translate | | |
| | | | |
| | | | |
| Armenia: National Centre for AIDS | Searched following in English | | |
| Prevention | Inject drug Use | 0 | |
| http://www.armaids.am | IDU | 0 | |
| | People who inject drugs | 2 | 1 |
| | PWID | 4 | |
| | OST | 0 | |
| | "opiate substitution" | 0 | |
| | MMT | 0 | |
| | Methadone | 3 | |
| | Buprenorphine | 0 | |
| | Opioid agonist | 0 | |
| | OAT | 0 | |
| | Medication Assisted | 0 | |
| | MAT | 0 | |
| | "Drug Treatment" | 0 | |
| | "harm reduction" | 2 | |
| | "needle provision" | 0 | |
| | "Needle and Syringe Program" | 2 | |
| | NSP | 0 | |
| | "Syringe Exchange Program" | 0 | |
| | SEP | 0 | |
| | "Antiretroviral Therapy" | 5 | |
| | ART | 7 | |
| | "Highly Active Antiretroviral Therapy" | 0 | |
| | HAART | 0 | |
| | "HIV Treatment" | 2 | |
| | Condom | 4 | |
| | "Targeted Information" | 0 | |
| | Counselling | 6 | |

| | VCT | 0 | |
|--|---|---------------|---|
| | "HIV Testing" | 2 | |
| | "Hepatitis C" | 3 | |
| | "Hep C" | 0 | |
| Did not translate acronyms as they would likely not translate. | "HIV" OR "AIDS" OR "HIV/AIDS" | 749 | |
| | Searched site again in Armenian translations: | | |
| | Ներարկել թմրամիջոցների օգտագործումը (Inject drug use) | | |
| | Ով մարդիկ ներարկել թմրանյութեր (People who inject drugs) | | |
| | «Opiate փոխարինում» (Opiate substitution) | | |
| | Մեթադոնային (Methadone) | 1 | |
| | Բուպրենորֆին (Burpenorphine) | | |
| | ափիոնային ագոնիստներով (Opioid agonist) | | |
| | դեղորայք Աջակցել (Medication assisted) | | |
| | «Drug คาเปกเน้» (Drug treatment) | | |
| | «Վնասի նվազեցումը» (harm reduction) | | |
| | «Ասեղ դրույթը» (needle provision) | | |
| | «Ասեղ եւ ներարկիչ ծրագիր» (needle & Syringe program) | | |
| | «Ներարկիչ փոխանակման ծրագիր" (Syringe exchange program) | | |
| | «Շակառետրովիրուսային բուժում» (antiretroviral therapy) | 20 | |
| | «Բարձր ակտիվ հակառետրովիրուսային թերապիա» (Highly Active antiretroviral therapy | 20 | |
| | | | |
| | «ՄԻԱՎ-ի բուժման» (HIV treatment) | | |
| | Պահպանակներ (condom) | 2 | |
| | «Թիրախային Տեղեկատվական» (targeted information) | 2 | |
| | Խորհրդատվական (counselling) | | |
| | «ՄԻԱՎ-ի թեստավորման» (HIV testing) | 3 | |
| | «Հեպատիտ C" (hepatitis C) | 0 | |
| | «ՄԻԱՎ-ի», OR «ՁԻԱՀ» OR «ՄԻԱՎ / ՁԻԱՀ-ի» "HIV" OR "AIDS" OR "HIV/AIDS" | 9 | |
| | | 538 | |
| http://www.ulac.lt | Inject Drug Use - english | No results in | 0 |
| Lithuania: AIDS Centre | IDU - english | quotes | 1 |
| | People Who Inject Drugs - english | 2 | 4 |
| | PWID – English | 34 | 0 |
| | | 4 | |
| | Sušvirkškite narkotikų vartojimo | | 0 |
| | ŠNV | 0 | 1 |
| | Švirkščiamuosius narkotikus vartojančių žmonių | 42 | 0 |
| | PWID – no translation | 3 | 0 |

| | 0 | |
|--|---------------|---|
| Inject drug Use | | 0 |
| IDU | No results in | 0 |
| People who inject drugs | quotes | 0 |
| PWID | 2 | 0 |
| | 7 | |
| OST | 3 | 0 |
| "opiate substitution" | | 0 |
| opiatų pakeitimo | 1 | 0 |
| MMT | 0 | 0 |
| Methadone | 0 | 0 |
| Metadonas | 0 | 0 |
| Buprenorphine | 1 | 0 |
| buprenorfinas | 0 | 0 |
| Opioid agonist | 1 | 0 |
| opioidų agonistas | 0 | 0 |
| OAT | 0 | 0 |
| Medication Assisted | 0 | 0 |
| Vaistai Assisted | 0 | 0 |
| MAT | 0 | 0 |
| "Drug Treatment" | 0 | 0 |
| narkotikų gydymo | 0 | 0 |
| "harm reduction" | 2 | 0 |
| žalos mažinimo | 0 | 0 |
| "needle provision" | 3 | O |
| adata nuostata | 0 | 0 |
| "Needle and Syringe Program" | No results in | 0 |
| Adatų ir švirkštų keitimo programa | | 0 |
| NSP | quotes 0 | 0 |
| "Syringe Exchange Program" | No results in | 0 |
| | | |
| Švirkštų keitimo programa SEP | quotes | 0 |
| | 0 | 0 |
| "Antiretroviral Therapy" | 0 | 0 |
| antiretrovirusinį gydymą | No results in | 0 |
| ART | quotes | 0 |
| "Highly Active Antiretroviral Therapy" | 0 | 0 |
| Labai aktyvus antiretrovirusinis gydymas | 16 | 0 |
| HAART | 7 | 0 |
| "HIV Treatment" | 0 | 0 |
| ŽIV gydymas | 5 | 0 |

| | Condom | 1 | 0 |
|--|---|---------------|---|
| | prezervatyvas | 0 | 0 |
| | "Targeted Information" | 2 | 0 |
| | Tikslinės Informacija | 8 | 0 |
| | Counselling | 0 | 0 |
| | Konsultavimas | 6 | 0 |
| | "VCT" | 0 | 0 |
| | "Hepatitis C" | No results in | 0 |
| | hepatitas C | quotes | 0 |
| | "Hep C" | 0 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" | 4 | 0 |
| | ŽIV / AIDS | 0 | 0 |
| | | 2 | |
| | | 8 | |
| | | 1 | |
| | | No results in | |
| | | quotes | |
| | | 14 | |
| | | 2 | |
| http://www.moz.gov.ua/ua/portal/ | Searched following in English | _ | |
| Armenia: National Centre for AIDS | Inject drug use | | |
| Prevention | IDU | | |
| | People who inject drugs | | |
| | PWID | | |
| | Continued search in Ukrianian: | | |
| Saved a file to 'oother hand search' from | Опіат заміна (Opiate substitution) | 0 | 0 |
| 'syringe exchange program' translation. Came | Метадон (methadone) | 190 | 1 |
| up in search results that were not exact | Бупренорфін (buprenorphine) | 28 | 1 |
| matches. | опіоїдними агоністами (Opioid agonist) | 0 | 0 |
| materies. | Медикаменти Assisted (medication assisted) | 0 | 0 |
| Changed translation of 'condom' to | Наркологічний (Drug treatment) | 121 | 0 |
| 'condoms'. Thought strange that condom | Зниження шкоди (harm reduction) | 17 | 1 |
| (кондом) came up with nothing. Translated | Положення голки (needle provision) | 0 | 0 |
| 'condoms'. Plural word looks completely | голька і Програма Шприц (Needle and syringe program) | 0 | 0 |
| different and got hits. | Програма обміну шприців (Syringe exchange program) | 0 | 0 |
| uniciciit anu got mis. | Антиретровірусна терапія (antiretroviral therapy) | 50 | 1 |
| Changed final search translation from AND | Високоактивна антиретровірусна терапія (Highly active antiretroviral therapy) | 3 | 0 |
| INJECT (ANDвпорснути) —no hits, to AND | | 3 868 | 1 |
| injecting (AND ін'єкційних) had hits. | Лікування ВІЛ (HIV treatment) | 93 | 0 |
| пјестив (АМД ін Єкційних) пад піть. | Презервативи (condoms) | 93 | 0 |
| | Цільова інформація (targeted information) | U | U |

| 1190 1440 530 OR AIDS OR HIV/AIDS AND injecting) 628 | |
|--|-------------------------------|
| 530 | 0 |
| | |
| OR AIDS OR HIV/AIDS AND injecting) 628 | 0 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| TC) | |
| 53) | |
| | |
| | |
| | |
| | |
| | |
| rugs" OR "PWID" OR "CIH" OR "ЛВІН" OR 0 | |
| | |
| n therapy" OR "Лікування залежності" OR 4 | 0 |
| | |
| | 0 |
| рвативи" OR "консультування" | |
| rugs" OR "PWID" OR "CIH" OR "ЛВІН" OR 173 | 1 |
| | |
| n therapy" OR "Лікування залежності" OR 211 | 0 |
| | |
| OR "APT" OR "Антиретровірусна терапія" OR 235 | 0 |
| and the base of the second sec | |
|)R "тестування" 189 | 0 |
| | 0 |
| | 0 |
| | 1 |
| | 1 |
| рвативи От консультування | |
| | |
| rugs" OR "PWID" OR "CIH" OR "ARIH" OR 147 | 1 |
| Table On The On the On The On The On | 1 |
| d r | ервативи" OR "консультування" |

| | "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лікування залежності" OR "Замісна підтримувальна терапія" OR "ЗПТ" | 561 | 1 |
|------------------------------|--|------|---|
| | "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "APT" OR "Антиретровірусна терапія" OR "лікування ВІЛ" | 533 | 0 |
| | "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестування" | 353 | 0 |
| | "Hepatitis C" OR "Hep C" OR "ВГС" OR "Гепатит С" | 164 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВІЛ" OR "СНІД" OR "ВІЛ/СНІД" | 2180 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR "обміну шприців" OR "зменшення шкоди" OR "презервативи" OR "консультування" | 304 | 0 |
| epublican AIDS Center | | | |
| http://www.aidscenter.kg/ru/ | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | 70 | 1 |
| | "Заместительная терапия" OR "ЗПТ" OR "ОЗТ" "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "АРТ" OR "Антиретровирусная терапия" OR | 31 | 0 |
| | "лечение ВИЧ" "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | 61 | 0 |
| | "Hepatitis C" OR "Hep C" OR "BГС" OR "Гепатит С" | 7 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 5 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 442 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 4 | 0 |
| http://www.kg.undp.org | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR | 39 | 1 |
| Cyrgyz office of UNDP | "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | | |
| | "Заместительная терапия" OR "ЗПТ" OR "ОЗТ" "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "АРТ" OR "Антиретровирусная терапия" OR | 22 | 0 |
| | "лечение ВИЧ" "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | 79 | 0 |
| | "Hepatitis C" OR "Hep C" OR "ВГС" OR "Гепатит С" | 37 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 9 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 1240 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 219 | 0 |
| ttp://www.aids.by | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR | 121 | 1 |
| elarussian knowledge portal | "Потребители инъекционных наркотиков" ОR "люди употребляющие инъекционные наркотики" | | |

| | "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR "Заместительная терапия" OR "ЗПТ" OR "ОЗТ" | 93 | 0 |
|--|--|------|---|
| | "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "APT" OR "Антиретровирусная терапия" OR "лечение ВИЧ" | 194 | 0 |
| | "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | 968 | 0 |
| | "Hepatitis C" OR "Hep C" OR "ВГС" OR "Гепатит С" | 50 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 2380 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 185 | 0 |
| Curatio foundation http://curatiofoundation.org/bbs-7cities-2015/ | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | 188 | 1 |
| | "Заместительная терапия" OR "ЗПТ" OR "OЗТ" "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "APT" OR "Антиретровирусная терапия" OR | 14 | 0 |
| | "лечение ВИЧ" "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | 162 | 0 |
| | "Hepatitis C" OR "Hep C" OR "ВГС" OR "Гепатит С" | 30 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 183 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 443 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 82 | 0 |
| Republican AIDS Center http://www.cnms.md/ | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | 0 | 1 |
| | "Заместительная терапия" OR "ЗПТ" OR "ОЗТ" "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "АРТ" OR "Антиретровирусная терапия" OR | 1 | 0 |
| | "лечение ВИЧ" "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | 44 | 0 |
| | "Hepatitis C" OR "Hep C" OR "BГС" OR "Гепатит С" | 10 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 4 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 165 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультировани | 7 | 0 |
| Republican AIDS Center http://www.rcaids.kz | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | 349 | 0 |
| | "Заместительная терапия" OR "ЗПТ" OR "OЗТ" "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "APT" OR "Антиретровирусная терапия" OR | 204 | 0 |
| | "лечение ВИЧ" | 317 | 0 |

| | "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" "Hepatitis C" OR "Hep C" OR "BГС" OR "Гепатит С" | 909 | 0 |
|-------------------------------|--|------|---|
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 87 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 5310 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 838 | 0 |
| Republican AIDS Center | "Injecting Drug Use" OR "IDU" OR "People who inject drugs" OR "PWID" OR "ПИН" OR "ЛУИН" OR "Потребители инъекционных наркотиков" OR "люди употребляющие инъекционные наркотики" | 19 | 0 |
| <u>πειμ.//www.nc-aiαs.τj/</u> | "Drug treatment" OR "OST" OR "MAT" OR "Substitution therapy" OR "Лечение зависимости" OR | | |
| | "Заместительная терапия" ОR "ЗПТ" ОR "ОЗТ" | 1 | 0 |
| | "ART" OR "HIV treatment" OR "Antiretroviral therapy" OR "APT" OR "Антиретровирусная терапия" OR | | |
| | "лечение ВИЧ" | 85 | 0 |
| | "VCT" OR "HCT" OR "HTC" OR "HIV testing" OR "ДКТ" OR "тестирование" | | |
| | "Hepatitis C" OR "Hep C" OR "BГС" OR "Гепатит С" | 95 | 0 |
| | "HIV" OR "AIDS" OR "HIV/AIDS" OR "ВИЧ" OR "СПИД" OR "ВИЧ/СПИД" | 7 | 0 |
| | "Harm reduction" OR "condoms" OR "counseling" OR "NSP" OR "SEP" OR "Syringe exchange" OR | 512 | 0 |
| | "обмен шприцев" OR "снижение вреда" OR "презервативы" OR "консультирование" | 39 | 0 |

| Total Screened: | Total First Pass: |
|------------------------|-------------------|
| 212,164 | 875 |
| | |

Appendix 5: First round email and social media requests for information

5.1 Example email

URGENT REQUEST

We are looking for data from around the world about HIV, hepatitis B and C (HBV and HCV) prevalence among people who inject drugs.

We are also seeking data on the prevalence of injecting drug use, and any surveys of people who inject drugs that may contain details about their demographics and drug use.

Do you have data from your country?

We are undertaking a systematic review of existing data about people who inject drugs. This work will inform a range of global data collection efforts, including the Global Burden of Disease 2016 project.

We are collecting data for every country on:

- prevalence of injecting drug use
- prevalence of HIV, HCV and HBV among people who inject drugs
- **demographics and drug use characteristics of people who inject drugs** (e.g., age, gender, duration of injection, main drug used, injecting and sexual risk behaviours)
- services provided to people who inject drugs:
 - o needle and syringe programmes
 - o opioid substitution therapy (methadone, buprenorphine etc.)
 - o HIV antiretroviral therapy (ART)
 - o HIV testing and counselling
 - o condom provision

You may be familiar with estimates that have previously been published on some of these topics, but the data are becoming old.

We have conducted a large search of the peer-reviewed literature, and are gathering as much grey literature (such as NGO and government reports) as possible. However, there will be material that our search will have missed.

Do you have any information that may be of use to us? Any assistance will be acknowledged in the reports we are writing on this subject. Due to the tight timelines of this project we can only consider material received **by Friday October 28**th **2016**.

Many thanks in anticipation of any information you can provide, and for circulating to other colleagues who may be able to assist.

Please direct all correspondence to global.reviews@unsw.edu.au

5.2 Example social media request

Help contribute data to a global review of injecting #drug use, #HIV and #hepatitis, and coverage of HIV #prevention services

Request for data about people who inject drugs

We are undertaking global reviews about people who inject drugs.

We seek information from every country on:

- · The prevalence of injecting drug use
- Characteristics of people who inject drugs
- HIV, hepatitis C and hepatitis B prevalence
- Services provided to people who inject
 - E.g. opioid substitution therapy, needles and syringes, HIV treatment

Do you know of information that may be of use?

If so, please email global.reviews@unsw.edu.au by Friday October 28th 2016

Your help is appreciated, and will be acknowledged in our reports.

Appendix 6: Data extraction guidelines

6.1 Decision rules for identifying data for extraction

- Preference is for the **most recent, national** data for each indicator. Recency is based on the year for which the indicator data refer, rather than year of publication (i.e. national data from 2014 published in 2015 are prioritised above national data from 2013 that are published in 2016)
- If only sub-national data are available, note 'Yes' for the most recent sub-national data. When you extract it, note the area that it refers to. If several sub-national sources are available (across multiple years) and no national data are available, note the most recent data source for each sub-national region for extraction.
- If national data are available but more recent sub-national data are available, note both national and sub-national data for extraction.
- If a single report presents national and sub-national data for the same time period, note the national data for extraction; you will also extract the sub-national data in the notes field of the extraction spreadsheet
- The *number of individual clients accessing a service* (i.e. unique clients not double counted) over a -month period and the *total number of occasions of service* (or service events) over a -month period are examined as separate indicators.
 - If only one piece of data on the number of clients accessing a service is available and it is not explicit whether or not this referred to 'individual clients' or 'occasions of service' then this data can be taken as 'occasions of service' and the ambiguity of the reported data and assumption made noted and reported as such.

6.2 General Extraction Instructions

- We are developing estimates of coverage for 1 year periods.
 - If data for shorter time periods only is given, include this. e.g. 1000 clients accessed NSPs in Sydney between October and December 2013
 - o If data is given in shorter time periods over the course of the year add up the most recent yearly total and enter this but also include the different totals for the smaller time periods in the additional information box also. E.g. 1000 clients Jan to March 2013; 1500 clients April to June 2013; 1500 clients July to September 2013; 1000 clients October to December 2013. Here you would enter 5000 clients accessed the NSP in 2013 but you would add the ¼ year breakdown in the additional information box
 - If data for longer time periods only is given include this e.g. between January 2013 and December 2014 100,000 needles were distributed
- If you have are extracting a reference that says that an intervention is not available in a country, please select the 'number of sites' record type, then record 0 in the number of sites.
- Remember to only extract the data from the report that are marked as "Yes" in the screening spreadsheet
- If you come across the same data or piece of information from different documents find the initial entry and enter this additional citation into the <citation> field. N.B. the piece of data must be the same.

6.2.1 Sub-national injecting population size estimates

- When calculating national level coverage statistics we will be using the estimates calculated for the prevalence review. However if we have information on service delivery for sub-national areas only we will need to use estimates of the size of the injecting population if we want to estimate coverage in that sub-national area.
- If data on service delivery is provided for a sub-national area and an estimate of the injecting population is also provided for that area include this estimate in the additional information field

 but make sure that as much information as possible on how this estimate was produced is included as we will need to assess the quality of the estimate and the method by which it was obtained.

6.2.2 "No programmes for PWID exist"

- If a document states "there are no programmes for PWID in country X" (or something similar) and if no programs or interventions are mentioned specifically enter into the NSP, HCT and condoms data forms that as these interventions are not available; also include the text from the document in the <additional information field>
- Also make entries for OST and ART if it is specifically mentioned that these are not available or that PWID are excluded from or do not access these interventions.

6.2.3 Similar pieces of data from different documents

• We are interested in the most recent and most reliable data available. In some cases having multiple references for a piece of information may strengthen our findings.

6.2.4 Area

- If the document doesn't specifically mention if the estimates are 'National' or "Sub-National":
 - o First: try to decide and label this keeping the rest of the report and other details in mind
 - If still not clear: then categorize it as 'Not Specified' and explain in additional information box that though the data has not been specifically described as 'National' or 'Sub-National', it probably is.
- If the area referred to is sub-national list explicitly what the location(s) is. For example if it is a province enter the name of the province. If it is multiple cities, enter all the city names.

6.2.5 Year of estimate/figure

- If the year of estimate has not been specified in a paper, then use the year of publication and make a note of this in the additional information box.
- If there is no year given for the estimate AND no year of publication given either then enter 9999
 in the year field.
- If the time frame for the estimate is presented as a range e.g. 2011-2014, then enter the most recent year as the "year of estimate" this would be 2014 in the example given here.
- The actual range of years (e.g. 4 year time period from 2011-2014) along with any relevant details will be entered in the additional information box.

6.2.6 Pieces of similar data from multiple locations

- Data from various numbers of sites can be collated for a city/province/state/country.
- For example, if a document gives the number of syringes distributed at all NSP sites in a state
 determine the total number and enter this in as the state-wide figure but also include the
 individual site data in the <Additional information> field at the bottom of the form

6.2.7 Time Period

- If the time period for the data refers to is a specific point in time or census date, for example the end of a year/month etc, then it will be categorized as "Single point in time".
- In such a case write the time frame given
- e.g. for "1000 people were given treatment at the end of 2013" enter "end of 2013" in the <Additional information> field at the bottom of the form

6.2.8 Number of sites

- Enter into this section whether or not an intervention is available and if so how many sites offering this intervention have been established.
- If the intervention is stated as not being available enter '0' into the <Number of sites> field

6.2.9 Survey Sample

- This section is intended to capture data on service coverage determined by investigating a sample of people who inject drugs from the total injecting population.
- Enter the total size of the sample in the field <Total sample number (n)>
- Enter the number of individuals from the sample exposed to/covered by/accessing/etc the intervention in the field <Number of people in contact with service>.
- Enter as much detail as possible on the how, where and when the sample was gathered as well as inclusion criteria etc. in the <Sample method/characteristics> free-text field
- Describe the nature of the contact/event counting as having been in contact with a service for the purpose of the study concerned.
- Enter in the <Time period referred> field information on what period of time was the nature of the contact refers to. For example if the study asked whether people had accessed an NSP in the last 12 months enter 12 months or 1 year into the <Time period referred> field.

6.2.10 Calculating numbers

- Wherever possible try and enter data in a form that is going to be most useful for us when
 reviewing the extracted data and reporting on the status of the provision of interventions across
 countries. This may involve making calculations to derive data to be entered based upon the data
 presented in a document.
- For example we want to try and obtain data on the number of people who have received a particular service and we want to then determine ourselves what level of coverage of the target population this is likely to represent. It is not necessary to determine this level of coverage when entering data into the database BUT it is important to try, if possible, to enter the data that would be required to make such a calculation. In some instances levels of coverage might be reported in a document such as: in country X at the end of 2011 OST covered 50% of the injecting population. It may also say that there are 5000 PWID in the country by their estimate hence we can assume that at the end of 2011 there were 2500 people receiving OST enter this data into the data entry form. From this we will be able to derive later what the coverage is likely to be using our own estimates of the size of the injecting population. In such cases enter all information and data relating to this into the <Additional information field>

6.2.11 Data range

• Enter a range if given for a piece of data. For example: 2500-3500 people accessed NSP in the last year, enter this 2500-3500 into the <Number of clients> field.

6.2.12 NSP Programmes vs. sites

• Different terminology may be used in the literature – in some instances the term 'needle syringe programme' or 'NSP' will refer to a single site; in other cases this may refer to a number of sites run by a single government or non-government organisation.

6.2.13 Needle and syringe programmes – distribution of equipment

- In most cases the number of sterile needles and syringes will be given as a single number (in many
 cases reflecting the supply of a single needle and syringe or combined syringe with attached)
 needle.
- In other instances the total number of syringes and the total number of needles may be provided separately in such cases enter the number of needles distributed in the <Number of needles/syringes> field and enter into the <Additional information> field details on how the data was presented in the document including both the total number of syringes and total number of needles.
- Some programmes will also give out material for the cleaning of used injecting equipment in particular bleach. In most instances the distribution of units of bleach will be counted separately from injecting equipment but in some cases this data will be not be disaggregated. In these cases enter the total as reported but clearly detail in the <Additional information> field that this data refers to not just needles and syringes

6.2.14 Needle and syringe programmes – modes of delivery

- The provision of needles and syringes in a NSP program can be delivered in a number of ways –
 through fixed sites, from vending machines or via out-reach which might include the use of a van
 or other vehicle, or even on foot may cover a particular route or regular sites or even home
 delivery.
- If there is information provided on the mode of delivery of NSPs include this in the <additional information> field.
- When recording the number of sites of NSP it may be difficult to determine how to count outreach programs – if in doubt include the details as they are reported in the document being extracted from.
- In some cases "out-reach" or "harm reduction services" described in some documents may in fact be referring to NSP programs see point 3.25 below.

6.2.15 Opioid substitution therapy – different types of OST

- Only data describing opioid agonists provided as maintenance were included as OST. Provision
 of substitute opioids for the purpose of detoxification as opposed to maintenance were not
 included.
- If data are for any type of OST other than Methadone (MMT) or Buprenorphine (BMT) (for example heroin, LAAM, tincture of opium) then select "OST Not specified" in the <Opioid substitution type> field and enter the details of this other type of opioid in the <Additional information> field.
- Data may be presented as the total number of people receiving OST, or may be disaggregated by
 injecting status. If data disaggregated by injecting status are presented, extract total clients,
 injecting clients and non-injecting clients separately, with a note in the <additional information>
 field that this is what you have done.
- Language describing OST may vary between documents. In most cases "methadone program" or "buprenorphine program" will refer to maintenance substitution programs and should be

included in the OST form. If it is not clear whether this is the case and you have doubts that perhaps this might refer to a detox program make a note of this in the <Additional information> field or enter this in the Other drug treatment form. Do not enter data if it is explicit that it refers to methadone- or buprenorphine assisted detoxification.

• If one type of OST is available and another is stated as not being available enter whatever information is available on the OST type that is available and for the type that is not available enter '0' into the <number of sites> field.

6.2.16 HIV testing and counselling (HTC)

- Only include information or data specific to HIV testing for people who inject drugs and NOT programmes or data for the general population.
- Programs or sites were considered as PWID specific (and hence clients of the services likely to be predominantly or exclusively PWID), as distinct from generalised services, if they were described as either:
 - a) targeting PWID specifically and not members of the general public;
 - b) delivered as part of a service or by a program that is PWID OR drug user specific e.g. at a needle exchange or drug treatment site;
 - c) an outreach program targeting PWID.

Services or programs targeting most at risk groups in general (including men who have sex with men, sex workers in addition to PWID) were not considered as PWID specific for the purpose of this review. Some prisons provide condoms to inmates some of which have significant PWID populations; however these programs were not selected for the purpose of this review.

6.2.17 ART

- Only include information or data specific to ART/HAART for people who inject drugs and NOT programmes or data for the general population.
- If document mentions "HIV treatment and care" for HIV positive injectors without specifying if this refers to ART/HAART then include this information in the ART form in the <Additional information> field.

6.2.18 Condom programmes

- Only include information or data specific to programmes targeting people who inject drugs and NOT programmes or data for the general population.
- In most cases data will concern programmes providing services for people who inject drugs that, in addition to other interventions, also distribute condoms (e.g. condoms via an NSP).

Appendix 7: Decision rules for summarising data and making adjustments to standardise data

7.1 Assumptions and data adjustments for standardisation of estimates

If data were reported for a period of time longer than 12 months then it was assumed that the rate
of access or distribution was constant over the duration of the reported time period and an
estimate for a 12 month period was derived accordingly.

For example: 24,000 syringes distributed by NSPs between July 2012 and December 2013.

i.e. an 18 month period

→ Assumed that [24,000/18] 1,333 distributed per month

→ Estimated 16,000 syringes distributed in 2013

• If the most recent data available on volume of equipment distributed or number of occasions of service were for a period of time less than 12 months duration it was assumed that the rate of access or distribution was consistent over the remainder of a 12 month period and an estimate for a 12 month period was derived accordingly.

For example: 12,000 NSP occasions of service between May and August 2013, i.e. a 4 month period

→ Assumed that [12,000/4] 3,000 NSP occasions of service per month

 \rightarrow Estimated 36,000 NSP occasions of service in 2013

- For some countries national level data were not available. If, however, data from mutually
 exclusive sub-national regions were available these were added together to derive either a national
 estimate (if these sub-national regions accounted for the entire country) or sub-national total. All
 sub-national data were noted and reported as such.
- If data on the number of clients accessing an intervention or the number of items distributed was available for only a subset of the total sites where an intervention is available it was assumed that the average rate of access or distribution per site reported was consistent for the sites from which data were not available in order to derive a national level estimate; all instances where these estimates were made were noted and reported as such.

For example: If 100,000 syringes were known to be distributed in a 12 month period by 40 out of a total of 60 NSP sites

 \rightarrow Assumed rate of distribution per site for the 40 sites where data available was the same as the rate for the 20 sites with no data available

 \rightarrow Estimated total of 150,000 syringes distributed by 60 sites

NSP: sites

If the number of sites is given for different modes of delivery it was assumed that these counts were mutually exclusive and were added together to get a total number of sites where NSPs are available.

For example: In Bulgaria 2 fixed sites, 91 outreach and 7 mobile vans

→ Assumed counts of different sites are mutually exclusive

 \rightarrow Estimated total of 100 sites where NSP is available.

NSP: needles and syringes distributed

In some cases the number of syringes and number of needles distributed were reported separately. For the purpose of this review we took the smaller of these two numbers as the total number of pieces of injecting equipment on the basis that for a single injecting episode with a sterile set of injecting equipment requires either a) a sterile combined needle/syringe or b) a sterile needle and a sterile syringe. This is based on the assumption that these separate counts do not include single unit syringes with needles attached.

• Condom distribution

For some countries it was reported that condoms are distributed by NSPs. It was then assumed that for that country all NSPs distributed condoms and if the number of NSP sites in the country was know these were added to the count of sites providing PWID specific condom distribution programs.

7.2 Calculation of indicator denominators

PWID and HIV positive PWID population size estimates

- PWID prevalence and HIV among PWID prevalence estimates reported in a recent review were used to derive estimates of the number of PWID and number of PWID living with HIV.
- No prevalence estimates were available for many countries where injecting and HIV among injectors has been reported. For these countries no country-level coverage estimates were reported in this review.
- For the purpose of this review it was assumed that the PWID and HIV population size was the same in the year for which these estimates were made as the year for which the intervention data was reported.

Appendix 8: Data verification – example email

Dear XX

An international group of researchers, led by Dr Sarah Larney and Professor Louisa Degenhardt, is developing estimates of the coverage of HIV prevention and treatment interventions for people who inject drugs. This work is supported by Open Society Foundations, Global Fund, UNAIDS, WHO, and UNODC.

Our estimates will be based on existing data relating to needle and syringe programs, opioid substitution therapy (i.e. methadone maintenance), antiretroviral treatment, voluntary counselling and testing, and condom distribution programmes for people who inject drugs.

We have reviewed data for each of these interventions from peer-reviewed publications and organisational reports identified through an extensive online search. I attach here a preliminary report of data identified for X country.

We would be grateful for any recent information or reports that may help to improve our current data for X country.

As we are working to a very tight deadline, we will need to receive any information you may have by 9 May 2017 in order for us to be able to include it in our estimates.

Please feel free to forward this email to anyone you think may have access to such information for X country.

Any assistance you are able to provide will be acknowledged. We look forward to receiving any information you may be able to share.

Kind regards

Global review of coverage of HIV prevention interventions for people who inject drugs: Preliminary data for X country

| NSP indicators | Data | National/sub-national | Year | Reference |
|---|------|-----------------------|------|-----------|
| N NSP sites | | | | |
| N needles and syringes distributed in a year | | | | |
| N PWID accessing an NSP in a year | | | | |
| Proportion of PWID accessing an NSP in a year | | | | |
| OST indicators | | | | |
| Forms of OST available | | | | |
| N OST sites | | | | |
| N OST patients at a given point in time | | | | |
| Proportion of PWID (or opioid dependent) | | | | |
| accessing OST in a year/at a given point in time | | | | |
| VCT indicators | | | | |
| N VCT sites specifically targeted to PWID | | | | |
| N PWID being tested for HIV in a year | | | | |
| Proportion of PWID reporting being tested for | | | | |
| HIV in the past year | | | | |
| ART indicators | | | | |
| Any formal restrictions on ART access for PWID | | | | |
| N PWID receiving ART in a year/at a given point in time | | | | |
| % (HIV+) PWID receiving ART at a given point in | | | | |
| time | | | | |
| Condom indicators | | | | |
| N sites distributing condoms targeted to PWID | | | | |
| N condoms distributed by targeted programs | | | | |
| N PWID receiving condoms from targeted | | | | |
| programs | | | | |

Appendix 9: Estimated regional and global populations of people who inject drugs, primary opioid injectors, and people who inject drugs living with HIV

| | N people who inject drugs ¹ | N primary opioid injectors ² |
|-------------------------|--|---|
| Eastern Europe | 3,025,000 (1,653,500, 5,008,000) | 73,500 (53,000, 96,000) |
| Western Europe | 1,009,500 (686,500, 1,386,500) | 78,000 (48,500, 11,1000) |
| East and Southeast Asia | 3,989,000 (3,041,000, 4,955,000) | 242,000 (148,000, 345,500) |
| South Asia | 1,023,500 (783,500, 1,263,000) | 4,033,500 (3,128,000, 5,002,000) |
| Central Asia | 281,500 (189,500, 416,500) | 2,484,500 (1,277,500, 3,873,000) |
| Caribbean | 79,500 (53,000, 118,000) | 1,691,500 (1,239,500, 2,180,500) |
| Latin America | 1,823,000 (1,392,000, 2,380,000) | 417,500 (101,500, 830,000) |
| North America | 2,557,000 (1,498,500, 4,428,000) | 1,858,000 (832,500, 3,083,500) |
| Pacific Islands³ | 22,500 (15,000, 33,500) | 19,000 (11,500, 27,000) |
| Australasia | 115,500 (83,000, 148,000) | 862,500 (650,500, 1,099,500) |
| Middle East and North | 349,500 (177,500, 521,500) | |
| Africa | | 1,142,500 (333,000, 2,283,500) |
| Sub-Saharan Africa | 1,378,000 (645,500, 3,080,000) | 702,000 (468,500, 980,500) |
| Global | 15,648,000 (10,219,000, 23,737,500) | 13,604,500 (8,291,500, 19,912,500) |

¹From Degenhardt et al.¹

9.1 Reference

1. Degenhardt, L, Peacock A, Colledge S, et al. A global profile of people who inject drugs: Systematic review of characteristics, prevalence of injecting and of HIV, hepatitis B and hepatitis C.

²Derived from prevalence estimates reported in Degenhardt et al.¹

³ Note that no estimates of the prevalence of injecting drug use have been located for the Pacific Islands and Territories, so the weighted observed global prevalence was used here. Considerable caution should be used with these estimates.

Appendix 10: Country-level coverage of NSP, OST, HIV testing and counselling, and HIV antiretroviral therapy, by region.

Table 10.1: Provision of needle-syringes, opioid substitution therapy, HIV testing and counselling, and antiretroviral therapy for people who inject drugs in Europe

| | Nee | dle and syringe pro | grammes | Opio | id substitution | therapy | | HIV testing | Antire | troviral therapy |
|---------------------------|--------------------|-----------------------------------|--------------------------|--------------------|-------------------------------|-----------------------------|--------------------------------|--|--|---|
| | NSP implemented | N N-S distributed ¹ | N-S per PWID per year | Forms available | N OST recipients ⁹ | OST recipients per 100 PWID | N PWID tested ¹⁰ | PWID tested for HIV in a year per 100 PWID | N PWID receiving ART ¹² | PWID receiving ART per 100 PWID living with HIV |
| Eastern Europe | | | | | | | | | | |
| Armenia | Yes | 512270 | 39 (18-58) | M | 430 | 3 (1-5) | 1983 | 15 (7-23) | NK | NK |
| Azerbaijan | Yes | 762000 | 18 (15-22) | M | 155 | <1 (<1-<1) | 5484 | 13 (11-16) | 133 ¹³ | NC |
| Belarus | Yes | 1088978 | 27 (16-72) | M | 978 | 2 (1-6) | 4466 | 11 (7-30) | NK | NK |
| Bosnia and Herzegovina | Yes | 1012774 | NC | M/B | 1395 | NC | NE | NE | 2 | NC |
| Bulgaria | Yes | 364111² | 20 (16-24) | M/O | 3423 | 18 (15-23) | 3276 | 18 (15-22) | NK | NK |
| Czech Republic | Yes | 6421095 | 137 (131-144) | M/B | 4000 | 9 (8-9) | 3603 | 8 (7-8) | NK | NK |
| Estonia | Yes | 2136691 | 249 (135-339) | M/B | 1166 | 14 (7-18) | NE | NE | NK | NK |
| Georgia | Yes | 3573405 | 31 (16-271) | M/B | 2500 | 2 (1-19) | 20543 | 18 (9-GTP) | NK | NK |
| Hungary | Yes | 188696 | 48 (32-91) | M/B | 669 | 17 (11-32) | 231 ¹¹ | 6 (4-11) | NK | NK |
| Latvia | Yes | 524949 | 37 (29-47) | M/B | 608 | 4 (3-5) | 882 | 6 (5-8) | NK | NK |
| Lithuania | Yes | 200630 | 42 (25-77) | M/B | 596 | 12 (8-23) | 5949 | GTP (75-GTP) | 182 | 47 (22- GTP) |
| Moldova | Yes | 2352097 | 196 (143-313) | М | 468 | 4 (3-6) | NE | NE | NK | NK |
| Poland | Yes | 10142 | NC | M/B | 2564 | NC | 217 | NC | NK | NK |
| Romania | Yes | 1425592 | 18 (13-24) | M/B | 547 | 1 (<1-1) | 163 | <1 (<1-<1) | NK | NK |
| Russian Federation | Yes | 3500000 | 2 (1-3) | None | 0 | 0 (0-0) | 241547 | 13 (8-24) | NK | NK |
| Slovakia | Yes | 347162 | 17 (10-24) | M/B/O | 600 | 3 (2-4) | NE | NE | NK | NK |
| Ukraine | Yes | 19400000 | 61 (33-113) | M/B | 9214 | 3 (2-5) | 149473 | 47 (25-87) | 7472 | 12 (7-30) |
| Western Europe | | | | | | | | | | |
| Albania | Yes | NE | NE | M/B | 578 | NC | NK | NK | NK | NK |
| Andorra | NK | NK | NK | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Austria | Yes | 5953919 | 321 (244-468) | M/B/O | 17599 | 95 (72-GTP) | NK | NK | 606 ⁵ | GTP |
| Belgium | Yes | 1034242 | 40 (28-57) | M/B/H | 16681 | 64 (45-91) | NK | NK | NK | NK |
| Croatia | Yes | 923650 | 146 (112-179) | M/B | 5061 | 80 (61-98) | NE | NE | NK | NK |
| Denmark | Yes | NE | NE | M/B | 6268 | 38 (33-49) | NK | NK | NK | NK |
| England | Yes | NE | NE | M/B/H | 140400 | 67 (62-72) | NE | NE | NK | NK |
| Finland | Yes | 5301000 | 312 (214-350) | M/B | 3000 | 18 (12-20) | 1562 | 9 (6-10) | NK | NK |
| France | Yes | 12314781 | 150 (127-186) | M/B/O | 168840 | GTP | NE | NE | NK | NK |
| FYR Macedonia | Yes | 352000 | NC | M/B | 1930 | NC | 1083 | NC | 2 | NC |
| Germany | Yes | 2085999 ³ | NC | M/B/H | 77200 | 59 (28-GTP) | NK | NK | NK | NK |
| Greece | Yes | 268157 | 53 (43-65) | M/B | 10082 | GTP | 5496 | GTP (88-GTP) | 605 | GTP |
| Iceland | Yes | NE | NE | В | NE | NE | NK | NK | NK | NK |

| Ireland | Yes | 393275 | 46 (37-62) | M/B | 9917 | GTP (93-GTP) | NK | NK | NK | NK |
|------------------|-----|----------------------|----------------------------|---------|-------|--------------|------------------|------------|-----------------|----|
| Italy | Yes | NE | NE | M/B | 60047 | 18 (13-26) | NK | NK | NK | NK |
| Luxembourg | Yes | 361392 | 165 (137-207) | M/B/O | 1078 | 49 (41-62) | NK | NK | NK | NK |
| Malta | Yes | 340644 | NC | M/B | 1026 | NC | 210 ⁵ | NC | NK | NK |
| Monaco | NK | NK | NK | M | NE | NE | NK | NK | NK | NK |
| Montenegro | Yes | 91954 ⁴ | NC | M/B | 367 | NC | 115 | NC | NK | NK |
| Netherlands | Yes | 259800 ⁵ | 414 (170-659) ⁸ | M/B/H | 7421 | GTP | NK | NK | 8 ¹⁴ | NC |
| Northern Ireland | Yes | 292390 | NC | M/B/H | 607 | NC | NE | NE | NK | NK |
| Norway | Yes | 2500192 ⁵ | 298 (247-350) ⁸ | M/B | 7498 | 89 (74-GTP) | NE | NE | NK | NK |
| Portugal | Yes | 1004706 | 63 (57-72) | M/B | 17011 | GTP (96-GTP) | NK | NK | NK | NK |
| San Marino | NK | NK | NK | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Scotland | Yes | 4376456 | 277 (249-321) | M/B | 3686 | 23 (21-27) | NE | NE | NK | NK |
| Serbia | Yes | NC ⁶ | NC ⁶ | М | 4336 | 15 (13-18) | 1912 | 7 (6-8) | NK | NK |
| Slovenia | Yes | 500757 | 85 (65-122) | M/B/O | 3261 | 55 (43-79) | NE | NE | NK | NK |
| Spain | Yes | 1483399 | 141 (84-428) | M/B/H | 61859 | GTP | 86 | <1 (<-1-3) | NK | NK |
| Sweden | Yes | 281391 | 34 (7-161) | M/B | 3679 | 45 (10-GTP) | NK | NK | NK | NK |
| Switzerland | Yes | 201881 ⁷ | 187 (156-234) | M/B/H/O | 17191 | GTP | NK | NK | NK | NK |
| Wales | Yes | 3398314 | NC | M/B | 1993 | NC | NE | NE | NK | NK |

Notes: References for number of needle-syringes distributed, number of OST clients, number of people who inject drugs receiving HIV tests, and number of people who inject drugs receiving ART are provided in Appendices 11-14. Data on service provision were located for the Channel Islands and Kosovo but are not separately reported here; please contact the authors for further details. No evidence of injecting drug use was identified for Greenland or Liechtenstein (Western Europe). NE – intervention exists in that country, but no data on the extent of service provision were located. NC – intervention exists and data on the extent of service provision were identified for this country, but no estimate of the prevalence of injecting drug use has been located for this country. NK – no information about the presence or absence of this intervention could be located for this country. M – methadone. B – buprenorphine. H – heroin. O – other forms of OST are prescribed. GTP – estimate greater than parity.

¹Data refer to needle-syringe distribution through specialised programmes over a 12 month period unless otherwise specified

²Global Fund support ended in July 2016 and there were concerns regarding sustainability of programs (see http://harm-reduction.org/country-profiles/bulgaria); it is not clear if these data reflect current distribution

³Sub-national distribution data; no national data are available and the sub-national data could not be used to generate a national estimate

⁴Since withdrawal of Global Fund support in June 2015, only one NSP (previously three) operates. No data were identified on current needle-syringe distribution, but coverage is reported to have declined (see http://harm-reduction.org/country-profiles/montenegro).

⁵Sub-national data; sufficient additional data available to generate a national estimate

⁶Since withdrawal of Global Fund support, NSPs have largely closed and are no longer available (see EHRN. The Impact of Transition from Global Fund Support to Governmental Funding on the Sustainability of Harm Reduction Programs: A Case Study from Serbia. Vilnius: Eurasian Harm Reduction Network, 2015). No data were identified to estimate current NSP coverage.

⁷Refers to syringe distribution over a 1 month period.

⁸Estimate based on sub-national data

⁹Refers to number of OST recipients at a given point in time unless otherwise specified

¹⁰Refers to number of PWID receiving an HIV test over a 12-month period unless otherwise specified. The geographic are to which data referred was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document.

¹¹Refers to number of PWID receiving an HIV test over a 6 month period.

¹²Refers to number of PWID receiving ART at a given time point unless otherwise specified. Caution must be used in interpreting this indicator as completeness of the data is often unclear. The geographic area to which data referred was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document.

¹³Refers to PWID initiating ART in 2014.

Table 10.2: Provision of needle-syringes, opioid substitution therapy, HIV testing and counselling, and antiretroviral therapy for people who inject drugs in Asia

| , | Needle | and syringe prog | grammes | Opio | id substitution | therapy | HI | V testing | Antiret | roviral therapy |
|--------------------|--------------------|-----------------------------------|--------------------------|--------------------|----------------------------------|-----------------------------------|-------------------------------|--|---|--|
| | NSP implemented | N N-S distributed ¹ | N-S per PWID per year | Forms available | N OST recipients ⁴ | OST recipients per 100 PWID | N PWID tested ⁶ | Number of PWID tested for HIV in a year per 100 PWID | N PWID receiving ART ⁹ | PWID receiving ART per 100 PWID living with HIV |
| East and Southeast | | | | | | | | | | |
| Asia | | | | | | | | | | |
| Brunei Darussalam | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Cambodia | Yes | NE | NE | M | 130 | 1 (1-1) | NE | NE | NK | NK |
| China | Yes | 11000000 | 4 (3-6) | М | 184000 | 7 (6-9) | NE | NE | NK | NK |
| Indonesia | Yes | 317842 | 2 (1-2) | M/B | 5329 | 3 (2-3) | NE | NE | NK | NK |
| Japan | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Laos | Yes | NE | NE | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Malaysia | Yes | NE | NE | M/B | 74816 | 27 (23-32) | NE | NE | NK | NK |
| Mongolia | Yes | NE | NE | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Myanmar | Yes | 13913025 | 80 (59-120) | М | 7872 | 5 (3-7) | 4540 | 3 (2-4) | NK | NK |
| Philippines | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Singapore | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| South Korea | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Taiwan | Yes | 3860518 | NC | M/B | 8789 | NC | NK | NK | NK | NK |
| Thailand | Yes | 138858 ² | 24 (2-46) ³ | M | 3646 | 7 (4-23) | 24583 | 48 (28-GTP) | NK | NK |
| Timor Leste | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Vietnam | Yes | 28366110 | 176 (142-231) | М | 50766 | 32 (25-41) | 145364 | 90 (73-GTP) | 2521 ² | 30 (7-53) ³ |
| South Asia | | | | | | | | | | |
| Afghanistan | Yes | NE | NE | М | NE | NE | 547 | 1 (0-2) | NK | NK |
| Bangladesh | Yes | NE | NE | М | 798 | 1 (1-1) | 4838 ⁷ | 7 (7-8) | 135 | 42 (26-94) |
| Bhutan | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| India | Yes | 16917292 | 86 (63-133) | B/O | 5124 | 3 (2-4) | NK | NK | NK | NK |
| Iran | Yes | 8578845 | 54 (41-80) | M/B/O | 640000 | GTP | NE | NE | 2404 | 11 (7-19) |
| Maldives | No | 0 | 0 (0-0) | М | 108 | 7 (3-GTP) | 21 ⁸ | 6 (2-GTP) | NK | NK |
| Nepal | Yes | 1521054 | 43 (41-46) | M/B | 1347 | 4 (4-4) | 15897 | 45 (43-48) | NK | NK |
| Pakistan | Yes | 7714524 | 18 (16-21) | None | 0 | 0 (0-0) | NE | NE | 1023 | <1 (<1-<1) |
| Sri Lanka | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Central Asia | | | · · | | | , , | | | | |
| Kazakhstan | Yes | 16347156 | 145 (98-216) | M | 292 | <1 (<1-<1) | 31376-50756 | 43 (19-68) | 2797 | 27 (19-45) |
| Kyrgyzstan | Yes | 7004861 | 246 (166-366) | M | 1673 | 6 (4-9) | 3704 | 13 (9-19) | 437 | 12 (8-21) |
| Tajikistan | Yes | 6539721 | 278 (188-414) | M | 550 | 2 (2-3) | 18192 | 77 (52- GTP) | 541 | 9 (6-15) |
| Turkmenistan | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Uzbekistan | Yes | 2601516 | 28 (19-41) | None | 0 | 0 (0-0) | NE | NE | NK | NK |

Notes: References for number of needle-syringes distributed, number of OST clients, number of people who inject drugs receiving HIV tests, and number of people who inject drugs receiving ART are provided in Appendices 11-14. Data on service provision were located for Hong Kong but are not separately reported here; please contact the authors for further details. No evidence of injecting drug use was identified for DPR Korea. NE – intervention exists in that country, but no data on the extent of service provision were located. NC – intervention exists and data on the extent of service provision were identified for this country, but no estimate of the prevalence of injecting drug use has been located for this country. NK – no information about the presence or absence of this intervention could be located for this country. M – methadone. B – buprenorphine. H – heroin. O – other forms of OST are prescribed. GTP – estimate greater than parity.

¹Data refer to needle-syringe distribution through specialised programmes over a 12 month period unless otherwise specified

²Sub-national data; sufficient additional data available to generate a national estimate

³Estimate based on sub-national data

⁴ Refers to number of OST recipients at a given point in time unless otherwise specified

⁵Source states that around 8,400 clients are registered with the methadone programme, and that daily attendance is around 6,400.

⁶ Refers to number of PWID receiving an HIV test over a 12-month period unless otherwise specified. The geographic are to which data referred was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document.

⁷Refers to number of PWID tested over a 6 month period.

⁸Refers to number of PWID tested over a 3 month period.

⁹Refers to number of PWID receiving ART at a given point in time unless otherwise specified. The geographic are to which data referred was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document.

Table 10.3: Provision of needle-syringes, opioid substitution therapy, HIV testing and counselling, and antiretroviral therapy for people who inject drugs in the Americas

| | Needle | e and syringe prog | rammes | Opio | oid substitution | therapy | HIV t | esting | Antire | troviral therapy |
|--------------------|-------------|--------------------------|-------------------------|-----------|-------------------------|-------------------------|----------------------------|------------------------|--------------------------------|---------------------------------|
| | NSP | N N-S | N-S per PWID per | Forms | N OST | OST recipients | N PWID tested ⁹ | PWID testing in | N PWID | PWID receiving ART |
| | implemented | distributed ¹ | year | available | recipients ⁵ | per 100 PWID | | a year per 100 PWID | receiving ART ¹⁰ | per 100 PWID living with HIV |
| Caribbean | | | | | | | | | | |
| Bahamas | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Bermuda | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Dominican Republic | Yes | 14398 | NC | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Haiti | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Jamaica | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Puerto Rico | Yes | 434052 | 15 (10-23) | M/B | NE | NE | NK | NK | NK | NK |
| Latin America | | | | | | | | | | |
| Argentina | Yes | NE | NE | М | NE | NE | NK | NK | NK | NK |
| Bolivia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Brazil | Yes | NE | NE | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Chile | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Colombia | Yes | NE | NE | М | NE | NE | NK | NK | NK | NK |
| Costa Rica | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Ecuador | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| El Salvador | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Guatemala | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Guyana | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Honduras | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Mexico | Yes | 1186348 | 8 (6-12) | M/B | 22647 | 15 (11-23) | 4193 | 3 (2-4) | NK | NK |
| Nicaragua | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Panama | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Paraguay | Yes | NE | NE | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Peru | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Suriname | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Uruguay | Yes | NE | NE | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Venezuela | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| North America | | | | | | | | | | |
| Canada | Yes | 45692898 ² | 148 (129-174) | M/B/H | 75073 ⁶ | 24 (21-29) | NK | NK | NK | NK |
| United States | Yes | 45868960 ³ | 30 (11-49) ⁴ | M/B | 432567 ⁷ | 19 (11-35) ⁸ | NE | NE | 24249 ¹¹ | 12 (7-30) ¹² |

Notes: References for number of needle-syringes distributed, number of OST clients, number of people who inject drugs receiving HIV tests, and number of people who inject drugs receiving ART are provided in Appendices 11-14. No evidence of injecting drug use was identified for Antigua & Barbados, Cuba, Dominica, Grenada, Saint Kitts & Nevis, Saint Lucia, Saint Vincent & the Grenadines, Trinidad & Tobago (Caribbean), Belize (Latin America). NE – intervention exists in that country, but no data on the extent of service provision were located. NC – intervention exists and data on the extent of service provision were identified for this country, but no estimate of the prevalence of injecting drug use has been located for this country. NK – no information about the presence or absence of this intervention could be located for this country. M – methadone. B – buprenorphine. H – heroin. O – other forms of OST are prescribed. GTP – estimate greater than parity.

¹ Data refer to needle-syringe distribution through specialised programmes over a 12 month period unless otherwise specified

²Estimation of number of needle-syringes distributed in 2015 based on multiple data sources (see appendix 10)

³Sub-national data; sufficient additional data available to generate a national estimate.

⁴Estimate based on sub-national data

⁵Refers to number of OST recipients at a given point in time unless otherwise specified

⁶Estimation of number of OST clients in 2015 based on multiple data sources (see appendix 11).

⁷Does not include people prescribed buprenorphine in office-based settings

⁸Underestimates coverage as no data are available regarding number of people prescribed buprenorphine in office-based settings.

⁹Refers to number of PWID receiving HIV testing in a 12 month period unless otherwise specified.

¹⁰Refers to PWID receiving ART at a given point in time unless otherwise specified.

¹¹Only includes patients in Ryan White-funded treatment programmes. Indicator used is patients who are virally suppressed with transmission category of injecting drug use.

¹²May underestimate coverage as numerator only includes patients in Ryan White-funded treatment programmes.

Table 10.4: Provision of needle-syringes, opioid substitution therapy, HIV testing and counselling, and antiretroviral therapy for people who inject drugs in Oceania

| | Nee | dle and syringe pr | ogrammes | Opi | ioid substitution | therapy | HIV | testing | Antiret | roviral therapy |
|---------------------------|--------------------|-----------------------------------|--------------------------|--------------------|----------------------------------|--------------------------------|-------------------------------|---|---|--|
| | NSP implemented | N N-S distributed ¹ | N-S per PWID per year | Forms available | N OST recipients ² | OST recipients per 100 PWID | N PWID tested ³ | PWID testing in a year per 100 PWID | N PWID receiving ART ⁴ | PWID receiving ART per 100 PWID living with HIV |
| Australasia | | | | | | | | | | |
| Australia | Yes | 42900000 | 461 (364-631) | M/B | 48522 | 52 (41-71) | NE | NE | NK | NK |
| New Zealand | Yes | 2780000 | 124 (93-185) | M/B | 5018 | 22 (17-33) | NK | NK | NK | NK |
| Pacific Islands | | | | | | | | | | |
| American Samoa | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Fed. States of Micronesia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Fiji | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| French Polynesia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Guam | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Kiribati | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Marshall Islands | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| New Caledonia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Northern Mariana Islands | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Palau | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Papua New Guinea | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Samoa | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Solomon Islands | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Tonga | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Vanuatu | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |

Notes: References for number of needle-syringes distributed, number of OST clients, number of people who inject drugs receiving HIV tests, and number of people who inject drugs receiving ART are provided in Appendices 11-14. No evidence of injecting drug use was identified for Nauru or Tuvalu (Pacific Islands). NE – intervention exists in that country, but no data on the extent of service provision were located. NC – intervention exists and data on the extent of service provision were identified for this country, but no estimate of the prevalence of injecting drug use has been located for this country. NK – no information about the presence or absence of this intervention could be located for this country. M – methadone. B – buprenorphine. H – heroin. O – other forms of OST are prescribed. GTP – estimate greater than parity.

¹Data refer to needle-syringe distribution through specialised programmes over a 12 month period unless otherwise specified

²Refers to number of OST recipients at a given point in time unless otherwise specified

³Refers to number of PWID receiving HIV testing in a 12 month period unless otherwise specified.

⁴Refers to number of PWID receiving ART at a given point in time unless otherwise specified.

Table 10.5: Provision of needle-syringes, opioid substitution therapy, HIV testing and counselling, and antiretroviral therapy for people who inject drugs in Africa and the Middle East

| | Ne | edle and syringe prograi | mmes | Opioid | substitution t | :herapy | | HIV testing | Antiret | roviral therapy |
|--------------------------------------|--------------------|--------------------------------|--------------------------|------------------------|----------------------------------|-----------------------------------|-------------------------------|--|--|--|
| | NSP implemented | N N-S distributed ¹ | N-S per PWID per year | Forms available | N OST recipients ⁴ | OST recipients per 100 PWID | N PWID tested ⁶ | Number of PWID tested for HIV past 12 months per 100 PWID* | N PWID receiving ART ¹⁰ | PWID receiving ART per 100 PWID living with HIV |
| Middle East and North Africa | | | | | | | | | | |
| Algeria | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Bahrain | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Cyprus | Yes | 164 | <1 (<1-1) | M/B/O | 252 | 48 (33-89) | NK | NK | NK | NK |
| Egypt | Yes | 892 | NC | None | 0 | 0 (0-0) | 454 ⁷ | NC | NK | NK |
| Iraq | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Israel | Yes | 214777 | NC | M/B | 4500 | NC | NK | NK | NK | NK |
| Jordan | Yes | 63396 | NC | None | 0 | 0 (0-0) | 146 | NC | NK | NK |
| Kuwait | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | 1321 | NC | NK | NK |
| Lebanon | Yes | 59071 | NC | В | 1700 ⁵ | NC | 176 ⁸ | NC | NK | NK |
| Libya | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Morocco | Yes | 238946 | 8 (5-16) | М | 628 | 2 (1-4) | NE | NE | NK | NK |
| Occupied Palestinian Territory | Yes | 7600² | NC | Available ³ | NE | NE | NE | NE | NK | NK |
| Oman | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Qatar | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Saudi Arabia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | 278 | NC | NK | NK |
| Sudan | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Syria | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Tunisia | Yes | 48000 | NC | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Turkey | No | 0 | 0 (0-0) | M/B | 12500 | NC | 2676 | NC | NK | NK |
| United Arab Emirates | No | 0 | 0 (0-0) | В | NE | NE | NK | NK | NK | NK |
| Yemen | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Sub-Saharan Africa | | | | | | | | | | |
| Angola | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Benin | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Burkina Faso | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Burundi | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Cameroon | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Cape Verde | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Chad | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |

| Cote d'Ivoire | No | 0 | 0 (0-0) | М | NE | NE | NK | NK | NK | NK |
|-----------------|-----|--------|--------------|------|------|-------------|-----------------|----------|-----|------------|
| Djibouti | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Dem. Rep. Congo | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Ethiopia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Gabon | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Gambia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Ghana | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Guinea | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Kenya | Yes | 271941 | 9 (5-31) | M | 1100 | 4 (2-12) | NE | NE | NK | NK |
| Liberia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Madagascar | Yes | 873 | <1 (<1-<1) | M | NE | NE | NE | NE | NK | NK |
| Malawi | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Mali | Yes | 5171 | NC | None | 0 | 0 (0-0) | 92 ⁹ | NC | NK | NK |
| Mauritius | Yes | 835656 | 118 (60-235) | M/O | 5517 | 78 (40-GTP) | NE | NE | NK | NK |
| Mozambique | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Niger | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Nigeria | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Rwanda | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Senegal | Yes | 16816 | NC | M/O | NE | NE | NK | NK | NK | NK |
| Seychelles | No | 0 | 0 (0-0) | М | NE | NE | NE | NE | NK | NK |
| Sierra Leone | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NE | NE | NK | NK |
| Somalia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| South Africa | Yes | 672626 | 9 (3-31) | M/B | NE | NE | 1596 | 2 (<1-7) | NK | NK |
| Swaziland | NK | NK | NK | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Tanzania | Yes | 514568 | 2 (1-3) | М | 3376 | 1 (1-2) | 5581 | 2 (1-3) | 363 | <1 (<1-<1) |
| Togo | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Uganda | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Zambia | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |
| Zimbabwe | No | 0 | 0 (0-0) | None | 0 | 0 (0-0) | NK | NK | NK | NK |

Notes: References for number of needle-syringes distributed, number of OST clients, number of people who inject drugs receiving HIV tests, and number of people who inject drugs receiving ART are provided in Appendices 11-14. No evidence of injecting drug use was identified for South Sudan (Middle East and North Africa), Botswana, Central African Republic, Comoros, Equatorial Guinea, Eritrea, Guinea Bissau, Lesotho, Mauritania, Namibia, Republic of the Congo, Sao Tome & Principe (Sub-Saharan Africa). NE – intervention exists in that country, but no data on the extent of service provision were located. NC – intervention exists and data on the extent of service provision were identified for this country, but no estimate of the prevalence of injecting drug use has been located for this country. NK – no information about the presence or absence of this intervention could be located for this country. M – methadone. B – buprenorphine. H – heroin. O – other forms of OST are prescribed. GTP – estimate greater than parity.

¹Data refer to needle-syringe distribution through specialised programmes over a 12 month period unless otherwise specified

²Refers to needle-syringe distribution over a 5 month period.

³Source indicates OST is available but does not specify forms.

⁴Refers to number of OST recipients at a given point in time unless otherwise specified

⁵Cumulative total patients 2014-2016.

⁶Refers to number of PWID receiving HIV tests over a 12 month period unless otherwise specified.

⁷Refers to number of PWID tested over a 2 year period.

⁸Time period not specified ⁹Sub-national data

 $^{^{10}}$ Refers to number of PWID receiving ART at a given point in time unless otherwise specified.

Appendix 11: Country-level needle and syringe program implementation indicators and references, by region

| | _ | ber of NSP | | | accessing NS ev data) | iP | | of NSP cl | | Number of need | dle-syringes o | |
|----------------------|--------|------------|--------|---|--------------------------|------|---------------------------------|-----------|------|-----------------------|----------------|---------|
| | N (pro | Year | Ref | % (95% CI) ¹ | Year | Ref | N ₂ | Year | Ref | N ¹² | Year | Ref |
| Eastern Europe | - " | ı cu | Itel | 70 (5570 CI) | rear | 1101 | - " | icui | itei | ., | , rear | · · · · |
| Armenia | 12 | 2014 | 1 | NE | NE | NE | 2,881 | 2013 | 2 | 512,270 | 2013 | 2 |
| Azerbaijan | 17 | 2014 | 3 | NE | NE | NE | NE NE | NE | NE | 762,000 | 2013 | 4 |
| Belarus | 34 | 2016 | 1 | 71 (68.8 ,73.2) | 2015 | 5 | 32,548 ⁶ | 2015 | 6 | 1,088,978 | 2015 | 6 |
| Bosnia & Herzegovina | 74 | 2016 | 7 | NE | NE | NE | 6,932 ⁷ | 2016 | 7 | 1,012,774 | 2015 | 7 |
| Bulgaria | 8 | 2016 | 8 | NE | NE | NE | 8,907 | 2014 | 8 | 364,111 ¹³ | 2015 | 9 |
| Czech Republic | 105 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 6,421,095 | 2015 | 9 |
| Estonia | 37 | 2015 | 11 | NE | NE | NE | NE | NE | NE | 2,136,691 | 2015 | 9 |
| Georgia | 14 | 2014 | 12 | 16-44 (7 sites) | 2015 | 13 | 13,253 | 2013 | 14 | 3,573,405 | 2014 | 14 |
| Hungary | 46 | 2016 | 1 | NE , | NE | NE | 4,442 | 2014 | 15 | 188,696 | 2015 | 9 |
| Latvia | 19 | 2016 | 1 | NE | NE | NE | NE | NE | NE | 524,949 | 2015 | 9 |
| Lithuania | 11 | 2014 | 16 | 75 (not able to estimate CI) ² | 2012 | 17 | NE | NE | NE | 200,630 | 2015 | 9 |
| Moldova | 28 | 2016 | 18 | 23-59 (5 sites) | 2013 | 19 | 10,369 | 2015 | 18 | 2,352,097 | 2015 | 18 |
| Poland | 34 | 2014 | 10 | 29.2 (20.3 ,39.3)2 | 2014 | 20 | 1,465 | 2014 | 21 | 10,142 | 2015 | 9 |
| Romania | 2 | 2016 | 1 | NE | NE | NE | 399 | 2013 | 22 | 1,425,592 | 2015 | 9 |
| Russian Federation | 20 | 2016 | 23 | 5 (not able to calculate CI) | 2016 | 23 | 15 regions: 34,246 | 2016 | 23 | 3,500,000 | 2016 | 23 |
| Slovakia | 5 | 2015 | 1 | NE | NE | NE | 2,114 NSP: | 2014 | 24 | 347,162 | 2015 | 9 |
| Ukraine | 1667 | 2016 | 1 | 37.4 (36.4 ,38.4) | 2015 | 25 | 21,2817; Pharmacy: 22,078 | 2015 | 26 | 19,400,000 | 2015 | 26 |
| Western Europe | | | | | | | | | | | | |
| Albania | 2 | 2016 | 27 | NE | NE | NE | 80-150 | 2016 | 27 | NE | NE | NE |
| Andorra | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Austria | 37 | 2014 | 28 | NE | NE | NE | NE | NE | NE | 5,953,919 | 2015 | 9 |
| Belgium | 65 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 1,034,242 | 2015 | 9 |
| Croatia | 102 | 2014 | 1 | 66-99 (3 sites) ³ | 2015 | 29 | 394 ^{8, 9} | 2015 | 29 | 923,650 | 2015 | 9 |
| Denmark | NE | 2014 | 30 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| England (U.K.) | NE | 2016 | 31 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Finland | 40 | 2014 | 1, 271 | NE | NE | NE | NE | NE | NE | 5,301,000 | 2015 | 9 |
| France | 583 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 12,314,781 | 2014 | 9 |
| Germany | 156 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 2,085,9998 | 2013 | 10 |

| | Nun | nber of NSP | sites | % of PWID | accessing NS | SP | Number | of NSP cli | ents | Number of need | | |
|--------------------------|-----|-------------|--------|------------------------------|--------------|-----|---------------------------------|------------|------|-----------------------|------------|-----|
| | (pr | ogramme d | lata) | (surv | ey data) | | (progr | amme dat | ta) | (prog | ramme data |) |
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ⁵ | Year | Ref | N ¹² | Year | Ref |
| Greece | 16 | 2014 | 10 | NE | NE | NE | 27,282 | 2013 | 32 | 268,157 | 2015 | 9 |
| Iceland | 2 | 2017 | 33 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Ireland | 143 | 2014 | 1, 276 | NE | NE | NE | pharmacies: 360 ⁹ | 2012 | 34 | 393,275 | 2014 | 24 |
| Italy | 620 | 2014 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Luxembourg | 9 | 2016 | 35 | NE | NE | NE | 9,571 ⁸ | 2015 | 36 | 361,392 | 2015 | 9 |
| Macedonia (FYR) | 16 | 2016 | 37 | NE | NE | NE | 3,949 | 2015 | 38 | 352,000 | 2015 | 38 |
| Malta | 7 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 340,644 | 2015 | 9 |
| Monaco | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Montenegro | 1 | 2015 | 39 | NE | NE | NE | NE | NE | NE | NE ¹⁴ | NE | NE |
| Netherlands | 150 | 2012 | 10 | NE | NE | NE | NE | NE | NE | 259,800 ⁸ | 2013 | 40 |
| Northern Ireland (U.K.) | 6 | 2013 | 10 | NE | NE | NE | NE | NE | NE | 292,390 | 2014 | 9 |
| Norway | 33 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 2,500,1928 | 2015 | 9 |
| Portugal | 590 | 2014 | 10 | NE NE | NE | NE | NE | NE | NE | 1,004,706 | 2015 | 9 |
| San Marino | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Scotland (U.K.) | 99 | 2014 | 10 | NE | NE | NE | NE | NE | NE | 4,376,456 | 2015 | 9 |
| Serbia | 2 | 2015 | 41 | NE | NE | NE | 4,285 | 2013 | 42 | NK ¹⁵ | NK | NK |
| Slovenia | 10 | 2013 | 43 | NE | NE | NE | 1,792 | 2013 | 43 | 500,757 | 2015 | 9 |
| 0.010 | 10 | 2020 | | NE | NE | NE | NE | NE | NE | 300,737 | 2010 | |
| Spain | 614 | 2013 | 10 | | | | | | | 1 402 200 | 2014 | 9 |
| | _ | | 44 | | | | | | 44 | 1,483,399 | 2014 | |
| Sweden | 6 | 2015 | 44 | NE | NE | NE | 2,592 | 2014 | | 281,391 | 2015 | 9 |
| Switzerland | 40 | 2009 | 45 | NE | NE | NE | NE | NE | NE | 210,881 ¹⁶ | 2006 | 45 |
| Wales (U.K.) | 65 | 2014 | 10 | NE | NE | NE | 25,409 | 2014 | 10 | 3,398,314 | 2015 | 9 |
| East and South East Asia | | | | | | | | | | | | |
| Brunei Darussalam | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Cambodia | 5 | 2014 | 46 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| China | 814 | 2014 | 47 | NE | NE | NE | 56,000 | 2014 | 47 | 11,000,000 | 2014 | 47 |
| Indonesia | 215 | 2013 | 48 | 50 (47.4 ,52.6) ⁴ | 2011 | 49 | 6,542 | 2016 | 50 | 317,842 | 2016 | 50 |
| Japan | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Lao PDR | 5 | 2016 | 51 | NE | NE | NE | 152 ⁷ | 2016 | 51 | NE | NE | NE |
| Malaysia | 692 | 2014 | 52 | NE | NE | NE | 85,693 | 2014 | 52 | NE | NE | NE |
| Mongolia | 1 | 2014 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Myanmar | 22 | 2013 | 53 | NE | NE | NE | NE | NE | NE | 13,913,025 | 2014 | 54 |
| Philippines | 0 | 2015 | 55 | 0 | 2015 | 55 | 0 | 2015 | 55 | 0 | 2015 | 55 |
| Republic of Korea | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Singapore | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Taiwan | 837 | 2016 | 56 | NE | NE | NE | NE | NE | NE | 3,860,518 | 2015 | 57 |

| | | ber of NSP | | | accessing NS | P | | r of NSP cli | | Number of need | | |
|--------------------------------|---------|------------|-----|--|--------------|-----|---------------------|--------------|-----|-----------------|-------------|-----|
| | ٠, | gramme d | | | ey data) | | | ramme dat | | | ramme data) | |
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ⁵ | Year | Ref | N ¹² | Year | Ref |
| Thailand | 42 | 2016 | 58 | 13-23 (2 studies) | 2016 | 59 | NE | NE | NE | 138,8588 | 2016 | 60 |
| Timor Leste | 0 | 2014 | 1 | 0 | 2014 | 1 | 0 | 2014 | 1 | 0 | 2014 | 1 |
| Viet Nam | 297 | 2016 | 1 | 35 (not able to estimate CI) | 2016 | 61 | 145,430 | 2016 | 61 | 28,366,110 | 2016 | 61 |
| South Asia | | | | | | | | | | | | |
| Afghanistan | 18 | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Bangladesh | 88 | 2014 | 62 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Bhutan | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| India | 266 | 2015 | 63 | NE | NE | NE | NE | NE | NE | 16,917,292 | 2015 | 63 |
| Iran, Islamic Republic | 580 | 2015 | 64 | 63.4 (59.1 ,67.4) ³ | 2007 | 65 | NE | NE | NE | 8,578,845 | 2016 | 66 |
| Maldives | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Nepal | 60 | 2014 | 67 | 88.3 (84.6 ,91.5) ³ | 2013 | 68 | NE | NE | NE | 1,521,054 | 2016 | 69 |
| Pakistan | 34 | 2014 | 1 | NE | NE | NE | 43,300 | 2014 | 70 | 7,714,524 | 2014 | 70 |
| Sri Lanka | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Central Asia | | | | | | | | | | | | |
| Kazakhstan | 155-168 | 2014 | 1 | 65 (not able to calculate CI) ² | 2014 | 71 | 60,705 | 2015 | 72 | 16,347,156 | 2015 | 72 |
| Kyrgyzstan | 48 | 2014 | 73 | 28.2 (25.3 ,31.3) | 2013 | 74 | 11,254 | 2014 | 73 | 7,004,861 | 2014 | 73 |
| Tajikistan | 51 | 2016 | 1 | NE | NE | NE | 9,202 | 2014 | 71 | 6,539,721 | 2015 | 75 |
| Turkmenistan | 0 | 2014 | 76 | 0 | 2014 | 76 | 0 | 2014 | 76 | 0 | 2014 | 76 |
| Uzbekistan | 235 | 2014 | 77 | NE | NE | NE | 26,900 ⁷ | 2014 | 71 | 2,601,516 | 2011 | 78 |
| Caribbean | | | | | | | · | | | | | |
| Bahamas | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Bermuda | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Commonwealth of Puerto Rico | 7 | 2016 | 79 | NE | NE | NE | 9,171 | 2013 | 79 | 434,052 | 2013 | 79 |
| Dominican Republic | 1 | 2016 | 1 | NE | NE | NE | NE | NE | NE | 14,398 | 2015 | 1 |
| Haiti | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Jamaica | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Latin America | | | | | | | | | | | | |
| Argentina | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Bolivia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Brazil | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Chile | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Colombia | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Costa Rica | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Ecuador | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |

| | 1 | ber of NSP | | | accessing NS | P | | r of NSP cli | | Number of need | | |
|---------------------------|------|------------|-------|-------------------------------|--------------|-----|----------------|--------------|-----|--------------------------|-------------|-------|
| | (pro | ogramme d | • | - | /ey data) | | | ramme dat | | | ramme data) | |
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ⁵ | Year | Ref | N ¹² | Year | Ref |
| El Salvador | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Guatemala | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Guyana | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Honduras | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Mexico | NE | 2015 | 80 | NE | NE | NE | NE | NE | NE | 1,186,348 | 2015 | 80 |
| Nicaragua | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Panama | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Paraguay | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Peru | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Suriname | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Uruguay | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Venezuela | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| North America | | | | | | | | | | | | |
| Canada | >700 | 2016 | 81-89 | NE | NE | NE | NE | NE | NE | 45,692,898 ¹⁷ | 2015 | 81-89 |
| United States | 241 | 2016 | 90 | 54 (not able to calculate CI) | 2015 | 91 | NE | NE | NE | 45,868,960 ⁸ | 2013 | 92 |
| Australasia | | | | | | | | | | | | |
| Australia | 102 | 2015 | 93 | NE | NE | NE | NE | NE | NE | 42,900,000 | 2015 | 93 |
| New Zealand | 23 | 2016 | 94 | NE | NE | NE | 10,000 | 2014 | 95 | 2,780,000 | 2015 | 94 |
| Pacific Island states and | | | | | | | | | | | | |
| territories | | | | | | | | | | | | |
| American Samoa | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Fed. States of Micronesia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Fiji | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| French Polynesia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Guam | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Kiribati | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Marshall Islands | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| New Caledonia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Northern Mariana Islands | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Palau | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Papua New Guinea | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Samoa | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Solomon Islands | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Tonga | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Vanuatu | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |

| | | nber of NSP | | | D accessing NS | P | | er of NSP cli | | Number of nee | | |
|----------------------------------|----|-------------|-----|-------------------------|----------------|-----|--------------------|---------------|-----|---------------------|--------------|-----|
| | | ogramme da | | • | vey data) | | | gramme dat | | | gramme data) | |
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ⁵ | Year | Ref | N ¹² | Year | Ref |
| Middle East and North Africa | | | | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Algeria | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Bahrain | 0 | 2014 | 96 | 0 | 2014 | 96 | 0 | 2014 | 96 | 0 | 2014 | 96 |
| Cyprus | 1 | 2014 | 1 | NE | NE | NE | NE | NE | NE | 164 | 2015 | 9 |
| Egypt | 9 | 2016 | 1 | NE | NE | NE | 3,465 ⁸ | 2011 | 97 | 892 | 2013 | 98 |
| Iraq | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Israel | NE | 2016 | 99 | NE | NE | NE | 2,500 ⁷ | 2015 | 99 | 214,777 | 2015 | 1 |
| Jordan | 4 | 2016 | 100 | NE | NE | NE | NE | NE | NE | 63,396 | 2015 | 1 |
| Kuwait | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Lebanon | 2 | 2016 | 101 | NE | NE | NE | 193 | 2016 | 101 | 59,071 | 2016 | 101 |
| Libyan Arab Jamahiriya | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Morocco | 7 | 2015 | 102 | NE | NE | NE | NE | NE | NE | 238,946 | 2014 | 102 |
| Occupied Palestinian Territories | 2 | 2011 | 103 | NE | NE | NE | 257 ¹⁰ | 2011 | 103 | 7,600 ¹⁰ | 2011 | 103 |
| Oman | 0 | 2014 | 104 | 0 | 2014 | 104 | 0 | 2014 | 104 | 0 | 2014 | 104 |
| Qatar | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Saudi Arabia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Sudan | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Syrian Arab Republic | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| , Tunisia | 3 | 2016 | 1 | NE | NE | NE | 11,000 | 2013 | 105 | 48,000 | 2013 | 105 |
| Turkey | 0 | 2016 | 1 | 0 | 2016 | 1 | Ô | 2016 | 1 | 0 | 2016 | 1 |
| United Arab Emirates | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Yemen | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Sub-Saharan Africa | | | | | | | | | | | | |
| Angola | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Benin | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Burkina Faso | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Burundi | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Cameroon | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Cape Verde | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Chad | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Cote d'Ivoire | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Dem Rep of the Congo | 0 | 2013 | 1 | 0 | 2013 | 1 | 0 | 2013 | 1 | 0 | 2013 | 1 |
| Djibouti | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Ethiopia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Gabon | 0 | 2016 | 10 | 0 | 2016 | 10 | 0 | 2016 | 10 | 0 | 2016 | 10 |

| | - | nber of NSP ogramme d | | | accessing NS vey data) | SP | | er of NSP cli | | Number of nee | dle-syringes o | |
|------------------------|----|--------------------------|-----|-------------------------|---------------------------|-----|---------------------|---------------|-----|-----------------|----------------|-----|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ⁵ | Year | Ref | N ¹² | Year | Ref |
| Gambia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Ghana | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Guinea | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Kenya | 13 | 2016 | 1 | NE | NE | NE | 4,500 ¹¹ | 2014 | 1 | 271,941 | 2014 | 106 |
| Liberia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Madagascar | 3 | 2014 | 107 | 5-46 (3 sites) | 2012 | 108 | NE | NE | NE | 873 | 2014 | 109 |
| Malawi | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Mali | NE | 2015 | 110 | NE | NE | NE | NE | NE | NE | 5,171 | 2015 | 110 |
| Mauritius | 49 | 2014 | 111 | NE | NE | NE | NE | NE | NE | 835,656 | 2015 | 111 |
| Mozambique | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Niger | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Nigeria | 0 | 2016 | 112 | 0 | 2016 | 112 | 0 | 2016 | 112 | 0 | 2016 | 112 |
| Rwanda | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Senegal | NE | 2016 | 1 | NE | NE | NE | NE | NE | NE | 16,816 | 2014 | 113 |
| Seychelles | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Sierra Leone | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Somalia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| South Africa | 5 | 2016 | 114 | 3 (3, 3) | 2016 | 114 | 2,465 | 2016 | 114 | 672,626 | 2016 | 114 |
| Swaziland | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Togo | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Uganda | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| United Rep of Tanzania | 5 | 2016 | 1 | NE | NE | NE | 1,942 | 2016 | 115 | 514,568 | 2016 | 115 |
| Zambia | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |
| Zimbabwe | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 | 0 | 2016 | 1 |

Notes: The following countries are not listed in this table, as we did not find documented evidence or reports of injecting drug use in these countries: Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, Cuba, Democratic People's Republic of Korea, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Nauru, Republic of Congo, Saint Kitts and Nevis, Saint Lucia, Sao Tome and Principe, Saint Vincent and Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu.

PWID – people who inject drugs

NSP – needle and syringe programmes

NE – intervention exists in that country, but no data on the extent of service provision were located.

NK – no information about the presence or absence of this intervention could be located for this country across the indicators assessed.

¹Data refer to NSP access in the past 12 months unless otherwise specified

²Time period in which NSP access was measured not specified

³Refers to lifetime history of NSP access

⁴Refers to NSP access in the past week

⁵Refers to number of clients in a 12-month period unless otherwise specified

⁶Refers to number of clients in a 6-month period

⁷Time period in which number of clients was measured not specified

⁸Sub-national data

⁹Refers to number of clients in a 1-month period

¹⁰Refers to needle-syringe distribution/number of clients over a 5-month period

¹¹Refers to number of clients in a 4-year period

¹²Data refer to national distribution through specialised needle and syringe programmes unless otherwise specified. Data are for a 12-month period unless otherwise specified.

¹³Global Fund support ended in July 2016 and there were concerns regarding sustainability of programmes ⁸; it is not clear if these data reflect current distribution.

¹⁴Since withdrawal of Global Fund support in June 2015, only one NSP (previously three) operates. No data were identified on current needle-syringe distribution, but coverage is reported to have declined (³⁹).

¹⁵Since withdrawal of Global Fund support, NSPs have largely closed and are no longer available (⁴¹). No data were identified on current needle-syringe distribution.

¹⁶Refers to needle-syringe distribution over a 1-month period

¹⁷Approximation based on several data sources

- 1. HRI. The Global State of Harm Reduction. . London: Harm Reduction International, 2016.
- 2. Lazarus JV, Delpech V, Sonnerborg A, Fuenzalida H, Subata E. HIV Programme Review in Armenia. Copenhagen: WHO Regional Office for Europe, 2015.
- 3. Republic of Azerbaijan. Country Progress Report: UNAIDS, 2014.
- 4. Burrows D, Boltaev A, Musa M, Gottgredsson M, Suleymanova J. Review of the HIV Programme in Azerbaijan. Copenhagen: WHO Regional Office for Europe, 2014.
- 5. Kecina EA. Behavioral features and knowledge level on the HIV/AIDS problem among consumers of injecting drugs. Minsk: Belarus State University, 2016.
- 6. Беларусь Р. Национальный отчет о достигнутом прогрессе в осуществлении глобальных мер в ответ на СПИД (по выполнению Политической Декларации по ВИЧ/СПИДу), 2016.
- 7. UNDP. Najvažnija dostignuća HIV-programa u Bosni i Hercegovini. United Nations Development Programme; 2016.
- 8. Eurasian Harm Reduction Network. Country Profile: Bulgaria. 2017. http://harm-reduction.org/country-profiles/bulgaria (accessed 30/5/17 2017).
- 9. EMCDDA. European Drug Report: Trends and Developments. Lisbon: European Monitoring Centre on Drugs and Drug Addiction, 2017.
- 10. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Table HSR-4-1. Health & Social Responses, Needle and Syringe Programmes, Sites Fixed, summary table, 2014. 2016. http://www.emcdda.europa.eu/data/stats2016#displayTable:HSR-4-1 (accessed 21/4/17 2017).
- 11. National Institute for Health Development. HIV in Estonia, Situation, Prevention, Treatment and Care, Narrative Report for Global AIDS Response Progress Reporting, 2016.
- 12. National Centre for Disease Control and Public Health. Global AIDS Response Progress Report Georgia, 2015.
- 13. Curatio International Foundation. HIV risk and prevention behaviors among people who inject drugs in seven cities in Georgia. http://curatiofoundation.org/wp-content/uploads/2016/03/PWID-BBS-Report-2015-ENG.pdf: Curatio International Foundation, 2015.
- 14. Eurasia Harm Reduction Network. Harm Reduction National Report 2015. 2015.
- 15. National Institute for Health Development. Hungary country overview. 2016. http://www.emcdda.europa.eu/countries/hungary.
- 16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Lithuania Country Overview. 2016. http://www.emcdda.europa.eu/countries/lithuania (accessed 4/20/17 2017).
- 17. Drug Tobacco and Alcohol Control Department. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA BY THE REITOX NATIONAL FOCAL POINT: LITHUANIA New Development, Trends, 2014.
- 18. Republic of Moldova South-East European Region National Coordination Council. Republic of Moldova Progress Report on HIV/AIDS, 2016.
- 19. CNMS. Integrated bio-behavioural study in key populations at higher risk: Key indicators. Chisinau: Centrul National de Management in Sanatate, 2013.
- 20. Malczewski A, Misiurek A, Bukowska B, et al. National Drug Report 2014 Poland, 2014.
- 21. European Monitoring Centre for Drugs and Drug Addiction. Poland country overview. 2016. http://www.emcdda.europa.eu/countries/poland.
- 22. MINISTRY OF ADMINISTRATION AND INTERIOR, NATIONAL ANTI-DRUG AGENCY, ROMANIAN MONITORING CENTRE FOR DRUGS AND DRUGS ADDICTION. NATIONAL REPORT ON DRUGS 2014: ROMANIA New Developments and Trends, 2014.
- 23. Sarang A. Personal communication email to S. Larney 2 May 2017.
- 24. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: Trends and Developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2016.
- 25. Barska G, Sazanov JA. Monitoring of conduct and HIV prevalence among people who inject drugs and their sexual partners 2015 (Russian). Kiev: Alliance for Public Health, 2016.
- 26. Alliance for Public Health. Annual Report 2015. Kiev: Alliance for Public Health, 2016.

- 27. Eurasian Harm Reduction Network (EHRN). Country Profile: Albania. 2017. http://harm-reduction.org/country-profiles/albania (accessed 30/5/17 2017).
- 28. Marotta PL, McCullagh CA. A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011. *International Journal of Drug Policy* 2016; 32: 3-10.
- 29. Handanagic S, Bozicevic I, Civljak M, et al. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys. *International Journal of Drug Policy* 2016; 32: 57-63.
- 30. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: Denmark New Developments and Trends, 2014.
- 31. Public Health England. Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs 2016.
- 32. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: GREECE New Development, Trends, 2014.
- 33. Jóhannesdóttir S. Personal communication email to S. Larney 24 April 2017.
- 34. Irish Focal Point. 2014 NATIONAL REPORT (2013 Data) TO THE EMCDDA by the Reitox National Focal Point, 2014.
- 35. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Luxembourg Country Overview. 2016. http://www.emcdda.europa.eu/countries/luxembourg (accessed 19/4/17 2017).
- 36. ARENDT DV, BIWERSI MG, DEVAUX MC, et al. Comite de Surveillance du SIDA, 2015.
- 37. Eurasian Harm Reduction Network (EHRN). The Impact of Transition from Global Fund Support to Governmental Funding on the Sustainability of Harm Reduction Programs: A Case Study from Macedonia, 2016.
- 38. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: A case study from Macedonia. Vilnius, 2016.
- 39. Eurasian Harm Reduction Network. Country Profile: Montenegro. 2016. http://harm-reduction.org/country-profiles/montenegro (accessed 30/5/17 2017).
- 40. van Laar M, Cruts G, van Ooyen-Houben M, et al. REPORT TO THE EMCDDA by the Reitox National Focal Point: THE NETHERLANDS DRUG SITUATION 2014, 2014.
- 41. Eurasian Harm Reduction Network. The Impact of Transition from Global Fund Support to Governmental Funding on the Sustainability of Harm Reduction Programs: A Case Study from Serbia. Vilnius: Eurasian Harm Reduction Network, 2015.
- 42. Ministy of Health of Serbia. Country Progress Report: Republic of Serbia, 2014.
- 43. National Institute of Public Health. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA by the Reitox National Focal Point: SLOVENIA NEW DEVELOPMENTS AND TRENDS, 2014.
- 44. Socialdepatementet. Ökad tillgänglighet till sprututbytesverksamheter i Sverige, 2015.
- 45. Arnaud S, Jeannin A, Dubois-Arber F. Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006. *International Journal of Drug Policy* 2011; 22(3): 226-32.
- 46. The National AIDS Authority (NAA). Cambodia Country Progress Report, Monitoring Progress Towards the 2011 UN Political Declaration on HIV and AIDS. Report to UNAIDS., 2015.
- 47. National Health and Family Planning Commission of the People's Republic of China. 2015 China AIDS Response Progress Report, 2015.
- 48. National AIDS Commission. Indonesia Country Progress Report 2014, Reporting Period 2012-2013. Report to UNAIDS., 2014.
- 49. Indonesia Ministry of Health. IBBS: 2011. Integrated Biological and Behavioural Survey 2011.
- 50. Siahaan I. Personal communication email to S. Larney 7 July 2017. 2017.
- 51. Centre for HIV/AIDS and STI (CHAS) and the Ministry of Health (MOH) on behalf of the National Committee for the Control of AIDS (NCCA). Lao PDR Country Progress Report, Global AIDS Response Progress Report, 2016, 2016.

- 52. Health MMo. Global AIDS Response Progress Report Malaysia 2015. 2015.
- 53. HIV And AIDS Data Hub for Asia-Pacific. HIV and AIDS Myanmar Data Hub for Asia-Pacific. 2014.
- 54. National AIDS Programme. Global AIDS Response Progress Report Myanmar. Report to UNAIDS., 2015.
- 55. HIV and AIDS Data Hub for Asia-Pacific. HIV and AIDS Data Hub for Asia-Pacific Review in slides People Who Inject Drugs, 2016.
- 56. Chen J. Harm reduction policy in Taiwan: Toward a comprehensive understanding of its making and effects. *Harm Reduction Journal* 2016; 13: 11.
- 57. Lin T, Chen CH, Chou P. Effects of combination approach on harm reduction programs: the Taiwan experience. *Harm Reduction Journal* 2016; 13(1): 23.
- 58. Thailand Ending AIDS. Thailand AIDS Response Progress Report 2015. Report to UNAIDS., 2015.
- 59. Aramrattana A. Global review of coverage of HIV prevention interventions for people who inject drugs: Preliminary data for Thailand. In: National Drugs and Alcohol Research Centre, editor.; 2017.
- 60. Ozone Foundation. STAR: Summary of Access to Targeted Groups, Referrals and Disposals of Clean Equipment/Condoms in 1-3 years of STAR project Activity, 2017.
- 61. Hai SV. Personal communication email to S. Larney, 23 May 2017. 2017.
- 62. UNAIDS. Country Progress Report: Bangladesh, 2014.
- 63. NATIONAL AIDS CONTROL ORGANIZATION (NACO). Chapter 24 NATIONAL AIDS CONTROL ORGANIZATION 2016.
- 64. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report; On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS, 2015.
- 65. Rahnama R, Mohraz M, Mirzazadeh A, et al. Access to harm reduction programs among persons who inject drugs: Findings from a respondent-driven sampling survey in Tehran, Iran. *International Journal of Drug Policy* 2014; 25(4): 717-23.
- 66. National AIDS Committee Secretariat Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report. Geneva: UNAIDS, 2017.
- 67. National Centre for AIDS and STD Control. Country Progress Report Nepal, 2015.
- 68. Ministry of Health and Population, National Centre for AIDS and STD Control. Integrated Biological and Behavioral Surveillance (IBBS) Survey among People who Inject Drugs (PWIDs) in Eastern Terai Highway Districts of Nepal Round V 2012, 2012.
- 69. National Centre for AIDS and STD Control. Factsheet 8: Targeted Intervention among Key Population in Nepal, as of July 2016. 2016.
- 70. NACP. Country Progress Report Pakistan. Report to UNAIDS.: National AIDS Control Program, 2015.
- 71. Rotberga S. Personal communication email to S. Larney, 16 October 2016. 2017.
- 72. Министерство здравоохранения и социального развития Республики Казахстан ГУ "Республиканский центр по профилактике и борьбе со СПИД". Проект Национальный доклад о достигнутом прогрессе восуществлении глобальных мер в ответ на СПИД, 2016.
- 73. UNDP. Annual report on the implementation of UNDP project in support of the government of the Krygyz Republic, funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria. http://www.aidscenter.kg/images/Orders/other/IBBS%20REPORT.doc: UNDP,, 2014.
- 74. Kyrgyzstan Republican AIDS Centre. Integrated Bio-behavioural Survey 2013. Bishkek: Kyrgyzstan Republican AIDS Centre, 2013.
- 75. Министерство здравоохранения и социальной защиты населения Республики Таджикистан Государственное учреждение «Республиканский центр по профилактике и борьбе с СПИД». ОТЧЕТ СТРАНЫ О ДОСТИГНУТОМ ПРОГРЕССЕ В ПРОТИВОДЕЙСТВИИ ЭПИДЕМИИ ВИЧ, 2016, 2016.

- 76. Boltaev AA, El-Bassel N, Deryabina A, et al. Scaling up HIV prevention efforts targeting people who inject drugs in Central Asia: A review of key challenges and ways forward. *Drug and Alcohol Dependence* 2013; 132S: 1-7.
- 77. Central Asia Drug Action Programme. Country overview: Uzbekistan. 2014. http://www.emcdda.europa.eu/publications/country-overviews/uz (accessed 13/2/17 2017).
- 78. Zabransky T, Mravcik V, Talu A, Jasaitis E. Post-soviet central Asia: A summary of the drug situation. *International Journal of Drug Policy* 2014; 25(6): 1186-94.
- 79. Torruella R. Personal communication email to S. Larney, 20 June 2017. 2017.
- 80. Centro Nacional para la Prevenci ión y el Contro I del VIH y el sida (CENSIDA). Informe Nacional de Avances en la Respuesta al VIH y el SIDA, 2016.
- 81. Taylor M. Personal communication email to S. Larney, 26 April 2017. 2017.
- 82. Buxton J. Personal communication email to J. Grebely, 2 February, 2017. 2017.
- 83. Street Connections. "Find help and supplies". 2017.

https://streetconnections.clickonce.ca/service map.php (accessed 13 June 2017.

- 84. Kirkland S, Ploem C, Dikaios K. Program evaluation for Mainline Needle Exchange: Contributing to a harm reduction landscape in Nova Scotia. Halifax: Atlantic Interdisciplinary Research Network for Social and Behavioural Issues in Hepatitis C and HIV, 2016.
- 85. Harold C. Personal communication email to J. Grebely, 14 June 2017. 2017.
- 86. CBC News. Needle exchange program sees big increases on Island. 2015. http://www.cbc.ca/news/canada/princeedwardisland/intravenousdrugsneedlespei1.3311772 (accessed 8 April 2017.
- 87. Noël L, Gagnon D, Cloutier R. Statistiques sur les services relatifs aux programmes de prévention du virus de l'immunodéficience humaine (VIH) et des hépatites B et C auprès des personnes utilisatrices de drogues par injection au Québec. Quebec: Institut National de Santé Publique du Québec, 2014.
- 88. Population Health Branch. Prevention and risk reduction programs and services in Sakatchewan: 2014-2015 fiscal year evaluation report. Regina: Ministry of Health, Sakatchewan, 2015.
- 89. Yetman G. Safe Works Access Program Project Annual Report. St. John's: AIDS Committee of Newfoundland & Labrador, 2017.
- 90. NASEN. Syringe Exchange Programs in the US by State. 2015.
- 91. Wejnert C, Hess KL, Hall HI, et al. Vital Signs: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs United States. *Morbidity and Mortality Weekly Report* 2016; 65(47).
- 92. Des Jarlais D, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas United States, 2013. 2013.
- 93. Iversen J, Linsen S, Kwon JA, Maher L. Needle Syringe Program National Minimum Data Collection: National Data Report 2016. Sydney: Kirby Institute, UNSW Sydney, 2016.
- 94. Noller G, Leafe K. Brief analysis of the New Zealand population of people who inject drugs (PWID): Estimates of population size, prevalence of BBVs, demographics and risk behaviours, and service provision: Needle Exchange Services Trust (NEST), 2016.
- 95. Ministry of Health. Country Progress Report New Zealand. Report to UNAIDS., 2014.
- 96. Kingdom of Bahrain. UNGASS Country Progress Report: Kingdom of Bahrain, 2014.
- 97. National AIDS Program Egypt. Global AIDS Response Progress Report 2012, 2012.
- 98. National AIDS Program Egypt. Global AIDS Response Progress Report: Egypt, 2014.
- 99. HarelFisch Y, Zadok Y, Hizi S. Israel Country Overview. 2016.

http://www.emcdda.europa.eu/countries/israel (accessed 13/2/17 2017).

- 100. The Ministry of Health/National AIDS Programme. Global AIDS Response Progress Report, 2014.
- 101. Haddad P. Personal communication email to S. Larney 7 June 2017. 2017.

- 102. ONUSIDA, Le Fonds mondial. Mise en oeuvre de la declaration politique sur le VIH/sida, 2015.
- 103. Ministry of Health. Country Progress Report: Occupied Palestinian Territory, 2012.
- 104. National AIDS Programme. COUNTRY PROGRESS REPORT SULTANATE OF OMAN, 2014.
- 105. Ministere de la Sante Publique. Rapport d'Activite sur la Riposte au SIDA-Tunisie, 2014.
- 106. National AIDS Control Council. Kenya AIDS Response Progress Report: Progress Towards Zero. Report to UNAIDS., 2014.
- 107. Système d'Information Multi-Sectorielle/Multi-Sector System (SIMS/MSIS). RAPPORT FINAL AU NIVEAU DES 37 VILLES: Cartographie et estimation de la taille des personnes cibles les plus exposées aux risques du VIH/Sida, 2014.
- 108. Focus Development Association, Service de Laboratoire National de Reference. Etude comportementale et biologique chez les consommateurs de drogues injectables dans les zones urbaines à Madagascar-2012, 2012.
- 109. Malagasy Miatrika ny Sida. Rapport sur la Reponse Face au VIH et au SIDA a Madagascar. Report to UNAIDS., 2014.
- 110. Toufik A. Rapport Final: Evaluation de la Reduction de la Demande de Drogues, 2016.
- 111. NAS. Country Progress Report 2015, Republic of Mauritius. Report to UNAIDS., 2015.
- 112. National Agency for the Control of AIDS (NACA). Global AIDS Response Country Progress Report, 2015.
- 113. Republique du Senegal Conseil National de Lutte Contre le Sida. Rapport de Situation sur la Riposte Nationale a l'Epidemie de VIH/Sida Senegal: 2013-2014. Report to UNAIDS., 2014.
- 114. Scheibe S, Shelly S. Personal communication email to S. Larney, 20 June 2017. 2017.
- 115. Asem J. Personal communication email to S. Larney, 30 May 2017. 2017.

Appendix 12: Country-level opioid substitution therapy implementation indicators and references, by region

| | Δν | ailable Fo | rms | % of PWID accessing | - | | Number of 0 | | |
|----------------------|------|------------|-----|--------------------------------|------|-----|----------------|------|-----|
| | AV | unable 10 | | (survey data | | | (programi | | |
| | Form | Year | Ref | % (95% CI) ¹ | Year | Ref | N ² | Year | Ref |
| Eastern Europe | | | | | | | | | |
| Armenia | М | 2015 | 1 | NE | NE | NE | 430 | 2014 | 1 |
| Azerbaijan | M | 2014 | 2 | NE | NE | NE | 155 | 2014 | 3 |
| Belarus | M | 2016 | 4 | NE | NE | NE | 978 | 2015 | 5 |
| Bosnia & Herzegovina | МВ | 2016 | 6 | NE | NE | NE | 1,395 | 2016 | 7 |
| Bulgaria | МО | 2014 | 4 | NE | NE | NE | 3,423 | 2015 | 8 |
| Czech Republic | МВ | 2014 | 4 | NE | NE | NE | 4,000 | 2015 | 8 |
| Estonia | МВ | 2014 | 4 | NE | NE | NE | 1,166 | 2015 | 9 |
| Georgia | МВ | 2016 | 4 | 3.9 (3.1 ,4.8) ³ | 2015 | 10 | 2,500 | 2015 | 11 |
| Hungary | МВ | 2014 | 4 | NE | NE | NE | 669 | 2015 | 8 |
| Latvia | МВ | 2016 | 12 | NE | NE | NE | 608 | 2015 | 8 |
| Lithuania | МВ | 2014 | 13 | 13.5 (not able to estimate CI) | 2010 | 14 | 596 | 2015 | 8 |
| Moldova | М | 2016 | 4 | NE NE | NE | NE | 468 | 2015 | 15 |
| Poland | МВ | 2016 | 4 | NE | NE | NE | 2,564 | 2015 | 8 |
| Romania | МВ | 2014 | 16 | NE | NE | NE | 547 | 2015 | 8 |
| Russian Federation | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Slovakia | МВО | 2014 | 17 | NE | NE | NE | 600 | 2015 | 8 |
| Ukraine | МВ | 2016 | 4 | 5 (4.6 ,5.5) | 2015 | 18 | 9,214 | 2017 | 19 |
| Western Europe | | | | | | | | | |
| Albania | МВ | 2016 | 20 | NE | NE | NE | 578 | 2016 | 20 |
| Andorra | None | 2014 | 4 | 0 | 2014 | 4 | 0 | 2014 | 4 |
| Austria | МВО | 2014 | 21 | NE | NE | NE | 17,599 | 2015 | 8 |
| Belgium | МВН | 2014 | 4 | NE | NE | NE | 16,681 | 2015 | 8 |
| Croatia | МВ | 2014 | 4 | 5-54 (3 sites) | 2015 | 22 | 5,061 | 2015 | 8 |
| Denmark | МВ | 2016 | 4 | NE . | NE | NE | 6,268 | 2014 | 8 |
| England (U.K.) | МВН | 2014 | 21 | NE | NE | NE | 140,400 | 2016 | 23 |
| Finland | МВ | 2014 | 4 | NE | NE | NE | 3,000 | 2014 | 8 |
| France | МВО | 2016 | 4 | NE | NE | NE | 168,840 | 2015 | 8 |
| Germany | МВН | 2014 | 4 | NE | NE | NE | 77,200 | 2015 | 8 |
| Greece | МВ | 2014 | 4 | NE | NE | NE | 10,082 | 2015 | 8 |
| Iceland | В | 2016 | 24 | NE | NE | NE | NE | NE | NE |
| Ireland | МВ | 2014 | 4 | NE | NE | NE | 9,917 | 2015 | 8 |
| Italy | МВ | 2014 | 4 | NE | NE | NE | 60,047 | 2015 | 8 |
| Luxembourg | МВО | 2016 | 25 | NE | NE | NE | 1,078 | 2015 | 8 |
| Macedonia (FYR) | МВ | 2016 | 26 | NE | NE | NE | 1,930 | 2015 | 26 |
| Malta | МВ | 2012 | 4 | NE | NE | NE | 1,026 | 2015 | 8 |

| | Δva | ailable Fo | rms | % of PWID accessi | - | | Number of 0 | | |
|-------------------------|------|------------|-----|--------------------------------|------|-----|----------------|-----------|-----|
| | 7.00 | | | (survey data | | | (programi | ne data) | |
| | Form | Year | Ref | % (95% CI)¹ | Year | Ref | N ² | Year | Ref |
| Monaco | M | 2015 | 27 | NE | NE | NE | NE | NE | NE |
| Montenegro | МВ | 2014 | 28 | NE | NE | NE | 367 | 2015 | 28 |
| Netherlands | МВН | 2014 | 4 | NE | NE | NE | 7,421 | 2014 | 8 |
| Northern Ireland (U.K.) | МВ | 2014 | 21 | NE | NE | NE | 607 | 2010 | 21 |
| Norway | МВ | 2014 | 21 | NE | NE | NE | 7,498 | 2015 | 29 |
| Portugal | МВ | 2013 | 30 | NE | NE | NE | 17,011 | 2015 | 8 |
| San Marino | M | 2010 | 31 | NE | NE | NE | NE | NE | NE |
| Scotland (U.K.) | МВ | 2014 | 32 | NE | NE | NE | 3,686 | 2012/2013 | 32 |
| Serbia | M | 2015 | 33 | 4 (2.6, 6) ³ | 2010 | 34 | 4,336 | 2015 | 33 |
| Slovenia | МВО | 2016 | 4 | NE | NE | NE | 3,261 | 2015 | 8 |
| Spain | МВН | 2014 | 4 | NE | NE | NE | 61,859 | 2014 | 8 |
| Sweden | МВ | 2012 | 35 | NE | NE | NE | 3,679 | 2015 | 8 |
| Switzerland | MBDO | 2014 | 4 | NE | NE | NE | 17,191 | 2006 | 36 |
| Wales (U.K.) | МВ | 2014 | 21 | NE | NE | NE | 1,993 | 2014 | 21 |
| East and Southeast Asia | | | | | | | · | | |
| Brunei Darussalam | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Cambodia | М | 2014 | 37 | NE | NE | NE | 130 | 2014 | 37 |
| China | М | 2014 | 38 | NE | NE | NE | 184,000 | 2014 | 39 |
| Indonesia | МВ | 2014 | 40 | 53.0 (50.4, 55.7) ³ | 2011 | 41 | 5,329 | 2013 | 40 |
| Japan | None | 2016 | 4 | o , | 2016 | 4 | 0 | 2016 | 4 |
| Lao PDR | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Malaysia | МВ | 2014 | 42 | NE | NE | NE | 74,816 | 2014 | 42 |
| Mongolia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Myanmar | М | 2016 | 43 | NE | NE | NE | 7,872 | 2014 | 44 |
| Philippines | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Republic of Korea | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Singapore | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Taiwan | МВ | 2015 | 45 | NE NE | NE | NE | 8,789 | 2015 | 45 |
| Thailand | М | 2014 | 46 | 21 (not able to estimate CI) | 2016 | 47 | 3,646 | 2014 | 46 |
| Timor Leste | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Viet Nam | M | 2016 | 48 | NE | NE | NE | 50,766 | 2016 | 48 |
| South Asia | | - | | | | | , | | |
| Afghanistan | M | 2016 | 4 | NE | NE | NE | NE | NE | NE |
| Bangladesh | M | 2017 | 49 | NE | NE | NE | 798 | 2016 | 49 |
| Bhutan | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| India | ВО | 2013 | 50 | NE | NE | NE | 5,124 | 2013 | 50 |
| Iran, Islamic Republic | МВО | 2016 | 51 | 42.1 (40.1, 44.1) | 2014 | 52 | 640,000 | 2016 | 51 |

| | Av | ailable Fo | rms | % of PWID acce (survey da | - | | Number of O | | |
|-----------------------------|------|------------|-----|------------------------------|------|-----|----------------|------|-----|
| | Form | Year | Ref | % (95% CI) ¹ | Year | Ref | N ² | Year | Ref |
| Maldives | М | 2014 | 53 | NE | NE | NE | 108 | 2012 | 54 |
| Nepal | МВ | 2016 | 55 | NE | NE | NE | 1,347 | 2016 | 55 |
| Pakistan | None | 2015 | 56 | 0 | 2015 | 56 | 0 | 2015 | 56 |
| Sri Lanka | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Central Asia | | | | | | | | | |
| Kazakhstan | М | 2016 | 4 | NE | NE | NE | 292 | 2015 | 57 |
| Kyrgyzstan | М | 2015 | 58 | NE | NE | NE | 1,673 | 2014 | 59 |
| Tajikistan | М | 2015 | 60 | NE | NE | NE | 550 | 2015 | 60 |
| Turkmenistan | None | 2013 | 61 | 0 | 2013 | 61 | 0 | 2013 | 61 |
| Uzbekistan | None | 2014 | 4 | 0 | 2014 | 4 | 0 | 2014 | 4 |
| Caribbean | | | | | | | | | |
| Bahamas | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Bermuda | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Commonwealth of Puerto Rico | МВ | 2016 | 4 | NE | NE | NE | NE | NE | NE |
| Dominican Republic | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Haiti | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Jamaica | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Latin America | | | | | | | | | |
| Argentina | М | 2015 | 4 | NE | NE | NE | NE | NE | NE |
| Bolivia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Brazil | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Chile | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Colombia | M | 2016 | 4 | NE | NE | NE | NE | NE | NE |
| Costa Rica | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Ecuador | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| El Salvador | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Guatemala | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Guyana | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Honduras | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Mexico | МВ | 2015 | 4 | NE | NE | NE | 22,647 | 2011 | 62 |
| Nicaragua | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Panama | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Paraguay | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Peru | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Suriname | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Uruguay | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Venezuela | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |

| | Ava | ailable For | ms | % of PWID acce | - | | Number of (| | |
|----------------------------------|----------------------|-------------|-----|---------------------------------------|------|-----|----------------------|-------------------|-------|
| | Form | Year | Ref | (survey da % (95% CI) ¹ | Year | Ref | (programı N² | rie data) Year | Ref |
| North America | FOIIII | real | Rei | % (93% CI)- | rear | Rei | IV- | Tear | Kei |
| Canada | MBD | 2016 | 63 | NE | NE | NE | 75,073 ⁵ | 2015 | 63,64 |
| | | | 65 | NE NE | | | • | | 65 |
| United States | M B | 2015 | 05 | INE | NE | NE | 432,567 ⁶ | 2015 | |
| Australasia | | 2015 | 66 | 14 0 (20 0 42 0) | 2045 | 67 | 40.522 | 2045 | 66 |
| Australia | M B | 2015 | 68 | 41.8 (39.8, 43.9) | 2015 | 69 | 48,522 | 2015 | 68 |
| New Zealand | МВ | 2016 | 08 | 48.1 (44.3, 51.8) | 2013 | 09 | 5,018 | 2012 | 08 |
| Pacific Islands | | | | | | | _ | | |
| American Samoa | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Fed. States of Micronesia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Fiji | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| French Polynesia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Guam | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Kiribati | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Marshall Islands | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| New Caledonia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Northern Mariana Islands | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Palau | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Papua New Guinea | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Samoa | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Solomon Islands | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Tonga | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Vanuatu | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Middle East and North Africa | | | | | | | | | |
| Algeria | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Bahrain | None | 2014 | 70 | 0 | 2014 | 70 | 0 | 2014 | 70 |
| Cyprus | МВО | 2014 | 4 | NE | NE | NE | 252 | 2015 | 8 |
| Egypt | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Iraq | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Israel | МВ | 2015 | 71 | NE | NE | NE | 4,500 | 2015 | 71 |
| Jordan | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Kuwait | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Lebanon | В | 2017 | 72 | NE | NE | NE | 1,700 ⁷ | 2016 | 72 |
| Libyan Arab Jamahiriya | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Morocco | М | 2015 | 4 | NE | NE | NE | 628 | 2014 | 73 |
| Occupied Palestinian Territories | Present ⁸ | 2016 | 74 | NE | NE | NE | NE | NE | NE |
| Oman | None | 2014 | 75 | 0 | 2014 | 75 | 0 | 2014 | 75 |
| Qatar | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |

| | Av | ailable Fo | rms | % of PWID acces | - | | Number of C | | |
|----------------------|------|------------|-----|-----------------|------|----------|----------------|------|-----|
| | | 1 | | (survey da | | | (programn | | |
| | Form | Year | Ref | % (95% CI)¹ | Year | Ref 4 | N ² | Year | Ref |
| Saudi Arabia | None | 2016 | 4 | 0 | 2016 | | 0 | 2016 | 4 |
| Sudan | None | 2016 | | 0 | 2016 | 4 | 0 | 2016 | · |
| Syrian Arab Republic | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Tunisia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Turkey | МВ | 2013 | 4 | NE | NE | NE | 12,500 | 2011 | 8 |
| United Arab Emirates | В | 2016 | 76 | NE | NE | NE | NE | NE | NE |
| Yemen | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Sub-Saharan Africa | | | | | | | | | |
| Angola | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Benin | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Burkina Faso | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Burundi | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Cameroon | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Cape Verde | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Chad | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Cote d'Ivoire | M | 2017 | 77 | NE | NE | NE | NE | NE | NE |
| Dem Rep of the Congo | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Djibouti | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Ethiopia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Gabon | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Gambia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Ghana | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Guinea | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Kenya | M | 2016 | 4 | NE | NE | NE | 1,100 | 2016 | 78 |
| Liberia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Madagascar | M | 2014 | 79 | NE | NE | NE | NE | NE | NE |
| Malawi | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Mali | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Mauritius | МО | 2014 | 80 | NE | NE | NE | 5,517 | 2014 | 80 |
| Mozambique | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Niger | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Nigeria | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Rwanda | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Senegal | МО | 2016 | 4 | NE | NE | NE | NE | NE | NE |
| Seychelles | M | 2015 | 4 | NE | NE | NE | NE | NE | NE |
| Sierra Leone | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |
| Somalia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 |

| | Av | ailable For | ms | | % of PWID accessing OST (survey data) | | | Number of OST clients (programme data) | | |
|------------------------|------|-------------|-----|---|---------------------------------------|-----|----------------|--|-----|--|
| | Form | Year | Ref | % (95% CI)¹ | Year | Ref | N ² | Year | Ref | |
| South Africa | МВ | 2016 | 4 | 11.3 (8.6, 14.6) ⁹ | 2013 | 81 | NE | NE | NE | |
| Swaziland | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Togo | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 | |
| Uganda | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 | |
| United Rep of Tanzania | M | 2016 | 82 | 11 (not able to estimate CI) ³ | 2016 | 82 | 3,376 | 2015 | 78 | |
| Zambia | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 | |
| Zimbabwe | None | 2016 | 4 | 0 | 2016 | 4 | 0 | 2016 | 4 | |

Notes:

The following countries are not listed in this table, as we did not find documented evidence or reports of injecting drug use in these countries: Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, Cuba, Democratic People's Republic of Korea, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Nauru, Republic of Congo, Saint Kitts and Nevis, Saint Lucia, Sao Tome and Principe, Saint Vincent and Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu.

PWID – people who inject drugs

OST – opioid substitution therapy

NE – intervention exists in that country, but no data on the extent of service provision were located.

NK – no information about the presence or absence of this intervention could be located for this country across the indicators assessed.

M – methadone.

B – buprenorphine.

D - diamorphine

O - other forms of OST

¹Refers to current OST unless otherwise specified

²N OST clients refers to number of clients at a single point in time unless otherwise noted. Where no information was provided as to whether the number of clients reported referred to a single point in time, or a cumulative number over a defined period, we assumed it referred to a single point in time.

³Refers to OST in the past 12 months

⁴Source states that around 8,400 clients are registered with the methadone programme, and that daily attendance is around 6,400.

⁵Approximation for 2015 based on several data sources

⁶ Does not include people prescribed buprenorphine in office-based settings

⁷Cumulative total patients 2014-2016

⁸Source states opioid substitution therapy exists, but form/s available not reported

⁹Refers to lifetime history of OST

- 1. Lazarus JV, Delpech V, Sonnerborg A, Fuenzalida H, Subata E. HIV Programme Review in Armenia. Copenhagen: WHO Regional Office for Europe, 2015.
- 2. Republic of Azerbaijan. Country Progress Report: UNAIDS, 2014.
- 3. Burrows D, Boltaev A, Musa M, Gottgredsson M, Suleymanova J. Review of the HIV Programme in Azerbaijan. Copenhagen: WHO Regional Office for Europe, 2014.
- 4. HRI. The Global State of Harm Reduction. . London: Harm Reduction International, 2016.
- 5. Беларусь Р. Национальный отчет о достигнутом прогрессе в осуществлении глобальных мер в ответ на СПИД (по выполнению Политической Декларации по ВИЧ/СПИДу), 2016.
- 6. UNDP. Najvažnija dostignuća HIV-programa u Bosni i Hercegovini. United Nations Development Programme; 2016.
- 7. Eurasian Harm Reduction Network (EHRN). The Impact of Transition from Global Fund Support to Governmental Funding on the Sustainability of Harm Reduction Programs: A Case Study from Bosnia and Herzegovina, 2016.
- 8. EMCDDA. European Drug Report: Trends and Developments. Lisbon: European Monitoring Centre on Drugs and Drug Addiction, 2017.
- 9. National Institute for Health Development. HIV in Estonia, Situation, Prevention, Treatment and Care, Narrative Report for Global AIDS Response Progress Reporting, 2016.
- 10. Curatio International Foundation. HIV risk and prevention behaviors among people who inject drugs in seven cities in Georgia. http://curatiofoundation.org/wp-content/uploads/2016/03/PWID-BBS-Report-2015-ENG.pdf: Curatio International Foundation, 2015.
- 11. World Health Organization (WHO). HIV Programme Review in Georgia. 2015.
- 12. EMCDDA. Latvia Country Overview. 2016. http://www.emcdda.europa.eu/countries/latvia.
- 13. National Centre for Communicable Diseases and AIDS. Country Progress Report: Lithuania, 2015.
- 14. Drug Tobacco and Alcohol Control Department. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA BY THE REITOX NATIONAL FOCAL POINT: LITHUANIA New Development, Trends, 2014.
- 15. Republic of Moldova South-East European Region National Coordination Council. Republic of Moldova Progress Report on HIV/AIDS, 2016.
- 16. Government of Romania. Country Progress Report on AIDS: Reporting period January 2014 December 2014, 2015.
- 17. National Monitoring Centre for Drugs. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox national Focal Point SLOVAKIA New Development and Trends, 2014.
- 18. Barska G, Sazanov JA. Monitoring of conduct and HIV prevalence among people who inject drugs and their sexual partners 2015 (Russian). Kiev: Alliance for Public Health, 2016.
- 19. Ukrainian Center for Disease Control. OST regular report. 2017. http://ucdc.gov.au.
- 20. Eurasian Harm Reduction Network (EHRN). Country Profile: Albania. 2017. http://harm-reduction.org/country-profiles/albania (accessed 30/5/17 2017).
- 21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Table HSR-3-1. Health & Social Responses, Opioid Substitution Treatment, Clients. 2016. www.emcdda.europa.eu/data/stats2016#displayTable:HSR-1-2 (accessed 21/4/17 2017).
- 22. Handanagic S, Bozicevic I, Civljak M, et al. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys. *International Journal of Drug Policy* 2016; 32: 57-63.
- 23. Public Health England. Adult substance misuse statistics from the National Drug Treatment Monitoring System. London: Public Health England, 2016.
- 24. Jóhannesdóttir S. Personal communication email to S. Larney 24 April 2017.
- 25. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Luxembourg Country Overview. 2016. http://www.emcdda.europa.eu/countries/luxembourg (accessed 19/4/17 2017).

- 26. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: A case study from Macedonia. Vilnius, 2016.
- 27. Monaco Pd. Declaration d'Engagement sur le VIH/SIDS: Rapport de Situation National 2014, 2015.
- 28. Eurasian Harm Reduction Network. Country Profile: Montenegro. 2016. http://harm-reduction.org/country-profiles/montenegro (accessed 30/5/17 2017).
- 29. FHI 360. People who shoot drugs with syringes and infection. 2016.
- 30. Santos AS, Duarte O. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: "PORTUGAL" New Developments, Trends, 2014.
- 31. World Health Organization. Resources for the prevention and treatment of substance use disorders. Country Profile: San Marino.

http://www.who.int/substance_abuse/publications/atlas_report/profiles/san_marino.pdf?ua=1; accessed 27 June 2017: World Health Organization, 2010.

- 32. National Services Scotland. Scottish Drugs Misuse Database (SDMD), 2014.
- 33. Ministry of Health of Serbia: Institute of Public Health of Serbia. Country Progress Report: January-December 2015, 2016.
- 34. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Serbia country overview. 2016. http://www.emcdda.europa.eu/countries/montenegro (accessed 13/2/17 2017).
- 35. Socialstyrelsen. Kartläggning av läkemedelsassisterad behandling vid opiatberoende, 2012.
- 36. Arnaud S, Jeannin A, Dubois-Arber F. Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006. *International Journal of Drug Policy* 2011; 22(3): 226-32.
- 37. The National AIDS Authority (NAA). Cambodia Country Progress Report, Monitoring Progress Towards the 2011 UN Political Declaration on HIV and AIDS. Report to UNAIDS., 2015.
- 38. National Health and Family Planning Commission of the People's Republic of China. 2015 China AIDS Response Progress Report, 2015.
- 39. Asia-Pacific HaADHf. National Response: China. 2015.
- 40. National AIDS Commission. Indonesia Country Progress Report 2014, Reporting Period 2012-2013. Report to UNAIDS., 2014.
- 41. Indonesia Ministry of Health. IBBS: 2011. Integrated Biological and Behavioural Survey 2011.
- 42. Health MMo. Global AIDS Response Progress Report Malaysia 2015. 2015.
- 43. Htwe MD. Myanmar Health Minister Statement 2016 2016.
- 44. National AIDS Programme. Global AIDS Response Progress Report Myanmar. Report to UNAIDS., 2015.
- 45. Lin T, Chen CH, Chou P. Effects of combination approach on harm reduction programs: the Taiwan experience. *Harm Reduction Journal* 2016; 13(1): 23.
- 46. Thailand Ending AIDS. Thailand AIDS Response Progress Report 2015. Report to UNAIDS., 2015.
- 47. Perngparn U. Personal communication email to S. Larney, 20 May 2017.
- 48. Hai SV. Personal communication email to S. Larney, 23 May 2017.
- 49. Faruque O. Personal communication email to S. Larney, 2 May 2017.
- 50. Department of AIDS Control. Statement Containing Brief Activities of the Department of AIDS Control in 2013, 2013.
- 51. National AIDS Committee Secretariat Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report. Geneva: UNAIDS, 2017.
- 52. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report; On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS, 2015.
- 53. Maldives MoH. Country Progress Report Maldives, 2016.
- 54. Asia-Pacific HaADHf. National Response: Maldives. 2015.

- 55. National Centre for AIDS and STD Control. Factsheet 8: Targeted Intervention among Key Population in Nepal, as of July 2016. 2016.
- 56. NACP. Country Progress Report Pakistan. Report to UNAIDS.: National AIDS Control Program, 2015.
- 57. Министерство здравоохранения и социального развития Республики Казахстан ГУ "Республиканский центр по профилактике и борьбе со СПИД". Проект Национальный доклад о достигнутом прогрессе восуществлении глобальных мер в ответ на СПИД, 2016.
- 58. World Health Organization, WHO. Evaluation of opioid substitution therapy in Kyrgyzstan. 2016.
- 59. UNDP. Annual report on the implementation of UNDP project in support of the government of the Krygyz Republic, funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria. http://www.aidscenter.kg/images/Orders/other/IBBS%20REPORT.doc: UNDP,, 2014.
- 60. Министерство здравоохранения и социальной защиты населения Республики Таджикистан Государственное учреждение «Республиканский центр по профилактике и борьбе с СПИД». ОТЧЕТ СТРАНЫ О ДОСТИГНУТОМ ПРОГРЕССЕ В ПРОТИВОДЕЙСТВИИ ЭПИДЕМИИ ВИЧ, 2016, 2016.
- 61. Boltaev AA, El-Bassel N, Deryabina A, et al. Scaling up HIV prevention efforts targeting people who inject drugs in Central Asia: A review of key challenges and ways forward. *Drug and Alcohol Dependence* 2013; 132S: 1-7.
- 62. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. Encuesta Nacional de Adicciones 2011. Mexico: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz/Secretaria de Salud, 2011.
- 63. Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. *Canadian Journal of Psychiatry* 2017; doi: 10.1177/0706743717711167.
- 64. Office of the Provincial Health Officer. BC Opioid Substitution Treatment System Performance Measures 2014/15-2015/16. Vancouver: British Columbia Ministry of Health, 2017.
- 65. Department of Health and Human Services. National Survey of Substance Abuse Treatment Services (N-SSATS): 2015, 2015.
- 66. Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics 2015. Canberra: Australian Institute of Health and Welfare, 2016.
- 67. Memedovic S, Iversen J, Geddes L, Maher L. Australian Needle and Syringe Program Survey: National Data Report 2011-2015: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: The Kirby Institute, 2016.
- 68. Deering D, Sellman JD, Adamson S. Opioid substitution treatment in New Zealand: a 40 year perspective. *The New Zealand Medical Journal* 2014; 127(1397).
- 69. Noller G, Leafe K. Brief analysis of the New Zealand population of people who inject drugs (PWID): Estimates of population size, prevalence of BBVs, demographics and risk behaviours, and service provision: Needle Exchange Services Trust (NEST), 2016.
- 70. Kingdom of Bahrain. UNGASS Country Progress Report: Kingdom of Bahrain, 2014.
- 71. HarelFisch Y, Zadok Y, Hizi S. Israel Country Overview. 2016. http://www.emcdda.europa.eu/countries/israel (accessed 13/2/17 2017).
- 72. Haddad P. Personal communication email to S. Larney 7 June 2017.
- 73. ONUSIDA, Le Fonds mondial. Mise en oeuvre de la declaration politique sur le VIH/sida, 2015.
- 74. UNODC. Supporting the establishment of an evidence based drug dependence treatment and rehabilitation systemf for the Palestine National Rehabilitation Center.
- https://www.unodc.org/middleeastandnorthafrica/en/project-profiles/psey13.html, accessed 27 June 2017: United Nations Office on Drugs and Crime, 2015.
- 75. National AIDS Programme. COUNTRY PROGRESS REPORT SULTANATE OF OMAN, 2014.
- 76. Haddad P. Personal communication email to S. Larney 3 July 2017.

- 77. Ztoua, Deze D, Mamadou K. Drug dependence treatment and care in Cote d'Ivoire: towards an opioid maintenance programme. UNODC Scientific Consultation on Drug Use Prevention and Treatment of Substance Use Disorders. Abidjan; 2017.
- 78. UNAIDS. DO NO HARM HEALTH, HUMAN RIGHTS AND PEOPLE WHO USE DRUGS. 2016.
- 79. Système d'Information Multi-Sectorielle/Multi-Sector System (SIMS/MSIS). RAPPORT FINAL AU NIVEAU DES 37 VILLES: Cartographie et estimation de la taille des personnes cibles les plus exposées aux risques du VIH/Sida, 2014.
- 80. NAS. Country Progress Report 2015, Republic of Mauritius. Report to UNAIDS., 2015.
- 81. Scheibe A, Brown B, dos Santos M. Final Report: Rapid assessment of HIV prevalence and HIV-related risks among people who inject drugs in five South African cities, 2015.
- 82. Makyao N. Personal communication email to S. Larney, 4 May 2017.

Appendix 13: Country-level HIV testing and counselling implementation indicators and references, by region

| | Evidence of HIV test | ing programmes targ PWID | eted towards | % of PWID obtaining an HIV t their result (survey data) | | nowing | | PWID receiving ramme data | |
|----------------------|----------------------|-----------------------------|--------------|---|------|--------|------------------|---------------------------|-----|
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref |
| Eastern Europe | | | | | | | | | |
| Armenia | NK | NK | NK | NE | NE | NE | 1,983 | 2013 | 1 |
| Azerbaijan | Yes | 2014 | 2 | NE | NE | NE | 5,484 | 2013 | 3 |
| Belarus | No | 2014 | 4 | 58% (55%, 60%) | 2015 | 5 | 4,466 | 2012 | 4 |
| Bosnia & Herzegovina | NK | NK | NK | 6-36% (5 sites) | 2012 | 6 | NE | NE | NE |
| Bulgaria | Yes | 2014 | 7 | 63% (not able to estimate CI) | 2012 | 7 | 3,276 | 2013 | 7 |
| Czech Republic | Yes | 2013 | 8 | NE | NE | NE | 3,603 | 2013 | 8 |
| Estonia | Yes | 2013 | 9 | 94% (91%, 96%) ³ | 2013 | 9 | NE | NE | NE |
| Georgia | Yes | 2015 | 10 | 15-27% (6 sites) | 2015 | 11 | 20,543 | 2014 | 10 |
| Hungary | Yes | 2013 | 12 | NE | NE | NE | 231 ⁷ | 2013 | 12 |
| Latvia | Yes | 2015 | 13 | NE | NE | NE | 882 | 2013 | 14 |
| Lithuania | Yes | 2014 | 15 | NE | NE | NE | 5,949 | 2013 | 16 |
| Moldova | NK | NK | NK | 4-47% (4 sites) | 2013 | 17 | NE | NE | NE |
| Poland | NK | NK | NK | NE | NE | NE | 217 | 2013 | 18 |
| Romania | NK | NK | NK | NE | NE | NE | 163 | 2013 | 19 |
| Russian Federation | Yes | 2016 | 20 | NE | NE | NE | 241,547 | 2014 | 21 |
| Slovakia | Yes | 2015 | 22 | NK | NK | NK | NK | NK | NK |
| Ukraine | NK | NK | NK | 39% (38%, 39%) | 2015 | 23 | 149,473 | 2015 | 24 |
| Western Europe | | | | | | | | | |
| Albania | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Andorra | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Austria | Yes | 2012 | 25 | NK | NK | NK | NK | NK | NK |
| Belgium | Yes | 2011 | 26 | NK | NK | NK | NK | NK | NK |
| Croatia | Yes | 2015 | 27 | 6-21% (3 sites) | 2015 | 28 | NE | NE | NE |
| Denmark | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| England (U.K.) | NK | NK | NK | 78% (77%, 80%) ⁴ | 2015 | 29 | NE | NE | NE |
| Finland | Yes | 2012 | 30 | NE | NE | NE | 1,562 | 2014 | 31 |
| France | Yes | 2016 | 32 | 91% (90%, 92%) ³ | 2012 | 32 | NE | NE | NE |
| Germany | Yes | 2014 | 33 | NK | NK | NK | NK | NK | NK |
| Greece | Yes | 2013 | 34 | 75% (72%, 78%) | 2013 | 34 | 5,496 | 2013 | 34 |
| Iceland | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ireland | Yes | 2012 | 35 | NK | NK | NK | NK | NK | NK |
| Italy | Yes | 2016 | 36 | NK | NK | NK | NK | NK | NK |
| Luxembourg | Yes | 2016 | 37 | NK | NK | NK | NK | NK | NK |

| | Evidence of HIV test | ing programmes targe PWID | eted towards | % of PWID obtaining an HIV t their result (survey data) | | nowing | | PWID receivi testing ramme data | |
|-------------------------|----------------------|------------------------------|--------------|---|------|--------|----------------|---------------------------------------|-----|
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref |
| Macedonia (FYR) | Yes | 2014 | 38 | 44% (not able to estimate CI) ⁴ | 2009 | 39 | 1,083 | 2015 | 40 |
| Malta | Yes | 2013 | 41 | NE | NE | NE | 2108 | 2013 | 41 |
| Monaco | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Montenegro | No | 2014 | 42 | NE | NE | NE | 115 | 2014 | 43 |
| Netherlands | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Northern Ireland (U.K.) | NK | NK | NK | 92% (87%, 96%)4 | 2015 | 29 | NE | NE | NE |
| Norway | NK | NK | NK | 35% (25%, 46%) | 2012 | 44 | NE | NE | NE |
| Portugal | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| San Marino | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Scotland (U.K.) | NK | NK | NK | 84% (not able to estimate CI) ³ | 2016 | 45 | NE | NE | NE |
| Serbia | Yes | 2013 | 46 | 25% (21%, 30%) | 2012 | 47 | 1,912 | 2013 | 46 |
| Slovenia | NK | NK | NK | 26% (18%, 35%) | 2013 | 48 | NE | NE | NE |
| Spain | NK | NK | NK | NE | NE | NE | 86 | 2015 | 49 |
| Sweden | Yes | 2014 | 50 | NK | NK | NK | NK | NK | NK |
| Switzerland | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Wales (U.K.) | NK | NK | NK | 75% (69%, 80%) ⁴ | 2015 | 29 | NE | NE | NE |
| East and Southeast Asia | | | | . , , | | | | | |
| Brunei Darussalam | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Cambodia | NK | NK | NK | 15% (not able to estimate CI) | 2010 | 51 | NE | NE | NE |
| China | NK | NK | NK | 73% (not able to estimate CI) ⁴ | 2015 | 52 | NE | NE | NE |
| Indonesia | NK | NK | NK | 72% (5 sites) ³ | 2015 | 53 | NE | NE | NE |
| Japan | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Lao PDR | No | 2016 | 54 | NK | NK | NK | NK | NK | NK |
| Malaysia | NK | NK | NK | 38% (35%, 40%) | 2014 | 55 | NE | NE | NE |
| Mongolia | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Myanmar | NK | NK | NK | NE | NE | NE | 4,540 | 2012 | 56 |
| Philippines | NK | NK | NK | 6% (not able to estimate CI) | 2013 | 57 | NE | NE | NE |
| Republic of Korea | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Singapore | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Taiwan | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Thailand | NK | NK | NK | 61% (not able to estimate CI) | 2014 | 58 | 24,583 | 2014 | 59 |
| Timor Leste | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Viet Nam | NK | NK | NK | 36% (not able to estimate CI) ⁴ | 2016 | 60 | 145,364 | 2016 | 60 |

| | Evidence of HIV test | ing programmes targ PWID | eted towards | % of PWID obtaining an HIV t their result (survey data | | nowing | Number of PWID receiving HIV testing (programme data) | | | |
|-----------------------------|----------------------|-----------------------------|--------------|--|------|--------|---|------|---------|--|
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref | |
| South Asia | | | | | | | | | | |
| Afghanistan | NK | NK | NK | NE | NE | NE | 547 | 2012 | 61 | |
| Bangladesh | Yes | 2017 | 62 | 56% (53%, 59%) ³ | 2015 | 63 | 4,838 ⁷ | 2016 | 64 | |
| Bhutan | No | 2011 | 65 | NK | NK | NK | NK | NK | NK | |
| India | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Iran, Islamic Republic | Yes | 2015 | 66 | 28% (26%, 29%) | 2014 | 66 | NE | NE | NE | |
| Maldives | Yes | 2015 | 67 | NE | NE | NE | 21 ⁹ | 2016 | 67 | |
| Nepal | Yes | 2015 | 68 | 28% (not able to estimate CI) | 2015 | 69 | 15,897 | 2016 | 70 | |
| Pakistan | NK | NK | NK | 7% (not able to estimate CI) | 2011 | 71 | NE | NE | NE | |
| Sri Lanka | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Central Asia | | | | | | | | | | |
| Kazakhstan | Yes | 2013 | 72 | NE | NE | NE | 31,376 - 50,756 | 2015 | 73, 892 | |
| Kyrgyzstan | NK | NK | NK | 34% (30%, 37%) | 2013 | 74 | 3,704 | 2015 | 73 | |
| Tajikistan | NK | NK | NK | NE | NE | NE | 18,192 | 2015 | 73 | |
| Turkmenistan | NK | NK | NK | NK | NK | NK | ŇK | NK | NK | |
| Uzbekistan | NK | NK | NK | 28% (not able to estimate CI) | 2013 | 75 | NE | NE | NE | |
| Caribbean | | | | | | | | | | |
| Bahamas | No | 2015 | 76 | NK | NK | NK | NK | NK | NK | |
| Bermuda | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Commonwealth of Puerto Rico | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Dominican Republic | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Haiti | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Jamaica | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Latin America | | | | | | | | | | |
| Argentina | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Bolivia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Brazil | Yes | 2014 | 77 | 13% (11%, 15%) | 2010 | 78 | NE | NE | NE | |
| Chile | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Colombia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Costa Rica | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Ecuador | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| El Salvador | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Guatemala | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Guyana | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Honduras | NK | NK | NK | NK | NK | NK | NK | NK | NK | |

| | Evidence of HIV testi | ng programmes targ PWID | eted towards | % of PWID obtaining an H their res (survey da | ult | nowing | Number of PWID receiving HIV testing (programme data) | | | |
|------------------------------|-----------------------|----------------------------|--------------|---|------|--------|---|------|-----|--|
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref | |
| Mexico | NK | NK | NK | NE | NE | NE | 4,193 | 2016 | 79 | |
| Nicaragua | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Panama | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Paraguay | NK | NK | NK | 12% (8%, 16%) | 2008 | 78 | NE | NE | NE | |
| Peru | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Suriname | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Uruguay | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Venezuela | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| North America | | | | | | | | | | |
| Canada | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| United States | NK | NK | NK | 52% (51%, 53%) | 2015 | 80 | NE | NE | NE | |
| Australasia | | | | | | | | | | |
| Australia | NK | NK | NK | 50% (48%, 52%) | 2015 | 81 | NE | NE | NE | |
| New Zealand | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Pacific Islands | | | | | | | | | | |
| American Samoa | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Fed. States of Micronesia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Fiji | No | 2015 | 82 | NK | NK | NK | NK | NK | NK | |
| French Polynesia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Guam | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Kiribati | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Marshall Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Nauru | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| New Caledonia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Northern Mariana Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Palau | Yes | 2015 | 83 | NK | NK | NK | NK | NK | NK | |
| Papua New Guinea | Yes | 2014 | 84 | NK | NK | NK | NK | NK | NK | |
| Samoa | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Solomon Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Tonga | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Vanuatu | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Middle East and North Africa | | | | | | | | | | |
| Algeria | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Bahrain | Yes ¹ | 2014 | 85 | NK | NK | NK | NK | NK | NK | |
| Cyprus | Yes | 2014 | 86 | NK | NK | NK | NK | NK | NK | |
| Egypt | Yes | 2011 | 87 | 9% (7%, 12%) ³ | 2010 | 87 | 454 ¹⁰ | 2009 | 88 | |

| | Evidence of HIV testi | ing programmes targ PWID | eted towards | % of PWID obtaining an H their res (survey da | ult | nowing | testing (programme data) | | | |
|----------------------------------|-----------------------|-----------------------------|--------------|---|------|--------|-----------------------------|------|-----|--|
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref | |
| Iraq | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Israel | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Jordan | NK | NK | NK | NE | NE | NE | 146 | 2015 | 89 | |
| Kuwait | NK | NK | NK | NE | NE | NE | 1,321 | 2014 | 90 | |
| Lebanon | NK | NK | NK | NE | NE | NE | 176 ¹¹ | 2016 | 91 | |
| Libyan Arab Jamahiriya | No | 2015 | 92 | NK | NK | NK | NK | NK | NK | |
| Morocco | NK | NK | NK | 9% (7%, 11%) | 2014 | 93 | NE | NE | NE | |
| Occupied Palestinian Territories | NK | NK | NK | 39-85% (3 sites) ⁴ | 2009 | 94 | NE | NE | NE | |
| Oman | No | 2014 | 95 | NK | NK | NK | NK | NK | NK | |
| Qatar | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Saudi Arabia | NK | NK | NK | NE | NE | NE | 278 | 2014 | 96 | |
| South Sudan | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Sudan | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Syrian Arab Republic | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Tunisia | NK | NK | NK | 19% (17%, 22%) | 2011 | 97 | NE | NE | NE | |
| Turkey | NK | NK | NK | NE | NE | NE | 2,676 | 2013 | 98 | |
| United Arab Emirates | No | 2014 | 99 | NK | NK | NK | NK | NK | NK | |
| Yemen | No | 2013 | 100 | NK | NK | NK | NK | NK | NK | |
| Sub-Saharan Africa | | | | | | | | | | |
| Angola | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Benin | NK | NK | NK | 93% (82%, 98%) | 2014 | 101 | NE | NE | NE | |
| Burkina Faso | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Burundi | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Cameroon | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Cape Verde | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Chad | No | 2010 | 39 | NK | NK | NK | NK | NK | NK | |
| Cote d'Ivoire | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Dem Rep of the Congo | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Djibouti | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| - Ethiopia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Gabon | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Gambia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Ghana | No | 2015 | 102 | NK | NK | NK | NK | NK | NK | |
| Guinea | NK | NK | NK | NK | NK | NK | NK | NK | NK | |
| Kenya | NK | NK | NK | 71% (67%, 74%) ⁵ | 2015 | 103 | NE | NE | NE | |
| Liberia | NK | NK | NK | NK | NK | NK | NK | NK | NK | |

| | Evidence of HIV testi | | eted towards | % of PWID obtaining an HIV t | | nowing | Number of | PWID receiv | ing HIV |
|------------------------|-----------------------|------|--------------|--------------------------------------|------|--------|--------------------------|-------------|---------|
| | PWID | | | <i>their result</i> (survey data) | | | testing (programme data) | | |
| | Yes/No | Year | Ref | % (95% CI) ² | Year | Ref | N ⁶ | Year | Ref |
| Madagascar | NK | NK | NK | 17-38% (3 sites) | 2012 | 104 | NE | NE | NE |
| Malawi | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Mali | Yes | 2015 | 105 | NE | NE | NE | 928 | 2015 | 105 |
| Mauritius | NK | NK | NK | 25% (22%, 28%) | 2013 | 106 | NE | NE | NE |
| Mozambique | NK | NK | NK | 22-25% (2 sites) | 2014 | 107 | NE | NE | NE |
| Niger | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Nigeria | NK | NK | NK | 54% (50%, 57%) ³ | 2014 | 108 | NE | NE | NE |
| Rwanda | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Senegal | Yes | 2014 | 109 | NK | NK | NK | NK | NK | NK |
| Seychelles | NK | NK | NK | 27% (22%, 32%) | 2011 | 110 | NE | NE | NE |
| Sierra Leone | NK | NK | NK | 1% (0%, 3%) | 2013 | 111 | NE | NE | NE |
| Somalia | No | 2014 | 112 | NK | NK | NK | NK | NK | NK |
| South Africa | NK | NK | NK | 55% (50%, 59%) | 2013 | 113 | 1596 | 2016 | 49 |
| Swaziland | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Togo | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Uganda | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| United Rep of Tanzania | Yes | 2016 | 114 | 67% (not able to estimate CI) | 2014 | 115 | 5,581 | 2016 | 114 |
| Zambia | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Zimbabwe | NK | NK | NK | NK | NK | NK | NK | NK | NK |

Notes:

The following countries are not listed in this table, as we did not find documented evidence or reports of injecting drug use in these countries: Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, Cuba, Democratic People's Republic of Korea, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Namibia, Nauru, Republic of Congo, Saint Kitts and Nevis, Saint Lucia, Sao Tome and Principe, Saint Vincent and Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu.

PWID – people who inject drugs

NE – intervention exists in that country, but no data on the extent of service provision were located.

NK – no information about the presence or absence of this intervention could be located for this country across the indicators assessed.

¹Compulsory HIV testing on entry to drug treatment centres

²Refers to testing in the past 12 months unless otherwise specified

³Refers to lifetime history of HIV testing

⁴Time-frame in which testing occurred not specified

⁵Refers to HIV testing in the past 3 months

⁶Refers to number of PWID receiving HIV tests over a 12 month period unless otherwise specified. Caution must be used in interpreting this indicator as completeness of the data is often unclear. Injecting drug use status may not be collected systematically in HIV testing programmes, and people who inject drugs may choose note to disclose their injecting status when seeking an HIV test. The geographic area to which data referred to was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document

⁷Refers to number of PWID tested over a 6 month period

⁸Sub-national data

⁹Refers to number of PWID tested over a 3 month period ¹⁰Refers to number of PWID tested over a 2 year period ¹¹Time period not specified

- 1. Lazarus JV, Delpech V, Sonnerborg A, Fuenzalida H, Subata E. HIV Programme Review in Armenia. Copenhagen: WHO Regional Office for Europe, 2015.
- 2. Republic of Azerbaijan. Country Progress Report: UNAIDS, 2014.
- 3. Burrows D, Boltaev A, Musa M, Gottgredsson M, Suleymanova J. Review of the HIV Programme in Azerbaijan. Copenhagen: WHO Regional Office for Europe, 2014.
- 4. World Health Organization Regional Office for Europe. HIV/AIDS treatment and care in Belarus: Evaluation Report 2014.
- 5. Kecina EA. Behavioral features and knowledge level on the HIV/AIDS problem among consumers of injecting drugs. Minsk: Belarus State University, 2016.
- 6. Bacak V, Dominkovic Z, Ler Z, et al. Behavioral and Biological Surveillance Study among Injection Drug Users in Bosnia and Herzegovina, 2012: A Respondent-Driven Sampling Survey. Institute for Public Health FB&H, 2012.
- 7. Republic of Bulgaria. Country Progress Report on Monitoring the 2013 Political Declaration on HIV/AIDS, the Dublin Declaration and the Universal Access in the Health Sector Response, 2014.
- 8. Mravčík V, Chomynová P, Grohmannová K, et al. National Report The Czech Republic 2013 Drug Situation, 2014.
- 9. REITOX National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: ESTONIA New developments, trends, 2014.
- World Health Organization (WHO). HIV Programme Review in Georgia. 2015.
- 11. Curatio International Foundation. HIV risk and prevention behaviors among people who inject drugs in seven cities in Georgia. http://curatiofoundation.org/wp-content/uploads/2016/03/PWID-BBS-Report-2015-ENG.pdf: Curatio International Foundation, 2015.
- 12. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: "HUNGARY" New Development, Trends, 2014.
- 13. Infectious Diseases Surveillance and Immunization Unit: Infectious Diseases Risk Analysis Department of Centre for Disease Prevention and Control of Latvia (CDPC). Country Progress Report Latvia. Report to UNAIDS., 2015.
- 14. Reitox National Focal Points. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA by the Reitox National Focal Point: LATVIA New Development, Trends, 2014.
- 15. National Centre for Communicable Diseases and AIDS. Country Progress Report: Lithuania, 2015.
- 16. Drug Tobacco and Alcohol Control Department. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA BY THE REITOX NATIONAL FOCAL POINT: LITHUANIA New Development, Trends, 2014.
- 17. CNMS. Integrated bio-behavioural study in key populations at higher risk: Key indicators. Chisinau: Centrul National de Management in Sanatate, 2013.
- 18. Malczewski A, Misiurek A, Bukowska B, et al. National Drug Report 2014 Poland, 2014.
- 19. MINISTRY OF ADMINISTRATION AND INTERIOR, NATIONAL ANTI-DRUG AGENCY, ROMANIAN MONITORING CENTRE FOR DRUGS AND DRUGS ADDICTION. NATIONAL REPORT ON DRUGS 2014: ROMANIA New Developments and Trends, 2014.
- 20. Sarang A. Personal communication email to S. Larney 2 May 2017.
- 21. Eurasian Harm Reduction Network. Evaluation of program and financial indicators: Russia, 2015.
- 22. Slovak Republic. Narrative report of HIV Preventive Programmes in the Slovak Republic as of 31-st December 2015, 2016.
- 23. Barska G, Sazanov JA. Monitoring of conduct and HIV prevalence among people who inject drugs and their sexual partners 2015 (Russian). Kiev: Alliance for Public Health, 2016.
- 24. Alliance for Public Health. Annual Report 2015. Kiev: Alliance for Public Health, 2016.
- 25. Unknown. Country Progress Report, 2012.

- 26. Van Beckhoven D, Deblonde J, Callens S, et al. Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants. *BMC Infectious Diseases* 2015; **15 (1) (no pagination)**(496).
- 27. Ministry of Health. Country Progress Report Croatia, 2016.
- 28. Handanagic S, Bozicevic I, Civljak M, et al. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys. *International Journal of Drug Policy* 2016; **32**: 57-63.
- 29. Public Health England. Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs 2016.
- 30. National Institute for Health and Welfare. Global AIDS Response Progress Reporting. Country Progress Report 2012: FINLAND, 2012.
- 31. National Institute for Health and Welfare. Finland Drug Situation 2014, 2015.
- 32. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: FRANCE New Developments, Trends, 2014.
- 33. Pfeiffer-Gerschel T, Jakob L, Stumpf D, Budde A, Rummel C. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: New Developments and Trends GERMANY, 2014.
- 34. Hellenic Center for Disease Control & Prevention. Global AIDS Response Progress Report 2014. Report to UNAIDS., 2014.
- 35. Irish Focal Point. 2014 NATIONAL REPORT (2013 Data) TO THE EMCDDA by the Reitox National Focal Point, 2014.
- 36. EMCDDA. Italy country review. 2016. http://www.emcdda.europa.eu/countries/italy.
- 37. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Luxembourg Country Overview. 2016. http://www.emcdda.europa.eu/countries/luxembourg (accessed 19/4/17 2017).
- 38. Petrusevska T. National Report The Former Yugoslav Republic of Macedonia, 2014.
- 39. UNAIDS. Global Report. 2010.
- 40. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: A case study from Macedonia. Vilnius, 2016.
- 41. REITOX Malta National Focal Point. 2014 NATIONAL REPORT (2013 Data) TO THE EMCDDA By the Reitox National Focal Point: MALTA New Developments and Trends, 2014.
- 42. Unknown. COUNTRY TABLE MONTENEGRO. Unknown.
- 43. Institute of Public Health for HIV/AIDS. Country Progress Report Montenegro. Report to UNAIDS., 2014.
- 44. Norwegian Institute for Drug and Alcohol Research (SIRUS). 2014 NATIONAL REPORT (mainly 2013 data) to the EMCDDA by the Reitox National Focal Point: 'NORWAY' New developments, trends, 2014.
- 45. Public Health England. Infections Among People who Inject Drugs in the UK, 2015, 2016.
- 46. Kilibarda B, Simić D, Baroš S, Brandić I. National Report on Drug Situation in Serbia, 2014.
- 47. Ministry of Health of the Republic of Serbia. Research Among Populations Most at Risk to HIV, 2012.
- 48. National Institute of Public Health. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA by the Reitox National Focal Point: SLOVENIA NEW DEVELOPMENTS AND TRENDS, 2014.
- 49. Servicios Sociales e Igualdad. Informe Nacional Sobre los Progresos Realizados en la Aplicación del GARPR Espana. Report to UNAIDS., 2016.
- 50. Public Health Agency of Sweden. 2014 National Report (2013 data) to the EMCDDA by the Reitox National Focal Point, 2014.
- 51. The National AIDS Authority (NAA). Cambodia Country Progress Report, Monitoring Progress Towards the 2011 UN Political Declaration on HIV and AIDS. Report to UNAIDS., 2015.
- 52. HIV and AIDS Data Hub for Asia-Pacific. HIV and AIDS Data Hub for Asia-Pacific Review in slides People Who Inject Drugs, 2016.

- 53. Stoicescu C. Personal communication email to S. Larney, 10 June 2017.
- 54. Centre for HIV/AIDS and STI (CHAS) and the Ministry of Health (MOH) on behalf of the National Committee for the Control of AIDS (NCCA). Lao PDR Country Progress Report, Global AIDS Response Progress Report, 2016, 2016.
- 55. HIV/STI SECTION of Disease Control Division: Ministry of Health Malaysia. Global AIDS Response Progress Report Malaysia 2016, 2016.
- 56. National AIDS Programme. Progress Report 2012 National Strategic Plan for HIV/AIDS in Myanmar. 2012.
- 57. Asia-Pacific HaADHf. National Response: Philippines. 2015.
- 58. Thailand Ending AIDS. Thailand AIDS Response Progress Report 2015. Report to UNAIDS., 2015.
- 59. Perngparn U. Personal communication email to S. Larney, 20 May 2017.
- 60. Hai SV. Personal communication email to S. Larney, 23 May 2017.
- 61. WHO. From HIV testing to lifelong care and treatment. Access to the continuum of HIV care and treatment in the Eastern Mediterranean Region: World Health Organization. Regional Office for the Eastern Mediterranean, 2014.
- 62. Faruque O. Personal communication email to S. Larney, 2 May 2017.
- 63. National AIDS/STD Control Programme (NASP). Mapping Study and Size Estimation of Key Populations in Bangladesh for HIV Programs 2015-2016, 2016.
- 64. Save the Children. Continuation of the prioritized HIV prevention services among key populations in Bangladesh, 2017.
- 65. World Health Organization (WHO). HEALTH SECTOR RESPONSE TO HIV IN THE SOUTH-EAST ASIA REGION. 2013.
- 66. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report; On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS, 2015.
- 67. Maldives MoH. Country Progress Report Maldives, 2016.
- 68. National Centre for AIDS and STD Control. Factsheet 8: Targeted Intervention among Key Population in Nepal, as of July 2015. 2015.
- 69. World Health Organization (WHO). Cascade of HIV testing, care and treatment services, 2014 & 2015: country profile. 2016.
- 70. National Centre for AIDS and STD Control. Factsheet 8: Targeted Intervention among Key Population in Nepal, as of July 2016. 2016.
- 71. NACP. Country Progress Report Pakistan. Report to UNAIDS.: National AIDS Control Program, 2015.
- 72. Terlikbayeva A, Zhussupov B, Primbetova S, et al. Access to HIV counseling and testing among people who inject drugs in Central Asia: Strategies for improving access and linkages to treatment and care. *Drug and Alcohol Dependence* 2013; **132**(Suppl 1): S61-S4.
- 73. PEPFAR. Central Asia PEPFAR Regional Operational Plan (ROP): PEPFAR, 2016.
- 74. Kyrgyzstan Republican AIDS Centre. Integrated Bio-behavioural Survey 2013. Bishkek: Kyrgyzstan Republican AIDS Centre, 2013.
- 75. Uzbekistan. НАЦИОНАЛЬНЫЙ ДОКЛАД О ХОДЕ ВЫПОЛНЕНИЯ ДЕКЛАРАЦИИ О ПРИВЕРЖЕННОСТИ ДЕЛУ БОРЬБЫ С ВИЧ/СПИДСПЕЦИАЛЬНОЙ СЕССИИ ГЕНЕРАЛЬНОЙ, 2015.
- 76. The Bahamas Ministry of Health. Global AIDS Reponse and Progress Reporting Monitoring the 2011 Political Declaration on HIV/AIDS, 2015.
- 77. Ministry of Health's (MoH) Health Surveillance Secretariat (HSS). The Brazilian Response to HIV and AIDS Narrative Report,, 2015.
- 78. World Health Organization (WHO), UNAIDS, UNICEF. GLOBAL HIV/AIDS RESPONSE. 2011.
- 79. Magis C. Global review of coverage of HIV prevention interventions for people who inject drugs: Preliminary data for Mexico.

- 80. Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs. 2015.
- 81. Memedovic S, Iversen J, Geddes L, Maher L. Australian Needle and Syringe Program Survey: National Data Report 2011-2015: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: The Kirby Institute, 2016.
- 82. Ministry of Health and Medical Services. Fiji HIV & AIDS Response Progress Report, 2016.
- 83. HIV/AIDS & STI Program Ministry of Health. 2015 Global AIDS Progress Report, 2016.
- 84. Unknown. Interim Global AIDS Response Progress & Universal Access Reports Papua New Guinea, 2014.
- 85. Kingdom of Bahrain. UNGASS Country Progress Report: Kingdom of Bahrain, 2014.
- 86. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: CYPRUS New Developments, Trends, 2014.
- 87. National AIDS Program Egypt. Global AIDS Response Progress Report 2012, 2012.
- 88. National AIDS Programme. Global AIDS Response Progress Report: Egypt, 2010.
- 89. HRI. The Global State of Harm Reduction. . London: Harm Reduction International, 2016.
- 90. Ministry of Health. State of Kuwait Global AIDS Response Progress Report 2015, 2015.
- 91. Haddad P. Personal communication email to S. Larney 7 June 2017.
- 92. National Centre for Disease Control. GARPR 2015 COUNTRY PROGRESS REPORT LIBYA, 2015.
- 93. ONUSIDA, Le Fonds mondial. Mise en oeuvre de la declaration politique sur le VIH/sida, 2015.
- 94. Ministry of Health. Country Progress Report: Occupied Palestinian Territory, 2012.
- 95. National AIDS Programme. COUNTRY PROGRESS REPORT SULTANATE OF OMAN, 2014.
- 96. KINGDOM OF SAUDI ARABIA: MINISTRY OF HEALTH. GLOBAL AIDS RESPONSE PROGRESS REPORT: COUNTRY PROGRESS REPORT 2015, KINGDOM OF SAUDI ARABIA, 2015.
- 97. Ministere de la Sante Publique. Rapport d'Activite sur la Riposte au SIDA-Tunisie, 2014.
- 98. TURKISH MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION (TUBİM). 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: TURKEY New Development, Trends and in-depth information on selected issues, 2014.
- 99. National AIDS Programme (NAP). COUNTRY PROGRESS REPORT UNITED ARAB EMIRATES, 2014.
- 100. Unknown. Country Progress Report 2013 Yemen, 2013.
- 101. RAPPORT DE SUIVI DE LA DECLARATION DE POLITIQUE SUR LE VIH/SIDA AU BENIN 2016, 2016.
- 102. Ghana AIDS Commission. Country AIDS Response Progress Report Ghana, 2015.
- 103. Bhattacharjee P, McClarty LM, Musyoki H, et al. Monitoring HIV Prevention Programme Outcomes among Key Populations in Kenya: Findings from a National Survey. *PLoS ONE* 2015; **10**(8): 1-11.
- 104. Focus Development Association, Service de Laboratoire National de Reference. Etude comportementale et biologique chez les consommateurs de drogues injectables dans les zones urbaines à Madagascar-2012, 2012.
- 105. Toufik A. Rapport Final: Evaluation de la Reduction de la Demande de Drogues, 2016.
- 106. NAS. Country Progress Report 2015, Republic of Mauritius. Report to UNAIDS., 2015.
- 107. República de Moçambique Conselho Nacional de Combate ao SIDA. Resposta Global à SIDA Relatório do Progresso, 2016 MOÇAMBIQUE, 2016.
- 108. Ministry of Health Nigeria. Integrated Biological and Behavioural Surveillance Survey (IBBSS) 2014, 2015.
- 109. Republique du Senegal Conseil National de Lutte Contre le Sida. Rapport de Situation sur la Riposte Nationale a l'Epidemie de VIH/Sida Senegal: 2013-2014. Report to UNAIDS., 2014.
- 110. National AIDS Council. Global AIDS Response Progress Report: Full Country Report Seychelles. Report to UNAIDS., 2015.
- 111. UNAIDS. Population Size Estimation of Key Populations August 2013. 2013.

- 112. Unknown. Progress report for Somali HIV and AIDS Response 2014, 2015.
- 113. Scheibe A, Brown B, dos Santos M. Final Report: Rapid assessment of HIV prevalence and HIV-related risks among people who inject drugs in five South African cities, 2015.
- 114. Makyao N. Personal communication email to S. Larney, 4 May 2017.
- 115. The United Republic of Tanzania. Global AIDS Response Country Progress Report. Report to UNAIDS., 2014.

Appendix 14: Country-level antiretroviral therapy implementation indicators and references, by region

| | % of PWID living | Number o | Number of PWID living with HIV receiving ART | | | | | |
|----------------------|-------------------------|------------|--|------------------|------------------|-----|--|--|
| | (su | rvey data) | | | (programme data) | | | |
| | % (95% CI) ¹ | Year | Ref | N ⁴ | Year | Ref | | |
| Eastern Europe | | | | | | | | |
| Armenia | NK | NK | NK | NK | NK | NK | | |
| Azerbaijan | NE | NE | NE | 133 ⁵ | 2014 | 1 | | |
| Belarus | NK | NK | NK | NK | NK | NK | | |
| Bosnia & Herzegovina | NE | NE | NE | 2 | 2013 | 2 | | |
| Bulgaria | NK | NK | NK | NK | NK | NK | | |
| Czech Republic | NK | NK | NK | NK | NK | NK | | |
| Estonia | 63% (56, 70%) | 2013 | 3 | NE | NE | NE | | |
| Georgia | NK | NK | NK | NK | NK | NK | | |
| Hungary | NK | NK | NK | NK | NK | NK | | |
| Latvia | NK | NK | NK | NK | NK | NK | | |
| Lithuania | NE | NE | NE | 182 | 2014 | 4 | | |
| Moldova | NK | NK | NK | NK | NK | NK | | |
| Poland | NK | NK | NK | NK | NK | NK | | |
| Romania | NK | NK | NK | NK | NK | NK | | |
| Russian Federation | NK | NK | NK | NK | NK | NK | | |
| Slovakia | NK | NK | NK | NK | NK | NK | | |
| Ukraine | 25% (23, 27%) | 2015 | 5 | 7,472 | 2017 | 6 | | |
| Western Europe | | | | | | | | |
| Albania | NK | NK | NK | NK | NK | NK | | |
| Andorra | NK | NK | NK | NK | NK | NK | | |
| Austria | NE | NE | NE | 606 ⁶ | 2015 | 7 | | |
| Belgium | NK | NK | NK | NK | NK | NK | | |
| Croatia | NK | NK | NK | NK | NK | NK | | |
| Denmark | NK | NK | NK | NK | NK | NK | | |
| England (U.K.) | NK | NK | NK | NK | NK | NK | | |
| Finland | NK | NK | NK | NK | NK | NK | | |
| France | NK | NK | NK | NK | NK | NK | | |
| Germany | NK | NK | NK | NK | NK | NK | | |
| Greece | NE | NE | NE | 605 | 2013 | 8 | | |
| Iceland | NK | NK | NK | NK | NK | NK | | |
| Ireland | NK | NK | NK | NK | NK | NK | | |
| Italy | NK | NK | NK | NK | NK | NK | | |
| Luxembourg | NK | NK | NK | NK | NK | NK | | |
| Macedonia (FYR) | NE | NE | NE | 2 | 2015 | 9 | | |
| Malta | NK | NK | NK | NK | NK | NK | | |

| | % of PWID living with HIV accessing ART | | | Number of | Number of PWID living with HIV receiving ART | | | |
|-------------------------|---|-----------|-----|------------------|--|-----|--|--|
| | | vey data) | | (programme data) | | | | |
| | % (95% CI) ¹ | Year | Ref | N ⁴ | Year | Ref | | |
| Monaco | NK | NK | NK | NK | NK | NK | | |
| Montenegro | NK | NK | NK | NK | NK | NK | | |
| Netherlands | NE | NE | NE | 87 | 2013 | 10 | | |
| Northern Ireland (U.K.) | NK | NK | NK | NK | NK | NK | | |
| Norway | NK | NK | NK | NK | NK | NK | | |
| Portugal | NK | NK | NK | NK | NK | NK | | |
| San Marino | NK | NK | NK | NK | NK | NK | | |
| Scotland (U.K.) | NK | NK | NK | NK | NK | NK | | |
| Serbia | NK | NK | NK | NK | NK | NK | | |
| Slovenia | NK | NK | NK | NK | NK | NK | | |
| Spain | NK | NK | NK | NK | NK | NK | | |
| Sweden | NK | NK | NK | NK | NK | NK | | |
| Switzerland | NK | NK | NK | NK | NK | NK | | |
| Wales (U.K.) | NK | NK | NK | NK | NK | NK | | |
| East and Southeast Asia | | | | | | | | |
| Brunei Darussalam | NK | NK | NK | NK | NK | NK | | |
| Cambodia | NK | NK | NK | NK | NK | NK | | |
| China | NK | NK | NK | NK | NK | NK | | |
| ndonesia | 27% (19, 38%) | 2008 | 11 | NE | NE | NE | | |
| lapan | NK | NK | NK | NK | NK | NK | | |
| Lao PDR | NK | NK | NK | NK | NK | NK | | |
| Malaysia | 5% (4, 6%) ² | 2014 | 12 | NE | NE | NE | | |
| Mongolia | NK | NK | NK | NK | NK | NK | | |
| Myanmar | NK | NK | NK | NK | NK | NK | | |
| Philippines | NK | NK | NK | NK | NK | NK | | |
| Republic of Korea | NK | NK | NK | NK | NK | NK | | |
| Singapore | NK | NK | NK | NK | NK | NK | | |
| Taiwan | NK | NK | NK | NK | NK | NK | | |
| Гhailand | NK | NK | NK | NK | NK | NK | | |
| Timor Leste | NK | NK | NK | NK | NK | NK | | |
| Viet Nam | NK | NK | NK | NK | NK | NK | | |
| South Asia | | | | | | | | |
| Afghanistan | NK | NK | NK | NK | NK | NK | | |
| Bangladesh | NK | NK | NK | 135 | 2016 | 13 | | |
| Bhutan | NK | NK | NK | NK | NK | NK | | |
| ndia | 25% (23, 27%) | 2013 | 14 | NE | NE | NE | | |
| Iran, Islamic Republic | NE | NE | NE | 2,404 | 2013 | 15 | | |

| | % of PWID living with HIV accessing ART | | | Number of | F PWID living with HIV re | eceiving ART | |
|-----------------------------|---|------------|-----|------------------|---------------------------|--------------|--|
| | | rvey data) | | (programme data) | | | |
| | % (95% CI)¹ | Year | Ref | N ⁴ | Year | Ref | |
| Maldives | NK | NK | NK | NK | NK | NK | |
| Nepal | NK | NK | NK | NK | NK | NK | |
| Pakistan | NE | NE | NE | 1023 | 2014 | 16 | |
| Sri Lanka | NK | NK | NK | NK | NK | NK | |
| Central Asia | | | | | | | |
| Kazakhstan | NE | NE | NE | 2,797 | 2015 | 17 | |
| Kyrgyzstan | NE | NE | NE | 437 | 2015 | 17 | |
| Tajikistan | NE | NE | NE | 541 | 2015 | 17 | |
| Turkmenistan | NK | NK | NK | NK | NK | NK | |
| Uzbekistan | NK | NK | NK | NK | NK | NK | |
| Caribbean | | | | | | | |
| Bahamas | NK | NK | NK | NK | NK | NK | |
| Bermuda | NK | NK | NK | NK | NK | NK | |
| Commonwealth of Puerto Rico | NK | NK | NK | NK | NK | NK | |
| Dominican Republic | NK | NK | NK | NK | NK | NK | |
| Haiti | NK | NK | NK | NK | NK | NK | |
| Jamaica | NK | NK | NK | NK | NK | NK | |
| Latin America | | | | | | | |
| Argentina | NK | NK | NK | NK | NK | NK | |
| Bolivia | NK | NK | NK | NK | NK | NK | |
| Brazil | NK | NK | NK | NK | NK | NK | |
| Chile | NK | NK | NK | NK | NK | NK | |
| Colombia | NK | NK | NK | NK | NK | NK | |
| Costa Rica | NK | NK | NK | NK | NK | NK | |
| Ecuador | NK | NK | NK | NK | NK | NK | |
| El Salvador | NK | NK | NK | NK | NK | NK | |
| Guatemala | NK | NK | NK | NK | NK | NK | |
| Guyana | NK | NK | NK | NK | NK | NK | |
| Honduras | NK | NK | NK | NK | NK | NK | |
| Mexico | NK | NK | NK | NK | NK | NK | |
| Nicaragua | NK | NK | NK | NK | NK | NK | |
| Panama | NK | NK | NK | NK | NK | NK | |
| Paraguay | NK | NK | NK | NK | NK | NK | |
| Peru | NK | NK | NK | NK | NK | NK | |
| Suriname | NK | NK | NK | NK | NK | NK | |
| Uruguay | NK | NK | NK | NK | NK | NK | |
| Venezuela | NK | NK | NK | NK | NK | NK | |

| | % of PWID living with HIV accessing ART (survey data) | | | Number of PWID living with HIV receiving ART (programme data) | | | |
|----------------------------------|---|------|-----|---|------|-----|--|
| | | | | | | | |
| | % (95% CI)¹ | Year | Ref | N ⁴ | Year | Ref | |
| North America | | | | | | | |
| Canada | NK | NK | NK | NK | NK | NK | |
| United States | 67% (63, 71) | 2012 | 18 | 24,249 ⁸ | 2015 | 19 | |
| Australasia | | | | | | | |
| Australia | NK | NK | NK | NK | NK | NK | |
| New Zealand | NK | NK | NK | NK | NK | NK | |
| Pacific Islands | | | | | | | |
| American Samoa | NK | NK | NK | NK | NK | NK | |
| Fed. States of Micronesia | NK | NK | NK | NK | NK | NK | |
| Fiji | NK | NK | NK | NK | NK | NK | |
| French Polynesia | NK | NK | NK | NK | NK | NK | |
| Guam | NK | NK | NK | NK | NK | NK | |
| Kiribati | NK | NK | NK | NK | NK | NK | |
| Marshall Islands | NK | NK | NK | NK | NK | NK | |
| Nauru | NK | NK | NK | NK | NK | NK | |
| New Caledonia | NK | NK | NK | NK | NK | NK | |
| Northern Mariana Islands | NK | NK | NK | NK | NK | NK | |
| Palau | NK | NK | NK | NK | NK | NK | |
| Papua New Guinea | NK | NK | NK | NK | NK | NK | |
| Samoa | NK | NK | NK | NK | NK | NK | |
| Solomon Islands | NK | NK | NK | NK | NK | NK | |
| Tonga | NK | NK | NK | NK | NK | NK | |
| Vanuatu | NK | NK | NK | NK | NK | NK | |
| Middle East and North Africa | | | | | | | |
| Algeria | NK | NK | NK | NK | NK | NK | |
| Bahrain | NK | NK | NK | NK | NK | NK | |
| Cyprus | NK | NK | NK | NK | NK | NK | |
| Egypt | NK | NK | NK | NK | NK | NK | |
| Iraq | NK | NK | NK | NK | NK | NK | |
| Israel | NK | NK | NK | NK | NK | NK | |
| Jordan | NK | NK | NK | NK | NK | NK | |
| Kuwait | NK | NK | NK | NK | NK | NK | |
| Lebanon | NK | NK | NK | NK | NK | NK | |
| Libyan Arab Jamahiriya | NK | NK | NK | NK | NK | NK | |
| Morocco | NK | NK | NK | NK | NK | NK | |
| Occupied Palestinian Territories | NK | NK | NK | NK | NK | NK | |
| Oman | NK | NK | NK | NK | NK | NK | |

| | % of PWID living with HIV accessing ART | | | Number of PWID living with HIV receiving ART | | | |
|----------------------|---|-----------|-----|--|------|-----|--|
| | | vey data) | | (programme data) | | | |
| | % (95% CI)¹ | Year | Ref | N ⁴ | Year | Ref | |
| Qatar | NK | NK | NK | NK | NK | NK | |
| Saudi Arabia | NK | NK | NK | NK | NK | NK | |
| South Sudan | NK | NK | NK | NK | NK | NK | |
| Sudan | NK | NK | NK | NK | NK | NK | |
| Syrian Arab Republic | NK | NK | NK | NK | NK | NK | |
| Tunisia | NK | NK | NK | NK | NK | NK | |
| Turkey | NK | NK | NK | NK | NK | NK | |
| United Arab Emirates | NK | NK | NK | NK | NK | NK | |
| Yemen | NK | NK | NK | NK | NK | NK | |
| Sub-Saharan Africa | | | | | | | |
| Angola | NK | NK | NK | NK | NK | NK | |
| Benin | NK | NK | NK | NK | NK | NK | |
| Burkina Faso | NK | NK | NK | NK | NK | NK | |
| Burundi | NK | NK | NK | NK | NK | NK | |
| Cameroon | NK | NK | NK | NK | NK | NK | |
| Cape Verde | NK | NK | NK | NK | NK | NK | |
| Chad | NK | NK | NK | NK | NK | NK | |
| Cote d'Ivoire | NK | NK | NK | NK | NK | NK | |
| Dem Rep of the Congo | NK | NK | NK | NK | NK | NK | |
| Djibouti | NK | NK | NK | NK | NK | NK | |
| Ethiopia | NK | NK | NK | NK | NK | NK | |
| Gabon | NK | NK | NK | NK | NK | NK | |
| Gambia | NK | NK | NK | NK | NK | NK | |
| Ghana | NK | NK | NK | NK | NK | NK | |
| Guinea | NK | NK | NK | NK | NK | NK | |
| Kenya | 16% (13, 19%) ³ | 2015 | 20 | NE | NE | NE | |
| Liberia | NK | NK | NK | NK | NK | NK | |
| Madagascar | NK | NK | NK | NK | NK | NK | |
| Malawi | NK | NK | NK | NK | NK | NK | |
| Mali | NK | NK | NK | NK | NK | NK | |
| Mauritius | NK | NK | NK | NK | NK | NK | |
| Mozambique | NK | NK | NK | NK | NK | NK | |
| Niger | NK | NK | NK | NK | NK | NK | |
| Nigeria | NK | NK | NK | NK | NK | NK | |
| Rwanda | NK | NK | NK | NK | NK | NK | |
| Senegal | NK | NK | NK | NK | NK | NK | |
| Seychelles | NK | NK | NK | NK | NK | NK | |

| | % of PWID living with HIV accessing ART (survey data) | | | Number of PWID living with HIV receiving ART (programme data) | | | |
|------------------------|---|------|-----|---|------|-----|--|
| | | | | | | | |
| | % (95% CI) ¹ | Year | Ref | N ⁴ | Year | Ref | |
| Sierra Leone | NK | NK | NK | NK | NK | NK | |
| Somalia | NK | NK | NK | NK | NK | NK | |
| South Africa | NK | NK | NK | NK | NK | NK | |
| Swaziland | NK | NK | NK | NK | NK | NK | |
| Togo | NK | NK | NK | NK | NK | NK | |
| Uganda | NK | NK | NK | NK | NK | NK | |
| United Rep of Tanzania | NE | NE | NE | 363 | 2016 | 21 | |
| Zambia | NK | NK | NK | NK | NK | NK | |
| Zimbabwe | NK | NK | NK | NK | NK | NK | |

Notes:

The following countries are not listed in this table, as we did not find documented evidence or reports of injecting drug use in these countries: Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, Cuba, Democratic People's Republic of Korea, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Namibia, Nauru, Republic of Congo, Saint Kitts and Nevis, Saint Lucia, Sao Tome and Principe, Saint Vincent and Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu.

NE – intervention exists in that country, but no data on the extent of service provision were located.

NK – no information about the presence or absence of this intervention could be located for this country across the indicators assessed.

PWID – people who inject drugs

ART – HIV antiretroviral therapy

¹Refers to proportion currently receiving ART unless otherwise specified

²Not specified if current ART. Unclear if denominator is all PWID or HIV+ PWID

⁴Refers to PWID receiving ART at a given point in time. Caution must be used in interpreting this indicator as completeness of the data is often unclear. Injecting drug use status may not be collected systematically in HIV treatment programmes, and people who inject drugs may choose note to disclose their injecting status when seeking ART. The geographic area to which data referred to was not often reported; we have assumed data are national unless specifically identified as sub-national in the source document

⁵Refers to people who inject drugs initiating ART in 2014

⁶Refers to patients at 7 sites participating in the Austrian HIV Cohort study

⁷Refers to people who inject drugs initiating ART in 2013

⁸Only includes patients in Ryan White-funded treatment programmes. Indicator used is patients who are virally suppressed with transmission category of injecting drug use

³Denominator is all PWID

- 1. Burrows D, Boltaev A, Musa M, Gottgredsson M, Suleymanova J. Review of the HIV Programme in Azerbaijan. Copenhagen: WHO Regional Office for Europe, 2014.
- 2. Pilav A, Babić D, Pljevljak J, et al. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA Bosnia and Herzegovina New Development and Trends, 2014.
- 3. REITOX National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: ESTONIA New developments, trends, 2014.
- 4. National Centre for Communicable Diseases and AIDS. Country Progress Report: Lithuania, 2015.
- 5. Barska G, Sazanov JA. Monitoring of conduct and HIV prevalence among people who inject drugs and their sexual partners 2015 (Russian). Kiev: Alliance for Public Health, 2016.
- 6. Ukrainian Center for Disease Control. ART regular report. 2017. http://phc.org.ua/uploads/documents/85ec49/43667fb2ada28042da20850649130824.pdf
- 7. Gisinger M, Kitchen M, Leierer G, et al. AIDS in Austria: 28th Report of the Austrian HIV Cohort Study, 2015.
- 8. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: GREECE New Development, Trends, 2014.
- 9. Eurasian Harm Reduction Network. The impact of transition from Global Fund support to governmental funding on the sustainability of harm reduction programs: A case study from Macedonia. Vilnius, 2016.
- 10. van Sighem A, Gras L, Smit C, Stolte I, Reiss P. Monitoring report 2014: Human Immunodeficiency Virus (HIV) Infection in the Netherlands, 2014.
- 11. Iskandar S, de Jong CA, Hidayat T, et al. Successful testing and treating of HIV/AIDS in Indonesia depends on the addiction treatment modality. *Journal of multidisciplinary healthcare* 2012; **5**: 329-36.
- 12. HIV/STI SECTION of Disease Control Division: Ministry of Health Malaysia. Global AIDS Response Progress Report Malaysia 2016, 2016.
- 13. Faruque O. Personal communication email to S. Larney, 2 May 2017.
- 14. Mehta SH, Lucas GM, Solomon S, et al. HIV care continuum among men who have sex with men and persons who inject drugs in India: barriers to successful engagement. *Clinical Infectious Diseases* 2015; **61**(11): 1732-41.
- 15. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report; On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS, 2015.
- 16. NACP. Country Progress Report Pakistan. Report to UNAIDS.: National AIDS Control Program, 2015.
- 17. PEPFAR. Central Asia PEPFAR Regional Operational Plan (ROP): PEPFAR, 2016.
- 18. Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs. 2015.
- 19. Health Resources and Services Administration. 2015: Division of Policy and Data, HIV/AIDS Bureau, Ryan White HIV/AIDS Program Annual Client-Level Data Report.
- 20. Bhattacharjee P, McClarty LM, Musyoki H, et al. Monitoring HIV Prevention Programme Outcomes among Key Populations in Kenya: Findings from a National Survey. *PLoS ONE* 2015; **10**(8): 1-11.
- 21. Makyao N. Personal communication email to S. Larney, 4 May 2017.

Appendix 15: Country-level condom distribution program indicators and references, by region

| | Number of condom distribution sites for PWID (programme data) | | | | | rgeted con | | of PWID r ns from ta programs gramme d | rgeted | Number of condoms distributed by PWID-targeted programs (programme data) | | | Number of condoms distributed per PWID per year (uncertainty interval) |
|-------------------------|---|------|-----|-------------------------|------|------------|--------|---|--------|--|------|-----|--|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N³ | Year | Ref | N ⁵ | Year | Ref | |
| Eastern Europe | | | | | | | | | | | | | |
| Armenia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Azerbaijan | 31 | 2014 | 1 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Belarus | NE | 2016 | 2 | 66 (64-69) | 2015 | 3 | NE | NE | NE | 1,018,813 | 2015 | 2 | 25 (15, 67) |
| Bosnia & Herzegovina | 12 | 2014 | 4 | NE | NE | NE | 4102 | 2013 | 4 | 103,421 | 2013 | 4 | NC |
| Bulgaria | 10 | 2013 | 5 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Czech Republic | 111 | 2013 | 6 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Estonia | 37 | 2015 | 7 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Georgia | NE | 2015 | 8 | 24 (22-26) | 2015 | 9 | NE | NE | NE | NE | NE | NE | NE |
| Hungary | 21 | 2013 | 10 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Latvia | 18 | 2015 | 11 | NE | NE | NE | NE | NE | NE | 908,94 | 2013 | 12 | 6 (5, 8) |
| Lithuania | 11 | 2014 | 13 | NE | NE | NE | 7720 | 2013 | 14 | 27,170 | 2013 | 14 | 6 (3, 12) |
| Moldova | NE | NE | NE | 27-55 (4 sites) | 2013 | 15 | NE | NE | NE | NE | NE | NE | NE |
| Poland | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Romania | NE | NE | NE | NE | NE | NE | 1711 | 2013 | 16 | 37,837 | 2013 | 16 | 0 (0, 1) |
| Russian Federation | 19 | 2016 | 17 | NE | NE | NE | 29140 | 2016 | 17 | 1,676,064 | 2016 | 17 | 1 (0, 2) |
| Slovakia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ukraine | NE | NE | NE | 35 (34-36) | 2015 | 18 | 212817 | 2015 | 19 | 4,800,000 | 2015 | 19 | 22 (10, 46) |
| Western Europe | | | | | | | | | | | | | |
| Albania | NE | 2014 | 20 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Andorra | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Austria | NE | 2014 | 21 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Belgium | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Croatia | NE | 2013 | 22 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Denmark | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| England (U.K.) | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Finland | NE | 2012 | 23 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| France | NE | 2014 | 24 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Germany | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |

| | Number of condom distribution sites for PWID (programme data) N Year Ref | | | (surve | rom targe grams ey data) | targeted condons ata) (pr | | er of PWID receiving oms from targeted programs rogramme data) | | Number of condoms distributed by PWID-targeted programs (programme data) | | | Number of condoms distributed per PWID per year (uncertainty interval) |
|-------------------------|---|------|----|-------------------------|--------------------------------|------------------------------|----------|--|-----|--|------|-----|--|
| | | | | % (95% CI) ¹ | Year | Ref | N³ | Year | Ref | N ⁵ | Year | Ref | |
| Greece | 15 | 2013 | 25 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Iceland | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ireland | NE | NE | NE | NE | NE | NE | NE | NE | NE | 4,024 | 2015 | 26 | 0 (0, 1) |
| Italy | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Luxembourg | NE | NE | NE | NE | NE | NE | NE | NE | NE | 61,552 | 2015 | 27 | 28 (23, 35) |
| Macedonia (FYR) | NE | NE | NE | NE | NE | NE | NE | NE | NE | 95,121 | 2011 | 28 | NC |
| Malta | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Monaco | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Montenegro | NE | 2014 | 29 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Netherlands | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Northern Ireland (U.K.) | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Norway | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Portugal | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| San Marino | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Scotland (U.K.) | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Serbia | 0 | 2015 | 30 | 0 | 2015 | 30 | 0 | 2015 | 30 | 0 | 2015 | 30 | NC |
| Slovenia | NE | 2010 | 31 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Spain | NE | 2016 | 32 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Sweden | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Switzerland | NE | 2011 | 33 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Wales (U.K.) | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| East and South | | | | | | | | | | | | | |
| East Asia | | | | | | | | | | | | | |
| Brunei Darussalam | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Cambodia | 1 | 2015 | 34 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| China | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Indonesia | NE NE | 2014 | 36 | 77 (75-80) ² | 2015 | 37 | NE | NE | NE | NE | NE | NE | NE |
| Japan | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Lao PDR | NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK | NK | NK | NK NK |
| Malaysia | NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Mongolia | NK NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK | NK | NK | NK NK |
| Myanmar | NK NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK NK | NK | NK | NK NK |
| Philippines | NK NK | NK | NK | NK NK | NK | NK | NK NK | NK | NK | NK NK | NK | NK | NK NK |

| | Number of condom distribution sites for PWID (programme data) | | | (surve | | • | Number of PWID receiving condoms from targeted programs (programme data) Number of condoms distributed by PWID-targeted programs (programme data) | | rgeted | grams | Number of condoms distributed per PWID per year (uncertainty interval) | | |
|-----------------------------|---|------|------|---|------|------|--|------|--------|----------------|--|------|-------------|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ³ | Year | Ref | N ⁵ | Year | Ref | |
| Republic of Korea | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Singapore | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Taiwan | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Thailand | 42 | 2014 | 38 | NE | NE | NE | NE | NE | NE | 115,036 | 2016 | 39 | 2 (1, 4) |
| Timor Leste | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Viet Nam | NE | 2012 | 40 | NE | NE | NE | 57336 | 2016 | 41 | NE | NE | NE | NE |
| South Asia | | | | | | | | | | | | | |
| Afghanistan | NE | 2014 | 42 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Bangladesh | 33 | 2017 | 43 | NE | NE | NE | 11944 | 2016 | 44 | 618,063 | 2016 | 44 | 9 (8, 10) |
| Bhutan | NK | NK | NK | NK | NK | NK | NK | NK | NK | ŃK | NK | NK | NK |
| India | NE | 2014 | 45 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Iran, Islamic Republic | NE | NE | NE | 34 (unable to estimate CI) ² | 2010 | 46 | NE | NE | NE | NE | NE | NE | NE |
| Maldives | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Nepal | NE | NE | NE | 86 (82-89) | 2012 | 47 | NE | NE | NE | 786,504 | 2016 | 48 | 22 (21, 24) |
| Pakistan | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Sri Lanka | NE | 2015 | 49 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Central Asia | | | | | | | | | | | | | |
| Kazakhstan | NE | NE | NE | NE | NE | NE | 60705 | 2015 | 50 | 5,799,539 | 2015 | 50 | 52 (35, 77) |
| Kyrgyzstan | NE | NE | NE | 28 (25-31) | 2013 | 51 | NE | NE | NE | NE | NE | NE | NE |
| Tajikistan | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Turkmenistan | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Uzbekistan | 235 | 2011 | 52 | NE | NE | NE | 203600 | 2011 | 52 | 2,300,000 | 2011 | 52 | 24 (16, 37) |
| Caribbean | | | _ | | | | | | _ | ,, | - | | (-/ - / |
| Bahamas | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Bermuda | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Commonwealth of Puerto Rico | 7 | 2013 | 53 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE NE |
| Dominican Republic | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Haiti | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Jamaica | NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK NK | NK | NK | NK NK |
| Latin America | INIX | 1417 | INIX | 1417 | INIX | 1417 | 141/ | IVIX | 1417 | INIX | 141/ | INIX | IAIX |

| | Number of condom distribution sites for PWID (programme data) N Year Ref | | | (surve | om targe grams ey data) | eted | condo (pro | r of PWID ms from ta programs ogramme o | argeted data) | Number of condoms distributed by PWID-targeted programs (programme data) | | | Number of condoms distributed per PWID per year (uncertainty interval) |
|------------------|---|------|-----|-------------------------|-------------------------------|------|----------------|--|------------------|--|------|-----|--|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ³ | Year | Ref | N ⁵ | Year | Ref | |
| Argentina | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Bolivia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Brazil | NE | 2010 | 54 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Chile | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Colombia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Costa Rica | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ecuador | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| El Salvador | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Guatemala | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Guyana | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Honduras | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Mexico | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Nicaragua | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Panama | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Paraguay | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Peru | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Suriname | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Uruguay | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Venezuela | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| North America | | | | | | | | | | | | | |
| Canada | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| United States | NE | NE | NE | 55 (54-56) | 2012 | 55 | NE | NE | NE | NE | NE | NE | NE |
| Australasia | | | | (, | _ | | | | | | | | |
| Australia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| New Zealand | NE | NE | NE | NE | NE | NE | NE | NE | NE | 23,958 | 2015 | 56 | 1 (1, 2) |
| Pacific Island | | | | | | | | | | | | | - (-, -, |
| states and | | | | | | | | | | | | | |
| territories | | | | | | | | | | | | | |
| American Samoa | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Fed. States of | | | | | | | | | | | | | |
| Micronesia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Fiji | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| French Polynesia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Guam | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Kiribati | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |

| | distr | nber of con ibution site programm | es for e data) | (surve | om targe grams y data) | • | condo (pro | r of PWID r ms from ta programs ogramme d | rgeted | Number of condoms distributed by PWID-targeted programs (programme data) | | | Number of condoms distributed per PWID per year (uncertainty interval) |
|-----------------------------|-------|---|-------------------|-------------------------|------------------------------|------|------------------|--|--------|--|------|------|--|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ³ | Year | Ref | N ⁵ | Year | Ref | |
| Marshall Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| New Caledonia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Northern Mariana Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Palau | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| | INK | INIX | INIX | INK | INK | INK | INIX | INIX | INK | INK | INK | INK | INK |
| Papua New Guinea | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Samoa | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Solomon Islands | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Tonga | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Vanuatu | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Middle East and | | | | | | | | | | | | | |
| North Africa | | | | | | | | | | | | | |
| Algeria | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Bahrain | 0 | 2014 | 57 | 0 | 2014 | 57 | 0 | 2014 | 57 | 0 | 2014 | 57 | 0 (0-0) |
| Cyprus | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Egypt | NE | NE | NE | NE | NE | NE | 535 ⁴ | 2014 | 58 | 900 ⁶ | 2014 | 58 | NC |
| Iraq | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Israel | NE | 2015 | 59 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Jordan | NE | NE | NE | NE | NE | NE | NE | NE | NE | 76,47 | 2013 | 60 | NC |
| Kuwait | 0 | 2014 | 61 | 0 | 2014 | 61 | 0 | 2014 | 61 | 0 | 2014 | 61 | 0 (0-0) |
| Lebanon | 2 | 2016 | 62 | NC | 2010 | 63 | 326 | 2016 | 62 | 29,482 | 2016 | 62 | NC |
| Libyan Arab Jamahiriya | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Morocco | NE | 2013 | 64 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Occupied | ''' | 2013 | 04 | | 142 | 142 | 142 | 142 | 142 | '\- | 142 | IVE. | I I |
| Palestinian | 2 | 2011 | 65 | NE | NE | NE | NE | NE | NE | 1,100 | 2011 | 65 | NC |
| Territories | _ | 2011 | 05 | | 142 | 142 | 142 | 142 | 142 | 1,100 | 2011 | 03 | 110 |
| Oman | 0 | 2014 | 66 | 0 | 2014 | 66 | 0 | 2014 | 66 | 0 | 2014 | 66 | 0 (0-0) |
| Qatar | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Saudi Arabia | NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK | NK | NK | NK NK |
| Sudan | NK | NK | NK | NK NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Syrian Arab | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK NK |
| Republic | INIX | | | IAIX | | 1417 | INIX | 1417 | 1417 | | 1417 | | IAIX |
| Tunisia | NE | 2012 | 67 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |

| | Number of condom distribution sites for PWID (programme data) | | | | | _ | condo | r of PWID r ms from ta programs ogramme d | rgeted | Number of condoms distributed by PWID-targeted programs (programme data) | | | Number of condoms distributed per PWID per year (uncertainty interval) |
|-------------------------|---|------|------|-------------------------|------|------|----------------|--|--------|--|------|------|--|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ³ | Year | Ref | N ⁵ | Year | Ref | |
| Turkey | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| United Arab Emirates | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Yemen | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Sub-Saharan | 1110 | 1410 | 1111 | IVIX | IVIX | TVIX | 1410 | IVIX | IVIX | IVIX | TVIX | TVIX | TVIC |
| Africa | | | | | | | | | | | | | |
| Angola | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Benin | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Burkina Faso | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Burundi | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Cameroon | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Cape Verde | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Chad | 0 | 2010 | 68 | 0 | 2010 | 68 | 0 | 2010 | 68 | 0 | 2010 | 68 | 0 (0-0) |
| Cote d'Ivoire | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Dem Rep of the | | | | | | | | | | | | | |
| Congo | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Djibouti | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ethiopia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Gabon | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Gambia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Ghana | 0 | 2015 | 69 | 0 | 2015 | 69 | 0 | 2015 | 69 | 0 | 2015 | 69 | 0 (0-0) |
| Guinea | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Kenya | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Liberia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Madagascar | NE | 2014 | 70 | 51-71 (3 sites) | 2012 | 71 | NE | NE | NE | NE | NE | NE | NE |
| Malawi | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Mali | 2 | 2015 | 72 | NE | NE | NE | NE | NE | NE | 33,419 | 2015 | 72 | NC |
| Mauritius | NE | 2014 | 73 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Mozambique | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Niger | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Nigeria | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Rwanda | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Senegal | 1 | 2014 | 74 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Seychelles | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |

| | Number of condom distribution sites for PWID (programme data) | | % of PWID receiving condoms from targeted programs (survey data) | | condo | Number of PWID receiving condoms from targeted programs (programme data) | | | condoms dis targeted pro ogramme da | • | Number of condoms distributed per PWID per year (uncertainty interval) | | |
|---------------------------|---|------|--|-------------------------|-------|--|----------------|------|---|----------------|--|-----|------------|
| | N | Year | Ref | % (95% CI) ¹ | Year | Ref | N ³ | Year | Ref | N ⁵ | Year | Ref | |
| Sierra Leone | NE | NE | NE | 16 (12-21) | 2013 | 75 | NE | NE | NE | NE | NE | NE | NE |
| Somalia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| South Africa | 7 | 2016 | 76 | NE | NE | NE | NE | NE | NE | NE | NE | NE | NE |
| Swaziland | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Togo | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Uganda | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| United Rep of Tanzania | NE | 2013 | 77 | NE | NE | NE | 3927 | 2016 | 78 | 305,083 | 2016 | 78 | 10 (7, 15) |
| Zambia | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |
| Zimbabwe | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK | NK |

Notes:

The following countries are not listed in this table, as we did not find documented evidence or reports of injecting drug use in these countries: Antigua and Barbuda, Barbados, Belize, Botswana, Central African Republic, Comoros, Cuba, Democratic People's Republic of Korea, Dominica, Equatorial Guinea, Eritrea, Greenland, Grenada, Guinea-Bissau, Lesotho, Liechtenstein, Mauritania, Namibia, Nauru, Republic of Congo, Saint Kitts and Nevis, Saint Lucia, Sao Tome and Principe, Saint Vincent and Grenadines, South Sudan, Trinidad and Tobago, and Tuvalu.

PWID – people who inject drugs

NE – intervention exists in that country, but no data on the extent of service provision were located.

NK – no information about the presence or absence of this intervention could be located for this country across the indicators assessed.

¹Refers to receipt of condoms from targeted programmes in the past 12 months unless otherwise specified

²Time period over which receipt of condoms from targeted programmes was measured not reported

³Refers to clients receiving condoms over a 12-month period unless otherwise specified

⁴Refers to number of clients receiving condoms over a 2-year period

⁵Refers to number of condoms distributed by targeted programmes over a 12 month period unless otherwise specified

⁶Refers to number of condoms distributed by targeted programmes over a 2-year period

15.1 Reference

- 1. World Health Organization Regional Office for Europe. Review of the HIV Programme in Azerbaijan, 2014.
- 2. Беларусь Р. Национальный отчет о достигнутом прогрессе в осуществлении глобальных мер в ответ на СПИД (по выполнению Политической Декларации по ВИЧ/СПИДу), 2016.
- 3. Кесіпа ЕА. ПОВЕДЕНЧЕСКИЕ ОСОБЕННОСТИ И УРОВЕНЬ ЗНАНИЙ ПО ПРОБЛЕМЕ ВИЧ/СПИД СРЕДИ ПОТРЕБИТЕЛЕЙ ИНЪЕКЦИОННЫХ НАРКОТИКОВ. http://www.aids.by/upload/iblock/4b9/Otchet%20epidnadzor%20PIN%202015.pdf, 2016.
- 4. Pilav A, Babić D, Pljevljak J, et al. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA Bosnia and Herzegovina New Development and Trends, 2014.
- 5. National Focal Point on Drugs and Drug Addictions. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the National Reitox Focal Point: BULGARIA New Development, Trends and in-depth information on selected issues, 2014.
- 6. Mravčík V, Chomynová P, Grohmannová K, et al. National Report The Czech Republic 2013 Drug Situation, 2014.
- 7. National Institute for Health Development. HIV in Estonia, Situation, Prevention, Treatment and Care, Narrative Report for Global AIDS Response Progress Reporting, 2016.
- 8. Eurasia Harm Reduction Network. Harm Reduction National Report 2015. 2015.
- 9. Curatio International Foundation. HIV risk and prevention behaviors among people who inject drugs in seven cities in Georgia. http://curatiofoundation.org/wp-content/uploads/2016/03/PWID-BBS-Report-2015-ENG.pdf: Curatio International Foundation, 2015.
- 10. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: "HUNGARY" New Development, Trends, 2014.
- 11. Infectious Diseases Surveillance and Immunization Unit: Infectious Diseases Risk Analysis Department of Centre for Disease Prevention and Control of Latvia (CDPC). Country Progress Report Latvia. Report to UNAIDS., 2015.
- 12. Reitox National Focal Points. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA by the Reitox National Focal Point: LATVIA New Development, Trends, 2014.
- 13. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). **Lithuania Country Overview**. 2016. http://www.emcdda.europa.eu/countries/lithuania (accessed 4/20/17 2017).
- 14. Drug Tobacco and Alcohol Control Department. 2014 NATIONAL REPORT (2013 DATA) TO THE EMCDDA BY THE REITOX NATIONAL FOCAL POINT: LITHUANIA New Development, Trends, 2014.
- 15. CNMS. Integrated bio-behavioural study in key populations at higher risk: Key indicators. Chisinau: Centrul National de Management in Sanatate, 2013.
- 16. MINISTRY OF ADMINISTRATION AND INTERIOR, NATIONAL ANTI-DRUG AGENCY, ROMANIAN MONITORING CENTRE FOR DRUGS AND DRUGS ADDICTION. NATIONAL REPORT ON DRUGS 2014: ROMANIA New Developments and Trends, 2014.
- 17. Sarang A. Personal communication email to S. Larney 2 May 2017.
- 18. Barska G, Sazanov JA. Monitoring of conduct and HIV prevalence among people who inject drugs and their sexual partners 2015 (Russian). Kiev: Alliance for Public Health, 2016.
- 19. Alliance for Public Health. Annual Report 2015. Kiev: Alliance for Public Health, 2016.
- 20. Brown A, Dvoriak S, Delpech V, Albania Institute of Public Health. HIV in Albania: A National Programme Report, 2014.
- 21. Weigl M, Busch M, Grabenhofer-Eggerth A, Horvath I, Klein C, Türscherl E. 2014 Report on the Drug Situation, 2014.
- 22. Government of the Republic of Croatia Office for Combating Drug Abuse. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA By the Office for Combating Drugs Abuse of the Government of the Republic of Croatia, 2014.
- 23. National Institute for Health and Welfare. Global AIDS Response Progress Reporting. Country Progress Report 2012: FINLAND, 2012.

- 24. Reitox National Focal Point. 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point: FRANCE New Developments, Trends, 2014.
- 25. Hellenic Center for Disease Control & Prevention. Global AIDS Response Progress Report 2014. Report to UNAIDS., 2014.
- 26. HIV Ireland. HIV Ireland Annual Report 2015, 2015.
- 27. ARENDT DV, BIWERSI MG, DEVAUX MC, et al. Comite de Surveillance du SIDA, 2015.
- 28. Petrusevska T. National Report The Former Yugoslav Republic of Macedonia, 2014.
- 29. Institute of Public Health for HIV/AIDS. Country Progress Report Montenegro. Report to UNAIDS., 2014.
- 30. Unknown. Serbia country table. Unknown.
- 31. Slovenia. UNGASS Country Progress Report Slovenia, 2010.
- 32. Servicios Sociales e Igualdad. Informe Nacional Sobre los Progresos Realizados en la Aplicación del GARPR Espana. Report to UNAIDS., 2016.
- 33. Arnaud S, Jeannin A, Dubois-Arber F. Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006. *International Journal of Drug Policy* 2011; **22**(3): 226-32.
- 34. The National AIDS Authority (NAA). Cambodia Country Progress Report, Monitoring Progress Towards the 2011 UN Political Declaration on HIV and AIDS. Report to UNAIDS., 2015.
- 35. Hong Kong Department of Health. Hong Kong Department of Health Annual Departmental Report 2010-2011 In: Health Do, editor. Hong Kong; 2011.
- 36. National AIDS Commission. Indonesia Country Progress Report 2014, Reporting Period 2012-2013. Report to UNAIDS., 2014.
- 37. Stoicescu C. Personal communication email to S. Larney, 10 June 2017.
- 38. Aramrattana A. Global review of coverage of HIV prevention interventions for people who inject drugs: Preliminary data for Thailand.
- 39. Ozone Foundation. STAR: Summary of Access to Targeted Groups, Referrals and Disposals of Clean Equipment/Condoms in 1-3 years of STAR project Activity, 2017.
- 40. Giang LM, Ngoc LB, Hoang VH, Mulvey K, Rawson RA. Substance use disorders and HIV in Vietnam since Doi Moi (Renovation): An overview. *Journal of Food and Drug Analysis* 2013; **21**(4 SUPPL.): S42-S5.
- 41. Hai SV. Personal communication email to S. Larney, 23 May 2017.
- 42. Islamic Republic of Afghanistan. Country Progress Report, 2014.
- 43. Faruque O. Personal communication email to S. Larney, 2 May 2017.
- 44. Save the Children. Continuation of the prioritized HIV prevention services among key populations in Bangladesh, 2017.
- 45. Department of AIDS Control. Statement Containing Brief Activities of the Department of AIDS Control in 2013, 2013.
- 46. National AIDS Committee Secretariat. Islamic Republic of Iran AIDS Progress Report on Monitoring of the United Nations General Assembly Special Session on HIV and AIDS. Report to UNAIDS., 2014.
- 47. Ministry of Health and Population, National Centre for AIDS and STD Control. Integrated Biological and Behavioral Surveillance (IBBS) Survey among People who Inject Drugs (PWIDs) in Eastern Terai Highway Districts of Nepal Round V 2012, 2012.
- 48. National Centre for AIDS and STD Control. Factsheet 8: Targeted Intervention among Key Population in Nepal, as of July 2016. 2016.
- 49. National STD/AIDS Control Program. Annual report 2015, 2016.
- 50. Министерство здравоохранения и социального развития Республики Казахстан ГУ "Республиканский центр по профилактике и борьбе со СПИД". Проект Национальный доклад о достигнутом прогрессе восуществлении глобальных мер в ответ на СПИД, 2016.
- 51. Kyrgyzstan Republican AIDS Centre. Integrated Bio-behavioural Survey 2013. Bishkek: Kyrgyzstan Republican AIDS Centre, 2013.

- 52. Central Asia Drug Action Programme. Country overview: Uzbekistan. 2014. http://www.emcdda.europa.eu/publications/country-overviews/uz (accessed 13/2/17 2017).
- 53. Torruella R. Personal communication email to S. Larney, 20 June 2017.
- 54. Organization of American States. The Drug Problem in the Americas: Drugs and Public Health, 2013.
- 55. Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs. 2015.
- Noller G, Leafe K. Brief analysis of the New Zealand population of people who inject drugs (PWID): Estimates of population size, prevalence of BBVs, demographics and risk behaviours, and service provision: Needle Exchange Services Trust (NEST), 2016.
- 57. Kingdom of Bahrain. UNGASS Country Progress Report: Kingdom of Bahrain, 2014.
- 58. National AIDS Program Egypt. Global AIDS Response Progress Report: Egypt, 2014.
- 59. Chemtob D. Global AIDS Response Progress Report 2016 Narrative Report from Israel: Ministry of Health, 2016.
- 60. The Ministry of Health/National AIDS Programme. Global AIDS Response Progress Report, 2014.
- 61. Ministry of Health. State of Kuwait Global AIDS Response Progress Report 2015, 2015.
- 62. Haddad P. Personal communication email to S. Larney 7 June 2017.
- 63. Mahfouda Z, Afifia R, Ramiaa S, et al. HIV/AIDS among female sex workers, injecting drug users and men who have sex with men in Lebanon: results of the first biobehavioral surveys. *AIDS* 2010; **24 (suppl. 2)**: S45-S54.
- 64. Ministere de la Sante. Mise en Oeuvre de la Declaration Politique sur le VIH/Sida. Report to UNAIDS., 2014.
- 65. Ministry of Health. Country Progress Report: Occupied Palestinian Territory, 2012.
- 66. National AIDS Programme. COUNTRY PROGRESS REPORT SULTANATE OF OMAN, 2014.
- 67. Ministere de la Sante Publique. Rapport d'Activite sur la Riposte au SIDA-Tunisie, 2014.
- 68. UNAIDS. Global Report. 2010.
- 69. Ghana AIDS Commission. Country AIDS Response Progress Report Ghana, 2015.
- 70. Système d'Information Multi-Sectorielle/Multi-Sector System (SIMS/MSIS). RAPPORT FINAL AU NIVEAU DES 37 VILLES: Cartographie et estimation de la taille des personnes cibles les plus exposées aux risques du VIH/Sida, 2014.
- 71. Focus Development Association, Service de Laboratoire National de Reference. Etude comportementale et biologique chez les consommateurs de drogues injectables dans les zones urbaines à Madagascar-2012, 2012.
- 72. Toufik A. Rapport Final: Evaluation de la Reduction de la Demande de Drogues, 2016.
- 73. NAS. Country Progress Report 2015, Republic of Mauritius. Report to UNAIDS., 2015.
- 74. Republique du Senegal Conseil National de Lutte Contre le Sida. Rapport de Situation sur la Riposte Nationale a l'Epidemie de VIH/Sida Senegal: 2013-2014. Report to UNAIDS., 2014.
- 75. UNAIDS. Population Size Estimation of Key Populations August 2013. 2013.
- 76. Scheibe S, Shelly S. Personal communication email to S. Larney, 20 June 2017.
- 77. Ratliff EA, McCurdy SA, Mbwambo JK, et al. An Overview of HIV Prevention Interventions for People Who Inject Drugs in Tanzania. *Advances in Preventive Medicine* 2013; **2013**: 183187.
- 78. Asem J. Personal communication email to S. Larney, 30 May 2017.

Appendix 16: Countries with coverage estimates for both NSP and OST, with coverage category according to WHO/UNAIDS/UNODC suggested implementation targets

| Country | Region | Percentage of | NSP | | OST | |
|----------------|------------------------------|---|--|--------------------------------|--|--------------------------------|
| | | estimated global injecting population | Needle-syringes distributed per person | Coverage level ¹ | OST clients per 100 people who inject drugs | Coverage level ² |
| Armenia | Eastern Europe | 0.08 | 39 (18-58) | Low | 3 (1-5) | Low |
| Australia | Australasia | 0.59 | 461 (364-631) | High | 52 (41-71) | High |
| Austria | Western Europe | 0.12 | 321 (244-468) | High | 95 (72-138) | High |
| Azerbaijan | Eastern Europe | 0.31 | 16 (6-183) | Low | 0.32 (0.12-4) | Low |
| Belarus | Eastern Europe | 0.26 | 27 (16-72) | Low | 2 (1-6) | Low |
| Belgium | Western Europe | 0.17 | 40 (28-57) | Low | 64 (45-91) | High |
| Bulgaria | Eastern Europe | 0.12 | 20 (16-24) | Low | 18 (15-23) | Low |
| Canada | North America | 1.96 | 148 (129-174) | Moderate | 24 (21-29) | Moderate |
| China | East and South East Asia | 16.27 | 4 (3-6) | Low | 7 (6-9) | Low |
| Croatia | Western Europe | 0.04 | 146 (112-180) | Moderate | 80 (61-98) | High |
| Cyprus | Middle East and North Africa | 0.00 | 0.22 (0.1-0.89) | Low | 34 (16-136) | Moderate |
| Czech Republic | Eastern Europe | 0.30 | 137 (131-144) | Moderate | 9 (8-9) | Low |
| Estonia | Eastern Europe | 0.05 | 249 (135-339) | High | 14 (7-18) | Low |
| Finland | Western Europe | 0.11 | 312 (214-350) | High | 18 (12-20) | Low |
| France | Western Europe | 0.52 | 150 (127-186) | Moderate | 206 (174-255) | High |
| Georgia | Eastern Europe | 0.73 | 31 (16-271) | Low | 2 (1-19) | Low |
| Greece | Western Europe | 0.03 | 53 (43-65 | Low | 200 (162-244) | High |
| Hungary | Eastern Europe | 0.03 | 48 (32-91) | Low | 17 (11-32) | Low |
| India | South Asia | 1.25 | 86 (63-133) | Low | 3 (2-4) | Low |
| Iran, Islamic | | | | | | |
| Republic | South Asia | 1.00 | 54 (41-80) | Low | 405 (307-597) | High |
| Ireland | Western Europe | 0.05 | 46 (37-62) | Low | 116 (93-156) | High |
| Kazakhstan | Central Asia | 0.71 | 145 (98-217) | Moderate | 0.26 (0.17-0.39) | Low |
| Kenya | Sub Saharan Africa | 0.31 | 6 (3-23) | Low | 2 (1-9) | Low |
| Kyrgyzstan | Central Asia | 0.18 | 246 (166-366) | High | 6 (4-9) | Low |
| Latvia | Eastern Europe | 0.09 | 37 (29-47) | Low | 4 (3-5) | Low |
| Lithuania | Eastern Europe | 0.03 | 42 (28-79) | Low | 12 (8-24) | Low |
| Luxembourg | Western Europe | 0.01 | 137 (165-207) | Moderate | 49 (41-62) | High |
| Mauritius | Sub Saharan Africa | 0.04 | 118 (60-235) | Moderate | 78 (40-155) | High |

| Mexico | Latin America | 0.96 | 8 (6-12) | Low | 15 (11-23) | Low |
|-----------------|------------------------------|-------|---------------|----------|---------------|----------|
| Moldova | Eastern Europe | 0.07 | 220 (46-0) | High | 4 (1-0) | Low |
| Morocco | Middle East and North Africa | 0.24 | 6 (3-26) | Low | 2 (1-7) | Low |
| Myanmar | East and South East Asia | 1.10 | 80 (59-120) | Low | 5 (3-7) | Low |
| Nepal | South Asia | 0.22 | 43 (41-46) | Low | 4 (4-4) | Low |
| Netherlands | Western Europe | 0.02 | 414 (170-659) | High | 225 (162-317) | High |
| New Zealand | Australasia | 0.14 | 124 (93-185) | Moderate | 22 (17-33) | Moderate |
| Norway | Western Europe | 0.05 | 298 (247-350) | High | 89 (74-105) | High |
| Portugal | Western Europe | 0.10 | 63 (57-72) | Low | 107 (96-122) | High |
| Romania | Eastern Europe | 0.52 | 18 (13-24) | Low | 1 (0.5-1) | Low |
| Scotland (U.K.) | Western Europe | 0.10 | 277 (249-320) | High | 23 (21-27) | Moderate |
| Slovakia | Eastern Europe | 0.13 | 17 (10-24) | Low | 3 (2-4) | Low |
| Slovenia | Western Europe | 0.04 | 85 (65-122) | Low | 55 (43-79) | High |
| Spain | Western Europe | 0.06 | 148 (120-185) | Moderate | 619 (501-773) | High |
| Sweden | Western Europe | 0.05 | 34 (7-161) | Low | 45 (10-210) | High |
| Switzerland | Western Europe | 0.09 | 187 (156-234) | Moderate | 127 (106-159) | High |
| Tajikistan | Central Asia | 0.15 | 278 (187-414) | High | 2 (2-3) | Low |
| Thailand | East and South East Asia | 0.37 | 15 (1-28) | Low | 6 (4-14) | Low |
| Ukraine | Eastern Europe | 2.03 | 61 (33-113) | Low | 3 (2-5) | Low |
| United Rep of | | | | | | |
| Tanzania | Sub Saharan Africa | 2.25 | 1 (1-2) | Low | 1 (1-1) | Low |
| United States | North America | 14.27 | 30 (11-49) | Low | 19 (11-35) | Low |
| Viet Nam | East and South East Asia | 1.02 | 176 (142-231) | Moderate | 32 (25-41) | Moderate |

¹Low: <100; moderate: 100-<200; high:≥200.

² Low: <20; moderate: 20-<40; high: ≥40

Appendix 17: Acknowledgement of individuals who provided data for this review

The following individuals/organizations generously provided time and expertise in submitting, critiquing and providing useful feedback on the data collected and used in this review, or directing us to individuals who could perform these tasks. Final responsibility for the selection and interpretation of data remain the responsibility of the authors alone.

Robert Ali; Hesham El Arabi; Apinun Aramrattana; Chris Archibald; Jiten Asem; Tasnim Aziz; Thorir Gudmundsson; Mawouena Bohm; Laurene Booyens, Julie Bruneau; Jane Buxton; Timothy Christie; Edona Deva; Artan Duraku; Durban University of Technology; Benham Farhoudi; Omar Faruque; Benedikt Fischer; Ali Ghaddar; Patricia Gonzalez-Zuniga; Patricia Haddad; Chris Harold; Joumana Hermez; Marjolein Jacobs; Svala Jóhannesdóttir; Eleni Kalamara; Lorinda Kroukamp, Paul Kurdyak; Labyrinth (Kosovo); Kathryn Leafe; Pamela Leece; Niklas Luhmann; Carlos Magis; Mohsen Malekinejad; David Marsh; Hlengiwe Mhlophe, Andre Noor; Alireza Noroozi; Claire O'Gorman; Susanna Ogunnaike-Cooke; OUT LGBT Wellbeing (South Africa); Ozone Foundation (Thailand); Usaneya Perngparn; Alessandro Pirona; Rakthai (Thailand); Cybelle Reiber; Right to Care (South Africa); Signe Rotberga; Pam Sabioni; Anya Sarang; Andrew Scheibe; Shaun Shelly; Omar Silverman; Claudia Stoicescu; Viny Sutriani; TB/HIV Care Association (South Africa); Aziz Tadjeddine; Nguyen Thi Minh Tam; Isabel Tavitian-Exley; Marliss Taylor; Khalid Tinasti; Rafael Torruella; Jallal Toufiq; Silas Quaye; University of Pretoria; Vo Hai Son; Ivan Varentsov; Annette Verster; Elise Weiss; Daniel Wolfe; Gerard Yetman; Katherine Young.